image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
c81d17a06ac93d4ed618867343cd5147c65ec0a46961c46e0b6db4b48f77cbe7.png | simple | <table><tr><td></td><td>Commitment</td><td>Promoting teamwork</td><td>RoleB</td><td>T&D</td><td>Information sharing</td></tr><tr><td>willing to put in a great deal of effort</td><td>0.74</td><td>0.51</td><td>0.67</td><td>0.52</td><td>0.53</td></tr><tr><td>talk up this coach to my friends as a great coach</td><td>0.86</td><td>0.56</td><td>0.52</td><td>0.51</td><td>0.58</td></tr><tr><td>would accept assignments in order to keep playing for my coach</td><td>0.79</td><td>0.47</td><td>0.38</td><td>0.45</td><td>0.50</td></tr><tr><td>my personal values and the coach’s values are similar</td><td>0.90</td><td>0.59</td><td>0.57</td><td>0.48</td><td>0.66</td></tr><tr><td>proud to tell others that I play for my coach</td><td>0.91</td><td>0.60</td><td>0.54</td><td>0.53</td><td>0.62</td></tr><tr><td>My coach really inspires the very best in me</td><td>0.91</td><td>0.56</td><td>0.54</td><td>0.48</td><td>0.60</td></tr><tr><td>glad that I chose to be athlete under the direction of my coach</td><td>0.92</td><td>0.63</td><td>0.52</td><td>0.56</td><td>0.62</td></tr><tr><td>really care about the future of my role under my coach</td><td>0.88</td><td>0.59</td><td>0.58</td><td>0.51</td><td>0.59</td></tr><tr><td>generally feel informed by my coach about changes in my role</td><td>0.63</td><td>0.59</td><td>0.44</td><td>0.41</td><td>0.89</td></tr><tr><td>My coach keeps me informed and up-to-date</td><td>0.61</td><td>0.58</td><td>0.42</td><td>0.41</td><td>0.87</td></tr><tr><td>I know what is expected of me</td><td>0.52</td><td>0.50</td><td>0.45</td><td>0.45</td><td>0.82</td></tr><tr><td>I get adequate feedback from my coach</td><td>0.64</td><td>0.61</td><td>0.48</td><td>0.60</td><td>0.86</td></tr><tr><td>My coach communicates to me frequently and honestly</td><td>0.62</td><td>0.53</td><td>0.46</td><td>0.55</td><td>0.90</td></tr><tr><td>get the information I need to do well</td><td>0.49</td><td>0.55</td><td>0.49</td><td>0.41</td><td>0.82</td></tr><tr><td>adequately complete assigned tasks that my coach gives me</td><td>0.53</td><td>0.40</td><td>0.83</td><td>0.34</td><td>0.43</td></tr><tr><td>fulfill responsibilities specified by my coach</td><td>0.60</td><td>0.42</td><td>0.89</td><td>0.38</td><td>0.48</td></tr><tr><td>perform tasks that are expected of me, by my coach</td><td>0.57</td><td>0.45</td><td>0.87</td><td>0.39</td><td>0.44</td></tr><tr><td>meet formal performance expectations</td><td>0.56</td><td>0.47</td><td>0.87</td><td>0.36</td><td>0.49</td></tr><tr><td>engage in activities assigned by my coach,</td><td>0.53</td><td>0.35</td><td>0.79</td><td>0.39</td><td>0.43</td></tr><tr><td>don’t neglect aspects of a student-athlete that I am obligated to</td><td>0.40</td><td>0.39</td><td>0.78</td><td>0.32</td><td>0.38</td></tr><tr><td>I don’t fail to perform essential duties of a student-athlete</td><td>0.40</td><td>0.34</td><td>0.73</td><td>0.26</td><td>0.39</td></tr><tr><td>My coach systematically trains and develops my student-athletic abilities</td><td>0.48</td><td>0.47</td><td>0.38</td><td>0.89</td><td>0.45</td></tr><tr><td>My coach trains me to gain many skills and abilities</td><td>0.50</td><td>0.46</td><td>0.39</td><td>0.90</td><td>0.47</td></tr><tr><td>I receive from my coach the training I need to do well as a student-athlete</td><td>0.51</td><td>0.46</td><td>0.36</td><td>0.89</td><td>0.48</td></tr><tr><td>I receive the training and support from my coach that I need to perform well as a student-athlete</td><td>0.59</td><td>0.54</td><td>0.39</td><td>0.90</td><td>0.58</td></tr><tr><td>My coach encourages decentralized decision making</td><td>0.48</td><td>0.79</td><td>0.41</td><td>0.39</td><td>0.51</td></tr><tr><td>My coach encourages my team members to decide about sports specific performances and operational problems</td><td>0.58</td><td>0.82</td><td>0.37</td><td>0.42</td><td>0.52</td></tr><tr><td>We (team members) regularly work as a team to perform various tasks</td><td>0.48</td><td>0.83</td><td>0.31</td><td>0.42</td><td>0.48</td></tr><tr><td>My coach promotes teamwork</td><td>0.56</td><td>0.80</td><td>0.48</td><td>0.52</td><td>0.58</td></tr></table> |
9464aed7f9177274462084c0c7ec28f806fc97c40af63140fe8d9b8e4042483e.png | simple | <table><tr><td>miRNA Family</td><td>miRNA name</td><td>PMA</td><td>MA</td><td>SCP</td><td>BCP</td></tr><tr><td><i>miR2118</i></td><td><i>osa-miR2118d</i></td><td></td><td>up</td><td>up</td><td></td></tr><tr><td></td><td><i>osa-miR2118p</i></td><td></td><td></td><td>up</td><td></td></tr><tr><td></td><td><i>osa-miR2118o</i></td><td></td><td></td><td>up</td><td>down</td></tr><tr><td></td><td><i>osa-miR2118i</i></td><td></td><td></td><td></td><td>up</td></tr><tr><td></td><td><i>osa-MIR2118i-p5</i></td><td></td><td></td><td>up</td><td></td></tr><tr><td></td><td><i>osa-MIR2118e-p5</i></td><td></td><td>up</td><td></td><td></td></tr><tr><td><i>miR2275</i></td><td><i>osa-miR2275d</i></td><td>down</td><td>down</td><td>down</td><td>up</td></tr><tr><td></td><td><i>mes-miR2275</i></td><td>down</td><td>down</td><td>down</td><td></td></tr><tr><td></td><td><i>osa-MIR2275c-p3</i></td><td></td><td>down</td><td>down</td><td>up</td></tr><tr><td></td><td><i>zma-miR2275b-3p_1ss10CT</i></td><td></td><td>down</td><td>down</td><td>up</td></tr><tr><td></td><td><i>zma-miR2275b-3p_1ss22AG</i></td><td></td><td>down</td><td>down</td><td>up</td></tr><tr><td></td><td><i>zma-miR2275a-3p_L-1</i></td><td>down</td><td>down</td><td></td><td></td></tr></table> |
4e9ba869ada1d6ed94e6a6bf7e1ccfd149e8baa93bc4369eb1dc56efbfe9646f.png | complex | <table><tr><td rowspan="3">Age (years)</td><td>≤45</td><td>>45</td></tr><tr><td colspan="2">Total = 510</td></tr><tr><td><i>n</i> = 101</td><td><i>n</i> = 409</td></tr><tr><td>Sex</td><td>53.1±</td><td>53.7±</td></tr><tr><td>Men</td><td>38.1</td><td>30.6</td></tr><tr><td>Women</td><td>61.9</td><td>69.4</td></tr><tr><td>Waist circumference <i>n</i> (%)</td><td>75 (74.3)</td><td>293 (71.6)</td></tr><tr><td>Men ≥102 cm, women ≥88 cm</td><td></td><td></td></tr><tr><td>Reduced HDL-C <i>n</i> (%)</td><td>98 (97.0)</td><td>382 (93.4)</td></tr><tr><td>Men <40 mg/dL</td><td></td><td></td></tr><tr><td>Women <50 mg/dL</td><td></td><td></td></tr><tr><td>Triglycerides ≥150 mg/dL or medical treatment of elevated TG <i>n</i> (%)</td><td>87 (86.1)</td><td>307 (75.0)</td></tr><tr><td>Blood pressure ≥130/≥85 mmHg or previous diagnosis of hypertension <i>n</i> (%)</td><td>29 (28.7)</td><td>250 (61.1)</td></tr><tr><td>Elevated fasting glucose ≥100 mg/dL or previous diagnosis of T2DM</td><td>68 (67.3)</td><td>296 (72.4)</td></tr></table> |
5ae234f51ae5be93b61c8e1a6917164b2752fbfea9f4ee69cf5c445906dfc8b9.png | complex | <table><tr><td colspan="2">Holeboard task measures and their definition</td></tr><tr><td>Measure</td><td>Definition</td></tr><tr><td>Working memory (WM)</td><td>A ratio defined by the number of visits that yield a food reward divided by the number of visits and re-visits to the rewarded set of holes</td></tr><tr><td>Reference memory (RM)</td><td>A ratio that is defined by the number of visits and re-visits to the rewarded set of holes divided by the number of visits and re-visits to all holes</td></tr><tr><td>Trial duration (TD)</td><td>The time between entering the holeboard and finding all four rewards (when not all rewards were found the maximum trial duration of 450 s was recorded)</td></tr><tr><td>Inter-visit interval (IVI)</td><td>The average time between two hole visits during a trial</td></tr><tr><td>Latency to the first visit (LFV)</td><td>The latency until the first visit during a trial</td></tr><tr><td>Latency to the first reward (LFR)</td><td>The latency until the first rewarded visit during a trial</td></tr><tr><td>Total visits (TV)</td><td>The total number of hole visits made during a trial</td></tr><tr><td>Unrewarded visits (URV)</td><td>The total number of unrewarded hole visits made during a trial</td></tr><tr><td>Rewarded visits (RV)</td><td>The total number of rewarded hole visits made during a trial</td></tr><tr><td>Number of visits until 1st reward (Vfirst)</td><td>The number of hole visits until the first reward was found</td></tr><tr><td>Number of visits until 2nd reward (Vsecond)</td><td>The number of hole visits between the first and second reward were found</td></tr><tr><td>Number of visits until 3rd reward (Vthird)</td><td>The number of hole visits between the second and third reward were found</td></tr><tr><td>Number of visits until 4th reward (Vfourth)</td><td>The number of hole visits between the third and fourth reward were found</td></tr></table> |
1ad07c6d332b22e21a158b29a1b76d80be881df54fe4d9765d8482e6c756eaa2.png | simple | <table><tr><td>Type of bacterial isolate</td><td>Total number of isolates</td><td>MDR<sup>a</sup> isolates, <i>N</i> (%)</td></tr><tr><td><i>S. aureus</i></td><td>40</td><td>18 (45)</td></tr><tr><td><i>K. pneumoniae</i></td><td>7</td><td>4 (57.1)</td></tr><tr><td>Other <i>Klebsiella</i> spp.</td><td>5</td><td>2 (40)</td></tr><tr><td><i>E. coli</i></td><td>15</td><td>7 (46.7)</td></tr><tr><td><i>Enterobacter</i> spp.</td><td>10</td><td>2 (20)</td></tr><tr><td><i>Citrobacter freundii</i></td><td>4</td><td>1 (25)</td></tr><tr><td><i>Serratia marcescens</i></td><td>5</td><td>1 (20)</td></tr><tr><td><i>P. shigelloides</i></td><td>1</td><td>0</td></tr><tr><td><i>Proteus</i> spp.</td><td>3</td><td>0</td></tr><tr><td><i>Acinetobacter</i> spp<i>.</i></td><td>5</td><td>1 (20)</td></tr><tr><td>Total</td><td>95</td><td>36 (37.9)</td></tr></table> |
135856825b906253936d386f0b6aed5d15ebb9116ba28d39d83e2ab7e243c231.png | complex | <table><tr><td></td><td>All</td><td>White British</td><td>Pakistani</td><td><i>p</i> value</td></tr><tr><td></td><td>8850</td><td>4119</td><td>4731</td><td></td></tr><tr><td colspan="5">Mother variables</td></tr><tr><td> Mother age at delivery</td><td>27.5 (5.61)</td><td>27.0 (6.05)</td><td>27.9 (5.16)</td><td><0.001</td></tr><tr><td> Mother education higher than A level</td><td>2540 (28.7%)</td><td>1162 (28.2%)</td><td>1372 (29.0%)</td><td>= 0.420</td></tr><tr><td> Housing tenure (Owner occupied)</td><td>5487 (62.0%)</td><td>2175 (52.8%)</td><td>3312 (70.0%)</td><td><0.001</td></tr><tr><td> Household in receipt of means tested benefits</td><td>3797 (42.9%)</td><td>1557 (37.8%)</td><td>2242 (47.4%)</td><td><0.001</td></tr><tr><td> Mother height (cm)</td><td>161.8 (6.35)</td><td>164.1 (6.23)</td><td>159.7 (5.72)</td><td><0.001</td></tr><tr><td> Mother weight (kg)</td><td>74.3 (15.6)</td><td>77.9 (16.5)</td><td>71.1 (14.0)</td><td><0.001</td></tr><tr><td> Mother BMI (at recruitment)</td><td>28.3 (5.47)</td><td>28.9 (5.72)</td><td>27.8 (5.19)</td><td><0.001</td></tr><tr><td> Parity 0</td><td>3513 (39.7%)</td><td>4283 (48.4%)</td><td>2841 (32.1%)</td><td><0.001</td></tr><tr><td> Parity 1</td><td>2558 (28.9%)</td><td>2788 (31.5%)</td><td>2354 (26.6%)</td><td></td></tr><tr><td> Parity 2+</td><td>2779 (31.4%)</td><td>1779 (20.1%)</td><td>3655 (41.3%)</td><td></td></tr><tr><td> Mother never smoked</td><td>6071 (68.6%)</td><td>3690 (41.7%)</td><td>8151 (92.1%)</td><td><0.001</td></tr><tr><td> Mother smoked before pregnancy</td><td>1478 (16.7%)</td><td>2673 (30.2%)</td><td>434 (4.9%)</td><td></td></tr><tr><td> Mother smoked during pregnancy</td><td>1301 (14.7%)</td><td>2496 (28.2%)</td><td>266 (3.0%)</td><td></td></tr><tr><td colspan="5">Child Variables</td></tr><tr><td> Birth-weight (g)</td><td>3238 (541)</td><td>3371 (547)</td><td>3147 (518)</td><td><0.001</td></tr><tr><td> Low birthweight (< 2500 g)</td><td>620 (7.0%)</td><td>443 (5.0%)</td><td>770 (8.7%)</td><td><0.001</td></tr><tr><td> Small For Gestational Age (GROW – 10th Decile)</td><td>902 (15.8%)</td><td>257 (6.24%)</td><td>645 (15.3%)</td><td><0.001</td></tr><tr><td> Gestation (weeks)</td><td>39.2 (1.72)</td><td>39.3 (1.76)</td><td>39.2 (1.68)</td><td>= 0.006</td></tr><tr><td> Pre-term birth (< 37 weeks)</td><td>439 (5.0%)</td><td>220 (5.3%)</td><td>219 (4.6%)</td><td>= 0.124</td></tr><tr><td> Gender (female)</td><td>4319 (48.8%)</td><td>4283 (48.4%)</td><td>4345 (49.1%)</td><td>= 0.542</td></tr><tr><td>GP appointments</td><td>20.0 (13.3)</td><td>16.0 (11.6)</td><td>23.5 (13.8)</td><td><0.001</td></tr><tr><td>Analgesic prescriptions</td><td>4.65 (4.97)</td><td>2.82 (3.10)</td><td>6.24 (5.68)</td><td><0.001</td></tr><tr><td>Antibiotic prescriptions</td><td>3.24 (3.90)</td><td>2.64 (3.26)</td><td>3.77 (4.32)</td><td><0.001</td></tr><tr><td>Bronchodilator prescriptions</td><td>1.44 (3.18)</td><td>1.49 (3.04)</td><td>1.40 (3.29)</td><td>= 0.184</td></tr><tr><td>Emergency hospital episodes</td><td>0.42 (1.00)</td><td>0.38 (0.83)</td><td>0.45 (1.12)</td><td>= 0.001</td></tr><tr><td>Elective hospital episodes</td><td>0.08 (0.61)</td><td>0.07 (0.36)</td><td>0.10 (0.77)</td><td>= 0.022</td></tr></table> |
e1aa7346256baf4a7127c4d9f9cac51c820bb5e257834fd473febb3988872cf7.png | complex | <table><tr><td colspan="4">GammaGap < 3.65 (g/dL)</td><td colspan="4">GammaGap ≥ 3.65 (g/dL)</td></tr><tr><td>Models <sup>a</sup></td><td>Tertiles of MAMC</td><td>Hazard Ratio (95% CI)</td><td><i>P</i> -value</td><td>Models <sup>a</sup></td><td>Tertiles of MAMC</td><td>Hazard Ratio (95% CI)</td><td><i>P</i> -value</td></tr><tr><td colspan="4">Aged 20–39 years</td><td colspan="4">Aged 20–39 years</td></tr><tr><td>Model 1</td><td>T2 v.s. T1T3 v.s. T1</td><td>0.86 (0.39–1.92)0.60 (0.25–1.41)</td><td>0.7210.241</td><td>Model 1</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.45 (0.36–5.81)1.31 (0.29–5.86)</td><td>0.5980.726</td></tr><tr><td>Model 2</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.16 (0.49–2.74)1.11 (0.31–3.95)</td><td>0.7400.869</td><td>Model 2</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.27 (0.30–5.40)1.06 (0.14–7.88)</td><td>0.7460.954</td></tr><tr><td>Model 3</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.28 (0.53–3.10)1.39 (0.38–5.12)</td><td>0.5870.622</td><td>Model 3</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.27 (0.29–5.48)1.09 (0.15–8.09)</td><td>0.7520.935</td></tr><tr><td>Model 4</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.28 (0.53–3.10)1.39 (0.38–5.14)</td><td>0.5860.621</td><td>Model 4</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.37 (0.32–5.94)1.14 (0.16–8.16)</td><td>0.6730.897</td></tr><tr><td colspan="4">Aged 40–59 years</td><td colspan="4">Aged 40–59 years</td></tr><tr><td>Model 1</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.52 (1.02–2.28)1.04 (0.69–1.55)</td><td>0.0400.863</td><td>Model 1</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.08 (0.47–2.45)0.90 (0.38–2.12)</td><td>0.8630.812</td></tr><tr><td>Model 2</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.14 (0.72–1.80)0.72 (0.41–1.25)</td><td>0.5690.240</td><td>Model 2</td><td>T2 v.s. T1T3 v.s. T1</td><td>0.86 (0.35–2.11)0.53 (0.18–1.58)</td><td>0.7420.255</td></tr><tr><td>Model 3</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.16 (0.74–1.84)0.75 (0.43–1.32)</td><td>0.5190.320</td><td>Model 3</td><td>T2 v.s. T1T3 v.s. T1</td><td>0.98 (0.39–2.47)0.67 (0.22–2.00)</td><td>0.9600.468</td></tr><tr><td>Model 4</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.17 (0.74–1.85)0.76 (0.44–1.34)</td><td>0.4950.346</td><td>Model 4</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.08 (0.42–2.79)0.67 (0.22–2.05)</td><td>0.8730.482</td></tr><tr><td colspan="4">Aged 60–90 years</td><td colspan="4">Aged 60–90 years</td></tr><tr><td>Model 1</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.54 (1.20–1.96)1.34 (1.03–1.73)</td><td>0.0010.028</td><td>Model 1</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.09 (0.73–1.64)1.17 (0.76–1.78)</td><td>0.6780.472</td></tr><tr><td>Model 2</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.11 (0.85–1.46)0.90 (0.65–1.25)</td><td>0.4480.521</td><td>Model 2</td><td>T2 v.s. T1T3 v.s. T1</td><td>0.60 (0.38–0.95)0.49 (0.29–0.83)</td><td>0.0280.008</td></tr><tr><td>Model 3</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.11 (0.84–1.46)0.90 (0.64–1.25)</td><td>0.4570.517</td><td>Model 3</td><td>T2 v.s. T1T3 v.s. T1</td><td>0.66 (0.42–1.04)0.53 (0.31–0.88)</td><td>0.0730.015</td></tr><tr><td>Model 4</td><td>T2 v.s. T1T3 v.s. T1</td><td>1.11 (0.84–1.47)0.87 (0.62–1.21)</td><td>0.4460.404</td><td>Model 4</td><td>T2 v.s. T1T3 v.s. T1</td><td>0.66 (0.42–1.04)0.57 (0.33–0.96)</td><td>0.0760.036</td></tr></table> |
67fb79ece48fbb413fddcbf3b3ca30e7f479059e461459fe54074e6434858839.png | complex | <table><tr><td> </td><td colspan="2">All</td><td colspan="2">All</td></tr><tr><td> </td><td>Boys</td><td>Girls</td><td>Black</td><td>White</td></tr><tr><td> </td><td>Mean ± SD</td><td>Mean ± SD</td><td>Mean ± SD</td><td>Mean ± SD</td></tr><tr><td>Sleep/Sedentary PA < 1.5 METs</td><td>1178.0 ± 88.9<sup>a</sup></td><td>1070.0 ± 108.4<sup>a</sup></td><td>1091.0 ± 103.1</td><td>1174.0 ± 122.3<sup>b</sup></td></tr><tr><td>Light 1.5 – 3.0 METs</td><td>234.1 ± 81.7<sup>a</sup></td><td>306.9 ± 85.5<sup>a</sup></td><td>296.0 ± 80.47</td><td>225.0 ± 99.5<sup>b</sup></td></tr><tr><td>Moderate PA >3 – 6 METs</td><td>33.2 ± 32.5<sup>a</sup></td><td>58.6 ± 39.0<sup>a</sup></td><td>46.2 ± 37.6</td><td>55.6 ± 40.8</td></tr><tr><td>Vigorous PA >6 METs</td><td>1.8 ± 2.7</td><td>2.5 ± 4.9</td><td>1.7 ± 3.2</td><td>3.9 ± 5.8<sup>b</sup></td></tr><tr><td>MVPA >3 METSs</td><td>35.0 ± 32.9<sup>a</sup></td><td>61.1 ± 52.2<sup>a</sup></td><td>47.9 ± 39.6</td><td>59.5 ± 41.8</td></tr><tr><td> </td><td colspan="2">Boys</td><td colspan="2">Girls</td></tr><tr><td> </td><td>Black</td><td>White</td><td>Black</td><td>White</td></tr><tr><td> </td><td>Mean ± SD</td><td>Mean ± SD</td><td>Mean ± SD</td><td>Mean ± SD</td></tr><tr><td>Sleep/Sedentary PA < 1.5 METs</td><td>1154.0 ± 85.1</td><td>1224.0 ± 78.6</td><td>1058.0 ± 96.48</td><td>1118.0 ± 139.5</td></tr><tr><td>Light 1.5 – 3.0 METs</td><td>259.0 ± 78.54</td><td>187.0 ± 65.5</td><td>316.3 ± 74.6</td><td>269.0 ± 114.1</td></tr><tr><td>Moderate PA >3 – 6 METs</td><td>25.9 ± 24.6</td><td>46.7 ± 40.7</td><td>56.9 ± 38.9</td><td>65.8 ± 39.1</td></tr><tr><td>Vigorous PA >6 METs</td><td>1.2 ± 1.7</td><td>2.8 ± 3.8</td><td>1.8 ± 3.9</td><td>5.1 ± 7.5</td></tr><tr><td>MVPA >3 METSs</td><td>27.2 ± 25.3</td><td>49.6 ± 40.5</td><td>58.8 ± 41.4</td><td>70.9 ± 41.1</td></tr></table> |
1c4eb567a9bd7f0fe4b2b2f3c2ef8ecf46aed9c6c7cda96243a91ee1f99dd061.png | simple | <table><tr><td>Household experiences in last 12 months</td><td>Adjusted Odds Ratio</td><td>95% Confidence Interval</td><td><i>p</i>-value</td></tr><tr><td>Household members falling sick</td><td>1.3</td><td>(0.9, 2.0)</td><td>0.182</td></tr><tr><td>Lifestyle related illness (major illness e.g., heart, kidney, liver)</td><td>1.6</td><td>(1.0,2.4)</td><td>0.043</td></tr><tr><td>Relationship problems between partners (arguing, not talking)</td><td>2.2</td><td>(1.1, 4.4)</td><td>0.022</td></tr><tr><td>Strained relationships within household</td><td>2.1</td><td>(1.1, 4.1)</td><td>0.032</td></tr><tr><td>Separation between spouses or partners</td><td>1.9</td><td>(0.5, 7.2)</td><td>0.367</td></tr><tr><td>Infidelity or cheating between spouses or partners</td><td>4.1</td><td>(1.2, 13.9)</td><td>0.023</td></tr><tr><td>Behavioral problems in children at home</td><td>3.1</td><td>(1.0, 9.6)</td><td>0.048</td></tr><tr><td>Antisocial problems of children at home/school</td><td>2.3</td><td>(0.9, 6.1)</td><td>0.101</td></tr><tr><td>Violent behavior</td><td>1.7</td><td>(0.6, 4.9)</td><td>0.312</td></tr><tr><td>Verbal abuse</td><td>1.8</td><td>(0.9, 3.7)</td><td>0.101</td></tr><tr><td>Police Intervention in household dispute</td><td>1.6</td><td>(0.5, 5.3)</td><td>0.406</td></tr><tr><td>Receiving a traffic ticket</td><td>2.7</td><td>(1.2, 5.9)</td><td>0.015</td></tr></table> |
13315c826ec0a132fe6fa19ec6ee1adefed95eb458b640b90047d0445e966252.png | simple | <table><tr><td></td><td>Group</td><td>Baseline</td><td>3 hours</td><td>5 hours</td><td>ANOVA (<i>P</i>)</td></tr><tr><td>Sublingual mucosa</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>MFI s</td><td>Sepsis</td><td>2.73 ± 0.24</td><td>1.56 ± 0.30<sup>a</sup></td><td>1.54 ± 0.34<sup>a</sup></td><td>0.001</td></tr><tr><td></td><td>Sham</td><td>2.89 ± 0.19</td><td>3.00 ± 0.00</td><td>3.00 ± 0.00</td><td>0.368</td></tr><tr><td>MFI l</td><td>Sepsis</td><td>3.00 ± 0.00</td><td>2.94 ± 0.19</td><td>3.00 ± 0.00</td><td>0.368</td></tr><tr><td></td><td>Sham</td><td>3.00 ± 0.00</td><td>3.00 ± 0.00</td><td>3.00 ± 0.00</td><td>0.999</td></tr><tr><td>PPV s, %</td><td>Sepsis</td><td>91.4 ± 3.3</td><td>71.0 ± 8.1<sup>a</sup></td><td>70.2 ± 8.4<sup>a</sup></td><td>0.011</td></tr><tr><td></td><td>Sham</td><td>95.0 ± 0.3</td><td>93.8 ± 1.9</td><td>94.3 ± 2.0</td><td>0.264</td></tr><tr><td>PVD s, 1/mm</td><td>Sepsis</td><td>14.5 ± 3.2</td><td>11.6 ± 2.7</td><td>12.4 ± 1.9</td><td>0.197</td></tr><tr><td></td><td>Sham</td><td>15.3 ± 1.8</td><td>15.4 ± 2.3</td><td>16.5 ± 2.0</td><td>0.100</td></tr><tr><td>TVD s, mm/mm<sup>2</sup></td><td>Sepsis</td><td>27.9 ± 2.4</td><td>27.8 ± 2.8</td><td>30.0 ± 3.6</td><td>0.197</td></tr><tr><td></td><td>Sham</td><td>29.9 ± 3.9</td><td>30.7 ± 2.8</td><td>32.6 ± 5.0</td><td>0.529</td></tr><tr><td>TVD l, mm/mm<sup>2</sup></td><td>Sepsis</td><td>6.0 ± 1.3</td><td>7.1 ± 1.1</td><td>7.3 ± 2.0</td><td>0.197</td></tr><tr><td></td><td>Sham</td><td>8.4 ± 1.4</td><td>8.2 ± 1.3</td><td>8.1 ± 3.3</td><td>0.761</td></tr><tr><td>Het MFI</td><td>Sepsis</td><td>0.17 ± 0.14</td><td>0.44 ± 0.40</td><td>0.37 ± 0.24</td><td>0.250</td></tr><tr><td></td><td>Sham</td><td>0.06 ± 0.11</td><td>0.00 ± 0.00</td><td>0.00 ± 0.00</td><td>0.368</td></tr><tr><td>Ocular conjunctiva</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>MFI s</td><td>Sepsis</td><td>2.74 ± 0.21</td><td>2.14 ± 0.33<sup>a</sup></td><td>2.00 ± 0.52<sup>a</sup></td><td>0.004</td></tr><tr><td></td><td>Sham</td><td>2.94 ± 0.10</td><td>2.83 ± 0.17</td><td>2.83 ± 0.29</td><td>0.867</td></tr><tr><td>MFI l</td><td>Sepsis</td><td>3.00 ± 0.00</td><td>2.98 ± 0.04</td><td>3.00 ± 0.00</td><td>0.135</td></tr><tr><td></td><td>Sham</td><td>2.94 ± 0.10</td><td>2.94 ± 0.10</td><td>3.00 ± 0.00</td><td>0.368</td></tr><tr><td>PPV s, %</td><td>Sepsis</td><td>93.4 ± 3.1</td><td>84.4 ± 4.2<sup>a</sup></td><td>78.4 ± 8.7<sup>a</sup></td><td>0.009</td></tr><tr><td></td><td>Sham</td><td>95.5 ± 0.3</td><td>94.4 ± 1.6</td><td>94.5 ± 1.2</td><td>0.441</td></tr><tr><td>PVD s, 1/mm</td><td>Sepsis</td><td>15.7 ± 3.0</td><td>12.7 ± 1.8<sup>a</sup></td><td>11.7 ± 3.6</td><td>0.042</td></tr><tr><td></td><td>Sham</td><td>16.9 ± 3.0</td><td>16.3 ± 3.6</td><td>15.2 ± 3.8</td><td>0.160</td></tr><tr><td>TVD s, mm/mm<sup>2</sup></td><td>Sepsis</td><td>29.5 ± 4.8</td><td>26.6 ± 3.9</td><td>25.9 ± 8.4</td><td>0.135</td></tr><tr><td></td><td>Sham</td><td>29.4 ± 6.3</td><td>29.1 ± 6.6</td><td>28.1 ± 7.8</td><td>0.761</td></tr><tr><td>TVD l, mm/mm<sup>2</sup></td><td>Sepsis</td><td>7.9 ± 2.0</td><td>7.4 ± 2.3</td><td>8.0 ± 1.5</td><td>0.846</td></tr><tr><td></td><td>Sham</td><td>8.6 ± 3.4</td><td>6.8 ± 1.8</td><td>8.5 ± 4.8</td><td>0.529</td></tr><tr><td>Het MFI</td><td>Sepsis</td><td>0.13 ± 0.12</td><td>0.38 ± 0.32</td><td>0.36 ± 0.31</td><td>0.113</td></tr><tr><td></td><td>Sham</td><td>0.06 ± 0.10</td><td>0.09 ± 0.09</td><td>0.10 ± 0.17</td><td>0.867</td></tr><tr><td>Jejunal mucosa</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>MFI s</td><td>Sepsis</td><td>2.89 ± 0.13</td><td>1.90 ± 0.32<sup>a</sup></td><td>2.10 ± 0.43<sup>a</sup></td><td>< 0.0001</td></tr><tr><td></td><td>Sham</td><td>3.00 ± 0.00</td><td>2.67 ± 0.14</td><td>2.64 ± 0.32</td><td>0.124</td></tr><tr><td>PPV v, %</td><td>Sepsis</td><td>95.2 ± 2.8</td><td>82.6 ± 6.4<sup>a</sup></td><td>84.3 ± 8.8<sup>a</sup></td><td>0.022</td></tr><tr><td></td><td>Sham</td><td>99.2 ± 1.4</td><td>92.0 ± 7.1</td><td>92.6 ± 1.7</td><td>0.368</td></tr><tr><td>MFI Het</td><td>Sepsis</td><td>0.11 ± 0.11</td><td>0.37 ± 0.19<sup>a</sup></td><td>0.50 ± 0.27<sup>a</sup></td><td>< 0.0001</td></tr><tr><td></td><td>Sham</td><td>0.00 ± 0.00</td><td>0.09 ± 0.01</td><td>0.10 ± 0.10</td><td>0.178</td></tr><tr><td>Rectal mucosa</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>MFI s</td><td>Sepsis</td><td>2.74 ± 0.15</td><td>1.95 ± 0.28<sup>a</sup></td><td>1.83 ± 0.19<sup>a</sup></td><td>< 0.0001</td></tr><tr><td></td><td>Sham</td><td>3.00 ± 0.00</td><td>2.92 ± 0.12</td><td>2.67 ± 0.12</td><td>0.156</td></tr><tr><td>PPV c</td><td>Sepsis</td><td>93.0 ± 1.5</td><td>78.6 ± 6.9<sup>a</sup></td><td>80.6 ± 6.3<sup>a</sup></td><td>0.018</td></tr><tr><td></td><td>Sham</td><td>97.1 ± 1.0</td><td>95.4 ± 1.6</td><td>93.1 ± 0.4</td><td>0.156</td></tr><tr><td>Het MFI</td><td>Sepsis</td><td>0.05 ± 0.08</td><td>0.36 ± 0.20<sup>a</sup></td><td>0.21 ± 0.14<sup>a</sup></td><td>0.015</td></tr><tr><td></td><td>Sham</td><td>0.00 ± 0.00</td><td>0.09 ± 0.12</td><td>0.28 ± 0.01</td><td>0.156</td></tr></table> |
d3a3cc082b4dd355856ad7ce9cd82d7616b0c9c412fef516b5fbbecc77951161.png | complex | <table><tr><td rowspan="2">Components of SPs</td><td colspan="3">Level of compliance </td></tr><tr><td>Always</td><td>Sometimes</td><td>Seldom</td></tr><tr><td>Wash hands before touching a patient</td><td>74 (18.2%)</td><td>82 (20.1%)</td><td>251 (61.7%)</td></tr><tr><td>Wash hands before clean or aseptic procedures</td><td>161 (39.6%)</td><td>144 (35.4%)</td><td>102 (25.1%)</td></tr><tr><td>Wash hands after body fluid exposure</td><td>375 (92.2%)</td><td>28 (6.8%)</td><td>4 (1%)</td></tr><tr><td>Wash hands after touching a patient</td><td>113 (27.8%)</td><td>124 (30.5%)</td><td>170 (41.8%)</td></tr><tr><td>Wash hands immediately after removal of gloves</td><td>328 (80.6%)</td><td>49 (12%)</td><td>30 (7.4%)</td></tr><tr><td>Wash hands between patient contact</td><td>79 (19.4%)</td><td>104 (25.6%)</td><td>224 (55%)</td></tr><tr><td>Wash hands after touching patient surroundings</td><td>91 (22.4%)</td><td>129 (31.7%)</td><td>187 (45.9%)</td></tr><tr><td>I provide nursing care considering all patients as potentially infectious</td><td>110 (27%)</td><td>132 (32.4%)</td><td>165 (40.5%)</td></tr><tr><td>I protect myself against body fluids of all patients regardless of their diagnosis</td><td>132 (32.4%)</td><td>151 (37.1%)</td><td>122 (30%)</td></tr><tr><td>I wear clean gloves whenever there is a possibility of exposure to any body fluids</td><td>361 (88.7%)</td><td>32 (7.9%)</td><td>14 (3.4%)</td></tr><tr><td>I change gloves between contacts with different patients</td><td>362 (88.9%)</td><td>39 (9.5%)</td><td>6 (1.5%)</td></tr><tr><td>I avoid wearing my gown out of hospital compounds</td><td>153 (37.6%)</td><td>232 (57%)</td><td>22 (5.4%)</td></tr><tr><td>I wear a waterproof apron whenever there is a possibility of body fluid splashing in my body</td><td>153 (37.6)</td><td>211 (51.8%)</td><td>43 (10.6%)</td></tr><tr><td>I wear eye goggles whenever there is a possibility of body fluid splashing in my face</td><td>88 (21.6%)</td><td>80 (19.7%)</td><td>238 (58.5%)</td></tr><tr><td>I sterilize all reusable equipment before being used on another patient</td><td>300 (73.7%)</td><td>88 (21.6%)</td><td>19 (4.7%)</td></tr><tr><td>I clean and disinfect equipment and environmental surfaces</td><td>156 (38.3%)</td><td>148 (36.4%)</td><td>103 (25.3%)</td></tr><tr><td>I segregate noninfectious wastes in black colour coded dust bin</td><td>123 (30.2%)</td><td>192 (47.2%)</td><td>92 (22.6%)</td></tr><tr><td>I segregate infectious medical wastes in yellow coloured coded dust bin</td><td>140 (34.4%)</td><td>177 (43.5%)</td><td>90 (22.1%)</td></tr><tr><td>I never bend needles with my hands</td><td>311 (76.4%)<sup><i>∗</i></sup></td><td>68 (16.7%)</td><td>28 (6.9%)</td></tr><tr><td>I avoid removing used needles from disposable syringes</td><td>221 (54.3%)</td><td>132 (32.4%)</td><td>54 (13.3%)</td></tr><tr><td>I place used sharps in puncture-resistant container at point of use</td><td>355 (87.2%)</td><td>41 (10%)</td><td>11 (2.8%)</td></tr><tr><td>I never recap needles</td><td>239 (58.7%)<sup><i>∗</i></sup></td><td>100 (24.6%)</td><td>68 (16.7%)</td></tr></table> |
78a6e04cf8cda813f45b68005e77113c362ad368184f379d2ac58b9772c11436.png | simple | <table><tr><td>Description</td><td>Yes</td><td>No</td></tr><tr><td></td><td>n = 10</td><td>n = 10</td></tr><tr><td>Separate containers for hazardous and non hazardous waste</td><td>5</td><td>5</td></tr><tr><td>Formal or informal HCW separation guideline</td><td>5</td><td>5</td></tr><tr><td>Labeling of the container</td><td>3</td><td>7</td></tr><tr><td>Personal protective equipment usage by HCW handlers</td><td>7</td><td>3</td></tr><tr><td>HCW transportation container with lid</td><td>0</td><td>10</td></tr><tr><td>Presence of interim HCW storage container</td><td>9</td><td>1</td></tr><tr><td>Treatment of infectious waste before disposing off</td><td>0</td><td>9</td></tr><tr><td>Ash remain disposal within close damping</td><td>8</td><td>2</td></tr><tr><td>Fencing the incinerator</td><td>7</td><td>3</td></tr><tr><td>Placental pit constructed with concrete</td><td>7</td><td>3</td></tr><tr><td>Focal person for HCW in Health center</td><td>10</td><td>0</td></tr><tr><td>Presence of SOP FOR HCW</td><td>6</td><td>4</td></tr><tr><td>Presence of HCW management committee</td><td>3</td><td>7</td></tr><tr><td>Registration book for any HCW injury or contamination</td><td>6</td><td>4</td></tr><tr><td>Managers concern on HCW</td><td>6</td><td>4</td></tr><tr><td>Needle stick injury in the past 12 months</td><td>8</td><td>2</td></tr><tr><td>Any risk to HCW handlers</td><td>7</td><td>3</td></tr></table> |
4e684eeda59b392f848fc6f75edda2b63a3fb451a9e5404e246af51e948e762a.png | complex | <table><tr><td>Level<sup>a</sup></td><td>Variable</td><td>n (%)</td><td>Crude PR<sup>b</sup> (95%CI)</td><td>p<sup>c</sup></td><td>Adjusted PR<sup>d</sup> (95%CI)</td><td>p<sup>c</sup></td></tr><tr><td colspan="7">Demographic and socioeconomic variables</td></tr><tr><td>1</td><td>Sex</td><td> </td><td> </td><td>0.004</td><td> </td><td>0.003</td></tr><tr><td> </td><td>Female</td><td>703 (60.3)</td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td> </td><td>Male</td><td>1,101 (65.1)</td><td>1.08 (1.02–1.14)</td><td> </td><td>1.08 (1.03–1.14)</td><td> </td></tr><tr><td>1</td><td>Age (years)</td><td> </td><td> </td><td>< 0.001</td><td> </td><td>0.021</td></tr><tr><td> </td><td>20–39</td><td>760 (67.1)</td><td>1.15 (1.06–1.24)</td><td> </td><td>1.10 (1.02–1.20)</td><td> </td></tr><tr><td> </td><td>40–59</td><td>675 (61.7)</td><td>1.05 (0.96–1.15)</td><td> </td><td>1.03 (0.94–1.12)</td><td> </td></tr><tr><td> </td><td>60 or more</td><td>369 (58.6)</td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td>1</td><td>Skin color/Race</td><td> </td><td> </td><td>0.565</td><td> </td><td>-</td></tr><tr><td> </td><td>White</td><td>1,436 (62.7)</td><td>1</td><td> </td><td>-</td><td> </td></tr><tr><td> </td><td>Black</td><td>222 (64.4)</td><td>1.02 (0.93–1.13)</td><td> </td><td>-</td><td> </td></tr><tr><td> </td><td>Other<sup>e</sup></td><td>146 (65.8)</td><td>1.05 (0.95–1.15)</td><td> </td><td>-</td><td> </td></tr><tr><td>1</td><td>Education (years)</td><td> </td><td> </td><td>0.005</td><td> </td><td>0.008</td></tr><tr><td> </td><td>0–4</td><td>284 (57.4)</td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td> </td><td>5–8</td><td>529 (66.5)</td><td>1.15 (1.06–1.26)</td><td> </td><td>1.16 (1.05–1.27)</td><td> </td></tr><tr><td> </td><td>9 or more</td><td>988 (63.3)</td><td>1.10 (1.01–1.20)</td><td> </td><td>1.13 (1.03–1.25)</td><td> </td></tr><tr><td>1</td><td colspan="2">Asset index (quintiles)</td><td> </td><td>0.058</td><td> </td><td>0.033</td></tr><tr><td> </td><td>1st (20% poorest)</td><td>371 (66.9)</td><td>1.15 (1.03–1.27)</td><td> </td><td>1.18 (1.06–1.33)</td><td> </td></tr><tr><td> </td><td>2nd</td><td>360 (66.9)</td><td>1.15 (1.03–1.28)</td><td> </td><td>1.15 (1.02–1.30)</td><td> </td></tr><tr><td> </td><td>3rd</td><td>367 (63.0)</td><td>1.08 ( 0.96–1.21)</td><td> </td><td>1.07 ( 0.95–1.21)</td><td> </td></tr><tr><td> </td><td>4th</td><td>365 (62.1)</td><td>1.06 (0.95–1.20)</td><td> </td><td>1.06 (0.94–1.19)</td><td> </td></tr><tr><td> </td><td>5th (20% wealthiest)</td><td>332 (58.3)</td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td colspan="7">Health status</td></tr><tr><td>2</td><td colspan="3">Use of drugs for chronic or eventual diseases</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>Chronic</td><td>1,005 (63.8)</td><td>1</td><td>0.590</td><td> </td><td>-</td></tr><tr><td> </td><td>Eventual</td><td>570 (36.2)</td><td>0.98 (0.91–1.05)</td><td> </td><td>-</td><td> </td></tr><tr><td>2</td><td colspan="6">Self-reported health status</td></tr><tr><td> </td><td>Excellent/Very good</td><td>555 (62.4)</td><td>1</td><td>0.071</td><td>1</td><td>0.026</td></tr><tr><td> </td><td>Good/Fair</td><td>1,157 (62.9)</td><td>1.00 (0.95–1.07)</td><td> </td><td>1.01 (0.95–1.08)</td><td> </td></tr><tr><td> </td><td>Poor</td><td>92 (72.4)</td><td>1.16 (1.02–1.32)</td><td> </td><td>1.20 (1.05–1.38)</td><td> </td></tr><tr><td colspan="7">Incorrect visual identification of similar medicines as generic drugs</td></tr><tr><td>3</td><td>No</td><td>1,325 (64.4)</td><td>1.07 (1.00–1.16)</td><td>0.052</td><td>0.98 (0.92–1.05)</td><td>0.608</td></tr><tr><td> </td><td>Yes</td><td>479 (60.0)</td><td>1</td><td> </td><td>1</td><td> </td></tr><tr><td colspan="7">Score of knowledge about generic drugs<sup>f</sup></td></tr><tr><td>3</td><td>0</td><td>14 (18.4)</td><td>1</td><td>< 0.001<sup>g</sup></td><td>1</td><td>< 0.001<sup>g</sup></td></tr><tr><td> </td><td>1</td><td>120 (34.3)</td><td>1.86 (1.14–3.03)</td><td> </td><td>2.01 (1.20–3.37)</td><td> </td></tr><tr><td> </td><td>2</td><td>514 (54.6)</td><td>2.96 (1.90–4.62)</td><td> </td><td>3.27 (2.04–5.27)</td><td> </td></tr><tr><td> </td><td>3</td><td>1,156 (77.7)</td><td>4.22 (2.70–6.58)</td><td> </td><td>4.66 (2.89–7.52)</td><td> </td></tr><tr><td> </td><td>Total</td><td>1,804 (63.2)</td><td> </td><td> </td><td> </td><td> </td></tr></table> |
f5f20aec8a684a74a1bace141e3750969e3364a1e3e0e2774bf52051b3fea4fd.png | simple | <table><tr><td></td><td><i>EPCAM</i></td><td><i>KRT8</i></td><td><i>KRT18</i></td><td><i>KRT5</i></td><td><i>KRT7</i></td><td><i>HER2</i></td><td><i>MUC1</i></td><td><i>EGFR</i></td></tr><tr><td><i>EpCAM</i></td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>KRT8</i></td><td>0.370**</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>KRT18</i></td><td>0.654**</td><td>0.760**</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>KRT5</i></td><td>-</td><td>0.335**</td><td>0.204*</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>KRT7</i></td><td>-</td><td>0.635**</td><td>0.279**</td><td>0.353**</td><td></td><td></td><td></td><td></td></tr><tr><td><i>HER2</i></td><td>0.441**</td><td>-</td><td>0.351**</td><td>-</td><td>-</td><td></td><td></td><td></td></tr><tr><td><i>MUC1</i></td><td>0.372**</td><td>–0.240*</td><td>-</td><td>-</td><td>–0.510**</td><td>0.468**</td><td></td><td></td></tr><tr><td><i>EGFR</i></td><td>-</td><td>–0.284**</td><td>-</td><td>-</td><td>–0.286**</td><td>0.314**</td><td>0.355**</td><td>1</td></tr></table> |
c8a46ea7477f86996a6b0d902eb914b554221a990f743a66d1240201f94da8a8.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2">Mean baseline level [mg/dL (mmol/L)]</td><td colspan="3">Difference between treatment groups </td></tr><tr><td></td><td></td><td>End-of-study</td></tr><tr><td>PROACTIVE [40]</td><td colspan="4"></td></tr><tr><td>HbA1c</td><td>7.9%</td><td></td><td>−6%</td><td></td></tr><tr><td>LDL</td><td>112 (2.9)</td><td></td><td>2%</td><td></td></tr><tr><td>HDL</td><td>42 (1.1)</td><td></td><td>9%</td><td></td></tr><tr><td>Triglycerides</td><td>159 (1.8)</td><td></td><td>−13%</td><td></td></tr><tr><td>DREAM [50]</td><td colspan="4">HbA1c and lipids not reported</td></tr><tr><td>ADOPT [49]</td><td>Median baseline level [mg/dL (mmol/L)]</td><td>Rosiglitazone versus Metformin</td><td></td><td>Rosiglitazone versus Glyburide</td></tr><tr><td>Glycated Hgb</td><td>7.4%</td><td>−2%</td><td></td><td>−6%</td></tr><tr><td>Total cholesterol</td><td>204 (5.28)</td><td>NR</td><td></td><td>NR</td></tr><tr><td>LDL</td><td>120 (3.11)</td><td>8%</td><td></td><td>5%</td></tr><tr><td>HDL</td><td>47 (1.22)</td><td>3%</td><td></td><td>6%</td></tr><tr><td>Triglycerides</td><td>161 (1.82)</td><td>−2%</td><td></td><td>−5%</td></tr><tr><td>RECORD [51, 77]</td><td>Mean baseline level [mg/dL (mmol/L)]</td><td colspan="3"></td></tr><tr><td>Glycated Hgb</td><td>7.9%</td><td></td><td>NR</td><td></td></tr><tr><td>LDL</td><td>127 (3.29)</td><td></td><td>NR</td><td></td></tr><tr><td>HDL</td><td>46 (1.20)</td><td></td><td>NR</td><td></td></tr><tr><td>Triglycerides</td><td>202 (2.28)</td><td></td><td>NR</td><td></td></tr></table> |
2b9fc87abe26c9e2205f57098e7df465c12ee61dca7a08cfa832661710c38bc4.png | complex | <table><tr><td rowspan="2">Themes</td><td rowspan="2">Statement</td><td rowspan="2">Agree/ disagree with the statement</td><td colspan="2">Univariate estimate</td><td colspan="2">Multivariate model</td></tr><tr><td>OR</td><td>95 % Cl</td><td>OR</td><td>95 % Cl</td></tr><tr><td rowspan="3">Physical and mental health</td><td rowspan="3">I feel physically worn out.</td><td>Disagree</td><td>Ref.</td><td></td><td>Ref.</td><td></td></tr><tr><td>Partly agree</td><td>2.3</td><td>1.7–2.9</td><td>1.7</td><td>1.3–2.3</td></tr><tr><td>Agree</td><td>3.6</td><td>2.7–4.7</td><td>2.3</td><td>1.7–3.2</td></tr><tr><td rowspan="3">Physical work environment</td><td rowspan="3">I can usually manage physical working demands of my daily work.</td><td>Agree</td><td>Ref.</td><td></td><td>Ref.</td><td></td></tr><tr><td>Partly agree</td><td>2.1</td><td>1.9–4.6</td><td>2.3</td><td>1.5–3.7</td></tr><tr><td>Disagree</td><td>3.1</td><td>2.2–4.4</td><td>2.4</td><td>1.7–3.5</td></tr><tr><td rowspan="6">Working pace and working time</td><td rowspan="3">The pace of work in my daily work is too rapid.</td><td>Disagree</td><td>Ref.</td><td></td><td>Ref.</td><td></td></tr><tr><td>Partly agree</td><td>0.8</td><td>0.7–1.1</td><td>0.6</td><td>0.5–0.8</td></tr><tr><td>Agree</td><td>1.3</td><td>1.0–1.6</td><td>0.8</td><td>0.7–1.1</td></tr><tr><td rowspan="3">I feel that I get enough rest/relaxation between my working days.</td><td>Agree</td><td>Ref.</td><td></td><td>Ref.</td><td></td></tr><tr><td>Partly agree</td><td>2.4</td><td>1.9–3.0</td><td>1.7</td><td>1.3–2.2</td></tr><tr><td>Disagree</td><td>2.1</td><td>1.7–2.7</td><td>1.8</td><td>1.4–2.4</td></tr></table> |
8621fa63b29c02efea427bdb210e3d896a8ba07299052095ee6eb94d2218aca5.png | complex | <table><tr><td rowspan="3">Aspect of treatment</td><td rowspan="2">No preference</td><td colspan="2">Expressed a preference</td></tr><tr><td>Given adequate choice</td><td>Not given adequate choice</td></tr><tr><td>n % (95 % CI)</td><td>n % (95 % CI)</td><td>n % (95 % CI)</td></tr><tr><td>Choice of venue</td><td>6855 47.7 (46.9-48.5)</td><td>5282 36.7 (35.9-37.5)</td><td>2242 15.6 (15.0-16.2)</td></tr><tr><td>Time of day of appointments</td><td>3950 27.4 (26.7-28.1)</td><td>8639 59.9 (59.1-60.7)</td><td>1837 12.7 (12.2-13.2)</td></tr><tr><td>Gender of therapist</td><td>10027 70.2 (69.5-71.0)</td><td>1769 11.9 (11.4-12.4)</td><td>2483 17.9 (16.8-18.0)</td></tr><tr><td>Language/ interpreter</td><td>11743 92.0 (91.5-92.5)</td><td>643 4.9 (4.5-5.3)</td><td>382 3.1 (2.8-3.4)</td></tr><tr><td>Type of treatment</td><td>6844 48.0 (47.2-48.8)</td><td>4981 34.9 (34.1-35.7)</td><td>2441 17.1 (16.5-17.7)</td></tr></table> |
ff0f0264075a6e0e1ba294a2fed7f71743da9cf5d6d8ad63bfaff023c46e808d.png | complex | <table><tr><td></td><td colspan="5">100% of training data</td><td colspan="5">50% of training data</td></tr><tr><td>Dimension</td><td>D5</td><td>D6</td><td>D7</td><td>D8</td><td>D9</td><td>D4</td><td>D5</td><td>D6</td><td>D7</td><td>D8</td></tr><tr><td>Classification accuracy</td><td>91.28%</td><td>91.52%</td><td>91.79%</td><td>90.01%</td><td>90.54%</td><td>89.50%</td><td>88.43%</td><td>88.60%</td><td>88.68%</td><td>87.60%</td></tr><tr><td>Training iterations</td><td>553</td><td>97</td><td>167</td><td>33</td><td>41</td><td>141</td><td>68</td><td>44</td><td>27</td><td>11</td></tr><tr><td>Learning parameter</td><td>0.45</td><td>0.42</td><td>0.54</td><td>0.75</td><td>0.63</td><td>0.51</td><td>0.54</td><td>0.72</td><td>0.72</td><td>0.84</td></tr></table> |
e16397211fcd18c02f5cb8650438e5c75adcd015eabc4cc5ac7937d3288ce308.png | simple | <table><tr><td>Amplicon</td><td>Age limit</td><td>Values considered</td><td><i>p_values</i></td></tr><tr><td><i>IGF2_shore</i></td><td>60</td><td>Correlation</td><td>0.00047***</td></tr><tr><td><i>IGF2AS</i></td><td>60</td><td>Correlation</td><td>0.022*</td></tr><tr><td><i>H19</i></td><td>60</td><td>Correlation</td><td>0.27</td></tr><tr><td><i>IGF2_island</i></td><td>60</td><td>Correlation</td><td>0.77</td></tr><tr><td><i>IGF2_shore</i></td><td>60</td><td>Euclidean distance</td><td>0.0075**</td></tr><tr><td><i>IGF2AS</i></td><td>60</td><td>Euclidean distance</td><td>0.023*</td></tr><tr><td><i>H19</i></td><td>60</td><td>Euclidean distance</td><td>0.48</td></tr><tr><td><i>IGF2_island</i></td><td>60</td><td>Euclidean distance</td><td>0.57</td></tr></table> |
d584f1622966cb19e65a73b31368a0e3bb7f4f87ebeee4f618913ed71e9bace6.png | simple | <table><tr><td>Crop</td><td>Cultural practice</td><td>Seeding rate (million seeds ha<sup>−1</sup>)</td><td>N fertilization at planting</td><td>N fertilization rate(kg N ha<sup>−1</sup>)</td><td>Planting date</td><td>Stubble height (cm)</td></tr><tr><td>Spring wheat</td><td>Traditional</td><td>2.23</td><td>Broadcast</td><td>101</td><td>Early April</td><td>20</td></tr><tr><td></td><td>Improved</td><td>2.98</td><td>Banded</td><td>101</td><td>Early May</td><td>30</td></tr><tr><td>Pea</td><td>Traditional</td><td>0.60</td><td>Broadcast</td><td>6</td><td>Early April</td><td>5</td></tr><tr><td></td><td>Improved</td><td>0.92</td><td>Banded</td><td>6</td><td>Early April</td><td>5</td></tr><tr><td>Barley hay</td><td>Traditional</td><td>2.23</td><td>Broadcast</td><td>67</td><td>Late April</td><td>5</td></tr><tr><td></td><td>Improved</td><td>2.98</td><td>Banded</td><td>67</td><td>Late April</td><td>5</td></tr><tr><td>Corn</td><td>Traditional</td><td>0.04</td><td>Broadcast</td><td>78</td><td>Early May</td><td>5</td></tr><tr><td></td><td>Improved</td><td>0.05</td><td>Broadcast</td><td>78</td><td>Early May</td><td>5</td></tr></table> |
820d993d9469d1e96af65a258f24ebaebcac988fadacb46b4d519a2a5178a33b.png | simple | <table><tr><td>Gene</td><td>Exon vs</td><td>Tag-seq vs</td><td>Exon vs</td></tr><tr><td> </td><td>RT-qPCR</td><td>RT-qPCR</td><td>tag-seq</td></tr><tr><td>CD74</td><td>0.964</td><td>0.964</td><td>0.927</td></tr><tr><td>HLA-DRA</td><td>1.000</td><td>0.952</td><td>0.952</td></tr><tr><td>BCL6</td><td>0.976</td><td>0.873</td><td>0.846</td></tr></table> |
ed23e8d0a7159d3bf2957d5545c8b9b8f068c5d38686289b15eed2d6715a39c0.png | simple | <table><tr><td>Hypothesis</td><td>Total cost</td><td>Cost difference<sup><i>a</i></sup></td><td>RMSD</td><td>Correlation</td><td>Features</td></tr><tr><td>Hypo1</td><td>106.849</td><td>98.098 </td><td>0.53586</td><td>0.963930</td><td> HBA, HBA, HY, RA</td></tr><tr><td>Hypo2</td><td>110.479</td><td>94.468 </td><td>0.58484</td><td>0.957944</td><td> HBA, HBA, HY</td></tr><tr><td>Hypo3</td><td>111.652</td><td>93.295 </td><td>0.59607</td><td>0.952531</td><td> HBA, HBA, HBA</td></tr><tr><td>Hypo4</td><td>112.733</td><td>92.214 </td><td>0.63861</td><td>0.949526</td><td> HBD, HY, HY</td></tr><tr><td>Hypo5</td><td>115.391</td><td>89.556 </td><td>0.66088</td><td>0.946132</td><td> HBA, HBA, HBA</td></tr><tr><td>Hypo6</td><td>116.238</td><td>88.709 </td><td>0.69439</td><td>0.938954</td><td> HBA, HBA, HBA</td></tr><tr><td>Hypo7</td><td>117.641</td><td>87.306 </td><td>0.72386</td><td>0.931788</td><td> HBA, HBD, HY</td></tr><tr><td>Hypo8</td><td>118.967</td><td>85.980 </td><td>0.78047</td><td>0.929203</td><td> HBA, HBD, HY</td></tr><tr><td>Hypo9</td><td>119.145</td><td>85.802 </td><td>0.85013</td><td>0.924316</td><td> HBD, HY, HY</td></tr><tr><td>Hypo10</td><td>120.562</td><td>84.385 </td><td>0.89086</td><td>0.917282</td><td> HBA, HBA, HY</td></tr></table> |
ce451ee275baf526855e39a15245a50018dad9976e55fe5ebf4f75d003107e8a.png | simple | <table><tr><td></td><td>Study sample (<i>n</i>=308)</td><td>Weekend all children (<i>n</i>=284)</td><td>Weekday non-daycare children (<i>n</i>=121)</td><td>Weekday daycare children (<i>n</i>=202)</td></tr><tr><td>Age [months, mean (SD)]</td><td>41.7 (10.3)</td><td>41.6 (10.0)</td><td>41.3 (11.3)</td><td>41.9 (9.6)</td></tr><tr><td>Sex (% girls)</td><td>48.4</td><td>48.2</td><td>48.8</td><td>45.5</td></tr><tr><td>Weight [kg, mean (SD)]</td><td>16.1 (3.0)</td><td>16.1 (3.0)</td><td>15.9 (2.7)</td><td>16.3 (3.2)</td></tr><tr><td>Height [cm, mean (SD)]</td><td>98.8 (7.8)</td><td>98.8 (7.7)</td><td>98.8 (8.0)</td><td>99.0 (7.8)</td></tr><tr><td>BMI [kg/m<sup>2</sup>, mean (SD)]</td><td>16.3 (1.5)</td><td>16.4 (1.5)</td><td>16.2 (1.4)</td><td>16.5 (1.5)</td></tr><tr><td>BMI percentile [mean (SD)]</td><td>60.7 (28.2)</td><td>60.8 (28.4)</td><td>58.8 (29.4)</td><td>62.8 (26.8)</td></tr><tr><td>Hispanic (%)</td><td>5.8</td><td>6.0</td><td>3.3</td><td>7.4</td></tr><tr><td>Race (%)</td><td></td><td></td><td></td><td></td></tr><tr><td> African-American</td><td>37.7</td><td>37.3</td><td>38.0</td><td>38.6</td></tr><tr><td> Caucasian</td><td>50.7</td><td>51.4</td><td>50.4</td><td>50.5</td></tr><tr><td> Others/missing</td><td>11.7</td><td>11.3</td><td>11.6</td><td>10.9</td></tr></table> |
e78c800b2b2d6ab6dfc9331c728f85fd25748ab52b838e50dc7aff150055beab.png | complex | <table><tr><td colspan="2">Protein profiling using LPITM FlowCells and LC-MS/MS</td><td colspan="2">Hybridoma-based phenotypic antibody screening</td><td colspan="2">Phage display-based phenotypic antibody screening</td></tr><tr><td>Advantages</td><td>Disadvantages</td><td>Advantages</td><td>Disadvantages</td><td>Advantages</td><td>Disadvantages</td></tr><tr><td>Direct comparison with normal matched tissue can be performed</td><td>Extremely reliant on quality of membrane preparation and extraction of membrane proteins</td><td>Screening antibodies can assign a potential mechanism of action</td><td>High cell requirement</td><td>Reduced cell requirement compared to hybridoma approach</td><td>Isolation of relatively low affinity antibodies and poor target identification success rate- requirement for complementary techniques for success of target identification</td></tr><tr><td>Sample fractionation possible and total survey of the membranome</td><td>Reliant on database annotations</td><td>Isolation of high affinity antibodies</td><td>Dominance of single targets and antibodies</td><td>Ability to perform initial screen against multiple cell types with relative ease</td><td> </td></tr><tr><td> </td><td>No function or mechanism of action associated with antigens identified</td><td>Functional in phenotypic screens</td><td>No ability to deselect against abundant antigens or comparator cell types</td><td>Screening can assign a potential mechanism of action</td><td> </td></tr><tr><td> </td><td> </td><td>High target identification success rate</td><td> </td><td>Ability to avoid dominance – can deselect against abundant antigens and comparator cell types</td><td> </td></tr><tr><td> </td><td> </td><td>Isolation of antibodies that can be used for target validation or as a therapeutic candidates</td><td> </td><td>Isolation of antibodies that can be used for target validation</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>Potential to identify target and therapeutic candidate</td><td> </td></tr></table> |
536d29638cee31e538d3803747ae1aa4342d4beeea61ceeda89f1f5df9bbc71d.png | simple | <table><tr><td></td><td>High confidence only</td><td>High or low confidence</td><td>HECTARa</td></tr><tr><td>Sensitivity</td><td>0.80</td><td>0.93</td><td>0.71</td></tr><tr><td>Specificity</td><td>0.99</td><td>0.82</td><td>0.94</td></tr><tr><td>MCC</td><td>0.82</td><td>0.74</td><td>0.67</td></tr></table> |
5a407fd8a6b6bc97b8af0ce7a83a0482f5be5bcde5f46fcdf146881473be32f0.png | simple | <table><tr><td> </td><td>PHC1</td><td>PHC2</td><td>PHC3</td><td>PHC4</td><td>PHC5</td><td>PHC6</td><td>PHC7</td><td>PHC8</td><td>PHC9</td><td>PHC10</td><td>PHC11</td><td>PHC12</td><td>PHC13</td></tr><tr><td>Efficiency indices</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Expected costs/patient, €</td><td>733.65</td><td>752.71</td><td>728.61</td><td>686.39</td><td>707.07</td><td>691.07</td><td>721.16</td><td>757.56</td><td>695.46</td><td>637.15</td><td>711.20</td><td>638.55</td><td>664.07</td></tr><tr><td>Observed costs/patient, €</td><td>775.79</td><td>600.87</td><td>752.10</td><td>772.50</td><td>807.85</td><td>693.66</td><td>694.88</td><td>757.02</td><td>693.06</td><td>678.34</td><td>666.05</td><td>648.02</td><td>527.16</td></tr><tr><td><i>Cost efficiency index</i></td><td>1.06</td><td>0.80</td><td>1.03</td><td>1.13</td><td>1.14</td><td>1.00</td><td>0.96</td><td>1.00</td><td>1.00</td><td>1.06</td><td>0.94</td><td>1.01</td><td>0.79</td></tr><tr><td>Number expected episodes/patient</td><td>4.73</td><td>4.80</td><td>4.93</td><td>4.57</td><td>4.66</td><td>4.59</td><td>4.46</td><td>4.61</td><td>4.56</td><td>3.98</td><td>4.46</td><td>4.23</td><td>4.49</td></tr><tr><td>Number observed episodes/patient</td><td>4.61</td><td>4.88</td><td>5.09</td><td>4.59</td><td>4.93</td><td>4.72</td><td>4.42</td><td>4.94</td><td>4.31</td><td>3.76</td><td>4.30</td><td>4.14</td><td>4.60</td></tr><tr><td><i>Episodes efficiency index</i></td><td>0.98</td><td>1.02</td><td>1.03</td><td>1.00</td><td>1.06</td><td>1.03</td><td>0.99</td><td>1.07</td><td>0.94</td><td>0.95</td><td>0.96</td><td>0.98</td><td>1.02</td></tr><tr><td>Number expected visits/patient</td><td>8.17</td><td>8.33</td><td>8.49</td><td>7.85</td><td>8.02</td><td>7.90</td><td>7.80</td><td>8.09</td><td>7.87</td><td>6.93</td><td>7.76</td><td>7.29</td><td>7.71</td></tr><tr><td>Number observed visits/patient</td><td>8.93</td><td>8.56</td><td>9.04</td><td>9.05</td><td>9.87</td><td>9.31</td><td>7.17</td><td>7.90</td><td>7.94</td><td>5.40</td><td>6.39</td><td>6.85</td><td>8.72</td></tr><tr><td><i>Visits efficiency index</i></td><td>1.09</td><td>1.03</td><td>1.07</td><td>1.15</td><td>1.23</td><td>1.18</td><td>0.92</td><td>0.98</td><td>1.01</td><td>0.89</td><td>0.99</td><td>0.93</td><td>1.13</td></tr><tr><td>Risk index</td><td>1.05</td><td>1.07</td><td>1.09</td><td>1.00</td><td>1.03</td><td>1.01</td><td>1.00</td><td>1.03</td><td>1.01</td><td>0.89</td><td>0.99</td><td>0.93</td><td>0.99</td></tr><tr><td>Effectiveness index</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>Synthetic index</i></td><td>50.67</td><td>59.19</td><td>54.93</td><td>55.53</td><td>56.62</td><td>56.72</td><td>46.18</td><td>55.56</td><td>50.09</td><td>53.25</td><td>59.42</td><td>56.57</td><td>64.09</td></tr></table> |
90f98c378a08397b499c64495102ef2f9ad4b1f128b8f2d5fe2232925e3349ba.png | simple | <table><tr><td>Probe sets</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>1</td><td>-</td><td><i>0.955</i></td><td>0962</td><td>0.942</td></tr><tr><td>2</td><td>-</td><td>-</td><td>0.946</td><td>0.927</td></tr><tr><td>3</td><td>-</td><td>-</td><td>-</td><td><i>0.983</i></td></tr><tr><td>4</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table> |
c188abe23ab4d6c3677d14867fb617a71ddbb11223500ad907e7ae35c6a14bbd.png | simple | <table><tr><td>Criterion</td><td>Inclusion</td><td>Exclusion</td></tr><tr><td>Time period</td><td>January 1990 and February 2012</td><td>Any study outside these dates</td></tr><tr><td>Language</td><td>English</td><td>Non-English</td></tr><tr><td>Type of article</td><td>Original research article published in a peer reviewed journal</td><td>Any article that was not original research and/or unpublished</td></tr><tr><td>Study focus</td><td>Community participation</td><td>No reference to community participation, i.e. individual consultation between health professional and client</td></tr><tr><td>Health service</td><td>Rural</td><td>No reference to rural health care services</td></tr><tr><td>Geographical place of study</td><td>International, developed countries</td><td>Developing countries</td></tr><tr><td>Population and sample</td><td>Mixed population sociodemographic</td><td>Reference to only a single sociodemographic factor i.e. gender, cultural group</td></tr></table> |
8dee6504b00ea7d83fe36e677d01dcb88e36e22a0a88b547ef2a8fb0f33444f5.png | simple | <table><tr><td>Name</td><td>Microalgae</td><td>Specificities</td></tr><tr><td>f/2 medium [148,149] </td><td>Coastal microalgae, diatoms</td><td>Enriched medium</td></tr><tr><td>K medium [146,150]</td><td>Oceanic microalgae</td><td>Trace metals</td></tr><tr><td>Pro99 [151]</td><td><i>Prochlorococcus</i> spp. and some picoeukaryotes</td><td>High ammonia concentrations, No vitamin requirement</td></tr><tr><td>MNK medium [152]</td><td>Oceanic coccolithophores</td><td>Enriched medium</td></tr></table> |
982ce80b912bed4c00cc7af18ff7caf28295235ab5b4849b8965b31a87d5bf4d.png | simple | <table><tr><td>Variables</td><td>Standardized coefficient (β)</td><td>P</td><td>Adjusted R<sup>2</sup></td></tr><tr><td>Men</td><td> </td><td> </td><td> </td></tr><tr><td>Lipoprotein(a), mg/dL</td><td>0.190</td><td>< 0.001</td><td>0.039</td></tr><tr><td><i>LDLR</i> g.3131C > T, yes/no</td><td>-0.179</td><td>< 0.001</td><td>0.070</td></tr><tr><td>Age, years</td><td>0.177</td><td>< 0.001</td><td>0.100</td></tr><tr><td>All study subjects</td><td> </td><td> </td><td> </td></tr><tr><td>Age, years</td><td>0.236</td><td>< 0.001</td><td>0.054</td></tr><tr><td>Lipoprotein(a), mg/dL</td><td>0.172</td><td>< 0.001</td><td>0.083</td></tr><tr><td><i>LDLR</i> g.3131C > T, yes/no</td><td>-0.146</td><td>< 0.001</td><td>0.103</td></tr></table> |
79f8562511ac80ef4f8a456e36aea45972e9afc4417b26dfa8e6afbfdbe76eb1.png | complex | <table><tr><td></td><td>Delta-<i>RF</i></td><td>Delta-<i>RF</i></td><td colspan="3"></td></tr><tr><td>Data</td><td>RAxML</td><td>FastTree-2</td><td colspan="3"></td></tr><tr><td>Indelible M2</td><td>0.021</td><td>0.014</td><td colspan="3"></td></tr><tr><td>RNAsim</td><td>0.677</td><td>0.660</td><td colspan="3"></td></tr><tr><td>Rose L1</td><td>0.036</td><td>0.054</td><td colspan="3"></td></tr><tr><td>Rose M1</td><td>0.136</td><td>0.030</td><td colspan="3"></td></tr><tr><td>Rose S1</td><td>0.010</td><td>0.007</td><td colspan="3"></td></tr></table> |
823dde2c51fb51482dfde4e7538d06c209bbfa99ed9aa462fe5bf50ae3a13ebd.png | complex | <table><tr><td></td><td colspan="2">Cluster 1 (<i>n </i>= 94, 17 families)</td><td colspan="2">Cluster 2 (<i>n </i>= 50, 12 families)</td><td colspan="2">Cluster 3 (<i>n </i>= 115, 25 families)</td></tr><tr><td></td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td></tr><tr><td>Sex (F/M)</td><td>48/46</td><td></td><td>24/26</td><td></td><td>50/65</td><td></td></tr><tr><td>Age</td><td>48.8</td><td>9.4</td><td>52.3</td><td>12.6</td><td>48.5</td><td>11.3</td></tr><tr><td>Education years</td><td>11.3<sup><i>a</i>,<i>b</i></sup></td><td>3.0</td><td>9.3</td><td>2.4</td><td>9.9</td><td>2.3</td></tr></table> |
f498ed64ff30cf7725af9d77834b32984f9589d942354ba55aa2fe3c58bfb62b.png | simple | <table><tr><td></td><td>Total</td><td>Condylar alterations</td><td>No condylar alterations</td><td><i>P</i></td></tr><tr><td>Total, n (% girls)</td><td>158 (73)</td><td>68 (78)</td><td>90 (70)</td><td><i>0.26</i></td></tr><tr><td>Duration, yrs, median (25/75th percentile)</td><td>2.5 (0.5/3.9)</td><td>2.8 (0.6/4.7)</td><td>2.3 (0.4/3.2)</td><td><i>0.21</i></td></tr><tr><td>“EU 1 any time”, n (%)</td><td>15 (9)</td><td>9 (13)</td><td>6 (7)</td><td><i>0.11</i></td></tr><tr><td>Number of “active disease periods”, median (25/75th percentile)</td><td>2.49 (1.0/3.0)</td><td>2.87 (1.0/4.0)</td><td>2.28 (1.0/3.0)</td><td><i>0.06</i></td></tr><tr><td>“Potent medication” any time, n (%)</td><td>75 (47)</td><td>41 (60)</td><td>34 (38)</td><td><i>0.01</i></td></tr><tr><td>Number of “medication periods”, median (25/75th percentile)</td><td>2.69 (1.0/4.0)</td><td>3.06 (1.0/4.0)</td><td>2.41 (1.0/3.0)</td><td><i>0.02</i></td></tr><tr><td>Both “MTX and TNF-alpha inhibitor” any time, n (%)</td><td>43 (27)</td><td>23 (34)</td><td>20 (22)</td><td><i>0.09</i></td></tr><tr><td>“EU 1 or potent medication” any time, n (%)</td><td>82 (52)</td><td>43 (63)</td><td>39 (43)</td><td><i>0.01</i></td></tr><tr><td>“EU 1 and potent medication” any time, n (%)</td><td>15 (10)</td><td>11 (16)</td><td>4 (4)</td><td><i>0.02</i></td></tr></table> |
f39e2ecde02539ab697ca01fee100d4588b5428e364d84a09f3130149dafb79f.png | complex | <table><tr><td>Spot No.</td><td>Protein name</td><td colspan="2">Expression volume<sup>*</sup></td><td><i>p</i>-value</td></tr><tr><td> </td><td> </td><td>Healthy</td><td>Ascites</td><td> </td></tr><tr><td>1</td><td>similar to keratin 10 isoform 2</td><td>0.141</td><td>0.150</td><td>0.081</td></tr><tr><td>2</td><td>chain A, crystal structures of chicken annexin v in complex with Ca<sup>2+</sup></td><td>0.042</td><td>0.057</td><td>0.076</td></tr><tr><td>3</td><td>similar to proteasome subunit alpha type 3</td><td>0.053</td><td>0.063</td><td>0.120</td></tr><tr><td>4</td><td>keratin, type II cytoskeletal 1</td><td>0.085</td><td>0.077</td><td>0.041</td></tr><tr><td>5</td><td>N-ethylmaleimide-sensitive factor</td><td>0.051</td><td>0.071</td><td>0.045</td></tr><tr><td>6</td><td>ring finger protein 170, isoform CRA_b</td><td>0.088</td><td>0.049</td><td>0.004</td></tr><tr><td>7</td><td>Rho GDP dissociation inhibitor (GDI) alpha</td><td>0.120</td><td>0.156</td><td>0.002</td></tr><tr><td>8</td><td>dihydropteridinereductase</td><td>0.122</td><td>0.128</td><td>0.053</td></tr><tr><td>9</td><td>ryncolin-1</td><td>0.080</td><td>0.121</td><td>0.004</td></tr><tr><td>10</td><td>translationally-controlled tumor protein homolog</td><td>0.131</td><td>0.160</td><td>0.014</td></tr><tr><td>11</td><td>similar to natural killer cell enhancing factor isoform 4</td><td>0.126</td><td>0.074</td><td>0.027</td></tr><tr><td>12</td><td>unnamed protein product</td><td>0.214</td><td>0.228</td><td>0.109</td></tr><tr><td>13</td><td>neutrophil cytosol factor 2 variant</td><td>0.129</td><td>0.150</td><td>0.216</td></tr><tr><td>14</td><td>glia maturation factor beta</td><td>0.046</td><td>0.046</td><td>0.039</td></tr><tr><td>15</td><td>keratin, type II cytoskeletal 1</td><td>0.193</td><td>0.387</td><td>0.177</td></tr><tr><td>16</td><td>serpin B3</td><td>0.171</td><td>0.231</td><td>0.057</td></tr><tr><td>17</td><td>chain A, the structure of chicken mitochondrial PEPCK.</td><td>0.084</td><td>0.130</td><td>0.006</td></tr><tr><td>18</td><td>hypothetical protein LOC100446659</td><td>0.432</td><td>0.894</td><td>0.114</td></tr></table> |
044fad67e0464765a00e190cdaf91804fdd8cbed5854f5120fd299e15802b746.png | complex | <table><tr><td></td><td colspan="5">Level of agreement</td><td></td></tr><tr><td></td><td>Agree strongly</td><td>Agree a little</td><td>Neither agree nor disagree</td><td>Disagree a little</td><td>Disagree strongly</td><td>Mean value</td></tr><tr><td></td><td>(5)</td><td>(4)</td><td>(3)</td><td>(2)</td><td>(1)</td><td></td></tr><tr><td>Tolerance of risk and uncertainty – all patients out-of-hours (OOH)*</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>1. When it comes to OOH-medicine I’m quite cautious</td><td>13</td><td>51</td><td>12</td><td>22</td><td>2</td><td>3.5</td></tr><tr><td>2. As an OOH-physician you think that you can deal with most things most of the time</td><td>18</td><td>63</td><td>6</td><td>11</td><td>2</td><td>3.8</td></tr><tr><td>3. I think my risk assessment is reasonably good, and I’m reasonably safe</td><td>27</td><td>67</td><td>4</td><td>2</td><td>0</td><td>4.2</td></tr><tr><td>4. All OOH-physicians take risks; it’s risk assessment OOH all the time (n = 99)</td><td>17</td><td>29</td><td>21</td><td>31</td><td>1</td><td>3.3</td></tr><tr><td>5. OOH-physicians are good at living with uncertainty and risk</td><td>9</td><td>48</td><td>31</td><td>11</td><td>1</td><td>3.5</td></tr><tr><td>6. I don’t worry about my decisions after I’ve made them</td><td>8</td><td>42</td><td>4</td><td>41</td><td>5</td><td>3.1</td></tr><tr><td>7. I sometimes go back and check on the patient’s outcome after a shift has finished</td><td>10</td><td>41</td><td>12</td><td>26</td><td>11</td><td>3.1</td></tr></table> |
bfe935bc5a8b8551a0a00910188ed68a298b71f23f3cca594c899b0c7094e40c.png | simple | <table><tr><td></td><td>Experiment group (<i>n</i> = 36)</td><td>Control group (<i>n</i> = 33)</td><td><i>P</i> values</td></tr><tr><td>Female/Male</td><td>22/14</td><td>19/14</td><td>0.821</td></tr><tr><td>Age (years)</td><td>36.36 ± 14.75</td><td>38.73 ± 12.18</td><td>0.945</td></tr><tr><td>BMI</td><td>23.92 ± 14.45</td><td>23.62 ± 13.25</td><td>0.921</td></tr><tr><td>Side: Left/Right</td><td>23/12</td><td>18/15</td><td>0.644</td></tr><tr><td>Cause: Strain/traffic injury (case)</td><td>20/16</td><td>18/15</td><td>0.876</td></tr><tr><td>Incidence of concomitant posterior dislocation of talus (%)</td><td>55.56% (20/36)</td><td>51.52% (17/33)</td><td>0.932</td></tr><tr><td>Posterior ankle fracture block accounts for the area of the articular surface (%)</td><td>42.16 ± 18.42</td><td>38.23 ± 20.73</td><td>0.522</td></tr><tr><td>Lauge-hansen system: supination-eversion type/ supination-external rotation type (case)</td><td>21/15</td><td>18/15</td><td>0.822</td></tr><tr><td>Danis-Weber system: B type/C type (case)</td><td>23/13</td><td>19/14</td><td>0.912</td></tr><tr><td>Time from injury to surgery (day)</td><td>7.62 ± 2.37</td><td>6.87 ± 3.18</td><td>0.774</td></tr><tr><td>Follow-up time (month)</td><td>17.69 ± 12.26</td><td>15.94 ± 10.66</td><td>0.681</td></tr></table> |
b798125af5dee8854d95e0c03967375234a988893fd0a52ae2b5d2c39a36626f.png | complex | <table><tr><td>Author; year</td><td>Specimen: lesser MTPJs</td><td>Age;Gender</td><td>PP dimensions</td></tr><tr><td>Johnston, Smith [15]</td><td>20 FF of 5 cadavers</td><td>NR</td><td>L: mean 19 mm;2<sup>nd</sup> MTPJ 16–23 mmW: mean 11 mm proximally, to 9 mm distally;2<sup>nd</sup> MTPJ 8–13 mmT: 2–5 mm</td></tr><tr><td>Deland, Lee [8]</td><td>30 FF of 6 cadavers</td><td>Median age 64 y;gender NR</td><td>L: mean 18.8 mm2<sup>nd</sup>, 3<sup>rd</sup> MTPJ: 20 mm mean4<sup>th</sup>, 5<sup>th</sup> MTPJ: 17 mm meanW: NRT: 2–4 mm</td></tr><tr><td>Deland and Sung [17]</td><td>8 FF of 1 cadaver (†, ‡)</td><td>68 y, F</td><td>NR</td></tr><tr><td rowspan="2">Gregg, Marks [14]</td><td>8 FF of 1 cadaver</td><td>19 y, F</td><td rowspan="2">Referring to Johnston et al.</td></tr><tr><td>8 soft-embalmed of 3 cadavers</td><td>Age NR;2x M, 1x F</td></tr><tr><td>Coughlin, Schutt [22]</td><td>16 FF cadavericspecimens, ‡</td><td>Age NR;10x F2x M4x NR</td><td>NR</td></tr></table> |
e448cf83cf9634a630585909c43947f0a0fb81da18a97dcdf8e1354f7b7b5fda.png | complex | <table><tr><td></td><td colspan="2">Median survival (days)</td><td rowspan="3"><i>P</i>-value</td><td rowspan="3">HR (95% CI)</td></tr><tr><td></td><td>“Good” (<i>n</i> = 25)</td><td>“Poor” (<i>n</i> = 7)</td></tr><tr><td>PFS</td><td>62</td><td>48</td><td>0.0011</td><td>0.18 (0.06–0.57)</td></tr><tr><td>OS</td><td>128</td><td>47</td><td>0.0078</td><td>0.31 (0.13–0.77)</td></tr></table> |
493118b90e2d44ab2485507d0e84b86c095f0bc9bbd3055539f9ec10400ab77d.png | simple | <table><tr><td>Accession</td><td>Predicted protein function</td><td>Signal peptides</td><td>Family</td><td>Ratio AX/A</td><td><i>P</i>-value</td><td>Ratio AX/X</td><td><i>P</i>-value</td></tr><tr><td>525580909</td><td>Swollenin</td><td>Y</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td></tr><tr><td>525584244</td><td>Cellobiohydrolase</td><td>Y</td><td>GH7</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td></tr><tr><td>525581542</td><td>Beta-glucosidase</td><td>Y</td><td>GH3</td><td>1.05</td><td>9.90E-20</td><td>82.65</td><td>2.29E-06</td></tr><tr><td>525581794</td><td>Beta-1,3-1,4-glucanase</td><td>Y</td><td>GH16</td><td>4.46</td><td>2.95E-08</td><td>0.65</td><td>0.9994203</td></tr><tr><td>525584431</td><td>Cellulose monooxygenase</td><td>Y</td><td>GH61</td><td>2.13</td><td>7.40E-07</td><td>1.14</td><td>0.8792061</td></tr><tr><td>525585914</td><td>Cellobiohydrolase</td><td>Y</td><td>GH6</td><td>7.15</td><td>8.39E-14</td><td>166.96</td><td>4.00E-11</td></tr><tr><td>525586734</td><td>Cellobiohydrolase</td><td>Y</td><td>GH7</td><td>0.80</td><td>9.90E-20</td><td>607.47</td><td>9.90E-20</td></tr><tr><td>525588012</td><td>Endo-beta-1,4-glucanase</td><td>Y</td><td>GH5</td><td>1.50</td><td>0.0002096</td><td>358.05</td><td>6.20E-12</td></tr><tr><td>525588754</td><td>Endo-beta-1,4-glucanase</td><td>Y</td><td>GH5</td><td>1.33</td><td>0.0011941</td><td>147.03</td><td>3.54E-08</td></tr></table> |
ecfd0a2e64d32c7cbeedbad345bceba4d68718b62da34dba1c7d2dccb44160c8.png | simple | <table><tr><td>Domain</td><td>Theme</td><td>Responses</td></tr><tr><td>Space Qualities</td><td>Nature</td><td>246</td></tr><tr><td></td><td>Park Features</td><td>285</td></tr><tr><td></td><td>“Sense of Place” <sup>1</sup></td><td>68</td></tr><tr><td>Physical</td><td>Physical Pursuits</td><td>1085</td></tr><tr><td></td><td>Physical Restoration</td><td>61</td></tr></table> |
e5deaf9975ba59dbccd5793eda6e787a6eb557fb822a286038864c008931dff8.png | complex | <table><tr><td></td><td>Homocysteine (Fluorescence) (μM)</td><td>Homocysteine (LCMS) (μM)</td><td>Methylmalonic Acid (LCMS) (μM)</td></tr><tr><td colspan="4">Group 1</td></tr><tr><td>Average</td><td>70.24</td><td>38.48</td><td>2.46</td></tr><tr><td>Standard deviation</td><td>20.68</td><td>19.40</td><td>1.29</td></tr><tr><td>Median</td><td>69.58</td><td>33.66</td><td>2.33</td></tr><tr><td>Max.</td><td>101.38</td><td>83.16</td><td>4.83</td></tr><tr><td>Min.</td><td>36.12</td><td>14.29</td><td>0.85</td></tr><tr><td colspan="4">Group 2</td></tr><tr><td>Average</td><td>58.74</td><td>41.01</td><td>4.11</td></tr><tr><td>Standard deviation</td><td>12.76</td><td>20.65</td><td>2.01</td></tr><tr><td>Median</td><td>53.79</td><td>40.36</td><td>3.60</td></tr><tr><td>Max.</td><td>86.52</td><td>68.28</td><td>7.71</td></tr><tr><td>Min.</td><td>44.33</td><td>12.44</td><td>2.03</td></tr><tr><td colspan="4">Group 3</td></tr><tr><td>Average</td><td>54.63</td><td>19.06</td><td>2.75</td></tr><tr><td>Standard deviation</td><td>12.76</td><td>11.10</td><td>0.98</td></tr><tr><td>Median</td><td>58.12</td><td>19.26</td><td>2.46</td></tr><tr><td>Max.</td><td>67.87</td><td>34.51</td><td>4.32</td></tr><tr><td>Min.</td><td>30.28</td><td>3.18</td><td>1.78</td></tr></table> |
0249723083e25cff3cad7bd24f6e11a7581e8ae1b2b33100e6fea3b3486218c0.png | complex | <table><tr><td rowspan="3">Trait</td><td colspan="4">PB performance</td><td colspan="4">CB performance</td></tr><tr><td colspan="2">PB offspring</td><td colspan="2">Sires</td><td colspan="2">PB offspring</td><td colspan="2">Sires</td></tr><tr><td>Mean</td><td>Mean difference</td><td>Mean</td><td>Mean difference</td><td>Mean</td><td>Mean difference</td><td>Mean</td><td>Mean difference</td></tr><tr><td>ADG</td><td>0.577 (0.026)</td><td>0.050 (0.021)</td><td>0.660 (0.040)</td><td>0.039 (0.016)</td><td>0.514 (0.033)</td><td>0.042 (0.027)</td><td>0.697 (0.047)</td><td>0.022 (0.012)</td></tr><tr><td>FCR</td><td>0.660 (0.020)</td><td>0.044 (0.015)</td><td>0.732 (0.036)</td><td>0.034 (0.012)</td><td>0.615 (0.023)</td><td>0.041 (0.018)</td><td>0.745 (0.040)</td><td>0.024 (0.010)</td></tr><tr><td>LM</td><td>0.699 (0.016)</td><td>0.039 (0.013)</td><td>0.716 (0.040)</td><td>0.047 (0.016)</td><td>0.540 (0.030)</td><td>0.032 (0.024)</td><td>0.724 (0.044)</td><td>0.019 (0.010)</td></tr><tr><td>pH</td><td>0.639 (0.024)</td><td>0.046 (0.018)</td><td>0.745 (0.039)</td><td>0.027 (0.011)</td><td>0.624 (0.025)</td><td>0.045 (0.018)</td><td>0.750 (0.040)</td><td>0.025 (0.011)</td></tr><tr><td>DL</td><td>0.768 (0.020)</td><td>0.030 (0.012)</td><td>0.768 (0.040)</td><td>0.044 (0.015)</td><td>0.680 (0.020)</td><td>0.026 (0.015)</td><td>0.741 (0.039)</td><td>0.030 (0.012)</td></tr><tr><td>IMF</td><td>0.626 (0.029)</td><td>0.042 (0.018)</td><td>0.688 (0.047)</td><td>0.034 (0.015)</td><td>0.548 (0.031)</td><td>0.038 (0.023)</td><td>0.730 (0.052)</td><td>0.018 (0.010)</td></tr></table> |
6bfadfb48b3e927b0e95b7737d650ed461703d123b5406b10e93c501607f6131.png | complex | <table><tr><td></td><td>Cases/controls (<i>n</i>)</td><td>Case-ratio</td><td>OR (95 % Cl)<sup>b</sup></td><td><i>p</i>-value</td><td>AUC (95 % Cl)<sup>b</sup></td></tr><tr><td>BI-RADS</td><td></td><td></td><td></td><td></td><td>0.63 (0.57–0.69)</td></tr><tr><td> D1</td><td>30/107</td><td>21.9</td><td>1 (reference)</td><td>-</td><td></td></tr><tr><td> D2</td><td>31/73</td><td>29.8</td><td>1.53 (0.85–2.75)</td><td>NS</td><td></td></tr><tr><td> D3</td><td>37/57</td><td>39.4</td><td>2.37 (1.32–4.25)</td><td>0.004</td><td></td></tr><tr><td> D4</td><td>23/22</td><td>51.1</td><td>3.93 (1.88–8.20)</td><td><0.001</td><td></td></tr><tr><td>Tabár</td><td></td><td></td><td></td><td></td><td>0.65 (0.59–0.71)</td></tr><tr><td> PI</td><td>38/96</td><td>28.4</td><td>1.81 (0.96–3.42)</td><td>NS</td><td></td></tr><tr><td> PII</td><td>18/83</td><td>17.8</td><td>1 (reference)</td><td>-</td><td></td></tr><tr><td> PIII</td><td>9/13</td><td>40.9</td><td>3.23 (1.20–8.75)</td><td>0.021</td><td></td></tr><tr><td> PIV</td><td>49/51</td><td>49.0</td><td>4.40 (2.31–8.38)</td><td><0.001</td><td></td></tr><tr><td> PV</td><td>7/16</td><td>30.4</td><td>1.97 (0.70–5.57)</td><td>NS</td><td></td></tr><tr><td rowspan="2">Automated texture (MTR)<sup>c</sup></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td>0.63 (0.57–0.69) cont.</td></tr><tr><td><i>0.63 (0.56–0.69) cat.</i></td></tr><tr><td> Q1</td><td>19/65</td><td>22.6</td><td>1 (reference)</td><td>-</td><td></td></tr><tr><td> Q2</td><td>24/65</td><td>27.0</td><td>1.27 (0.63–2.54)</td><td>NS</td><td></td></tr><tr><td> Q3</td><td>21/65</td><td>24.4</td><td>1.11 (0.54–2.25)</td><td>NS</td><td></td></tr><tr><td> Q4</td><td>57/64</td><td>47.1</td><td>3.04 (1.63–5.67)</td><td><0.001</td><td></td></tr><tr><td>BI-RADS + MTR</td><td></td><td></td><td></td><td></td><td>0.66 (0.60–0.72)</td></tr><tr><td> Q1</td><td>11/64</td><td>14.7</td><td>1 (reference)</td><td>-</td><td></td></tr><tr><td> Q2</td><td>23/65</td><td>26.1</td><td>2.06 (0.93–4.57)</td><td>NS</td><td></td></tr><tr><td> Q3</td><td>33/66</td><td>33.3</td><td>2.91 (1.36–6.25)</td><td>0.006</td><td></td></tr><tr><td> Q4</td><td>54/64</td><td>45.8</td><td>4.91 (2.35–10.24)</td><td><0.001</td><td></td></tr><tr><td>BI-RADS + Tabár</td><td></td><td></td><td></td><td></td><td>0.67 (0.61–0.72)</td></tr><tr><td> Q1</td><td>13/64</td><td>16.9</td><td>1 (reference)</td><td>-</td><td></td></tr><tr><td> Q2</td><td>19/64</td><td>22.9</td><td>1.46 (0.67–3.21)</td><td>NS</td><td></td></tr><tr><td> Q3</td><td>30/66</td><td>31.3</td><td>2.24 (1.07–4.67)</td><td>0.032</td><td></td></tr><tr><td> Q4</td><td>59/65</td><td>47.6</td><td>4.47 (2.24–8.94)</td><td><0.001</td><td></td></tr><tr><td>Tabár + MTR</td><td></td><td></td><td></td><td></td><td>0.68 (0.62–0.73)</td></tr><tr><td> Q1</td><td>13/65</td><td>16.7</td><td>1 (reference)</td><td>-</td><td></td></tr><tr><td> Q2</td><td>22/65</td><td>25.3</td><td>1.69 (0.79–3.64)</td><td>NS</td><td></td></tr><tr><td> Q3</td><td>24/65</td><td>27.0</td><td>1.85 (0.87–3.94)</td><td>NS</td><td></td></tr><tr><td> Q4</td><td>62/64</td><td>49.2</td><td>4.84 (2.43–9.66)</td><td><0.001</td><td></td></tr><tr><td>BI-RADS + MTR + Tabár</td><td></td><td></td><td></td><td></td><td>0.69 (0.63–0.74)</td></tr><tr><td> Q1</td><td>12/64</td><td>15.8</td><td>1 (reference)</td><td>-</td><td></td></tr><tr><td> Q2</td><td>16/66</td><td>19.5</td><td>1.29 (0.57–2.95)</td><td>NS</td><td></td></tr><tr><td> Q3</td><td>28/65</td><td>30.1</td><td>2.30 (1.08–4.91)</td><td>0.032</td><td></td></tr><tr><td> Q4</td><td>65/64</td><td>50.4</td><td>5.42 (2.67–10.98)</td><td><0.001</td><td></td></tr></table> |
711c8802cd69f43ea7ed53064fb8f91eb99b102e6d2beaee69f3bb244eecb91f.png | simple | <table><tr><td>Metric</td><td>SparseAssembler</td><td>Gossamer</td><td>Minia</td><td>SGA</td><td>Diginorm-Velvet</td><td>DiMA</td><td>ZeMA</td><td>Original Velvet</td></tr><tr><td>Total # of resultant contigs</td><td>2,218</td><td>6,927</td><td>2,887</td><td>2,652</td><td>2,143</td><td>3,582</td><td>5,580</td><td>2,164</td></tr><tr><td>N50 size in bp</td><td>3,211</td><td>607</td><td>2,246</td><td>2,275</td><td>3,369</td><td>1,822</td><td>989</td><td>3,245</td></tr><tr><td>Assembly Size in bp</td><td>4,985,042</td><td>4,372,958</td><td>4,502,157</td><td>4,386,839</td><td>4,580,783</td><td>4,581,634</td><td>4,676,725</td><td>4,603,060</td></tr><tr><td>Chaff bases in bp</td><td>490,566</td><td>370,300</td><td>51,725</td><td>110,663</td><td>67,933</td><td>129,282</td><td>307,705</td><td>69,147</td></tr><tr><td>Missing Reference Bases</td><td>34,461 (0.76%)</td><td>236,516 (5.14%)</td><td>119,552 (2.60%)</td><td>303,703 (6.60%)</td><td>22,572 (0.49%)</td><td>49,767 (1.08%)</td><td>47,324 (1.03%)</td><td>88,863 (1.93%)</td></tr><tr><td>Bad Trim</td><td>2,716</td><td>3,609</td><td>3,125</td><td>1,288</td><td>6,850</td><td>6,486</td><td>3,508</td><td>11,233</td></tr><tr><td>Translocation</td><td>1</td><td>1</td><td>1</td><td>1</td><td>5</td><td>1</td><td>5</td><td>2</td></tr><tr><td>Total Units Corrected</td><td>2,224</td><td>6,923</td><td>2,890</td><td>2,658</td><td>2,147</td><td>3,579</td><td>5,579</td><td>2,169</td></tr><tr><td>N50 size Corrected</td><td>3,201</td><td>607</td><td>2,239</td><td>2,267</td><td>3,326</td><td>1,812</td><td>988</td><td>3,232</td></tr><tr><td>Time (min:sec)</td><td>3:15</td><td>7:37</td><td>1:23</td><td>55:37</td><td>5:12</td><td>5:15</td><td>6:04</td><td>2:33</td></tr><tr><td>Memory Peak (GBs)</td><td>0.36</td><td>3</td><td>0.17</td><td>2.01</td><td>0.96</td><td>0.96</td><td>0.96</td><td>2.2</td></tr></table> |
da837ca8a43ee5ffa652e2ec557a13f55d4419be950ee6bf47f17a43e8be4b84.png | complex | <table><tr><td></td><td colspan="2">Total (<i>N</i> = 824)</td></tr><tr><td></td><td><i>N</i></td><td>%</td></tr><tr><td>Age, year</td><td></td><td></td></tr><tr><td>Median (Range)</td><td colspan="2">61 (21–97)</td></tr><tr><td>< 65</td><td>461</td><td>56.0.</td></tr><tr><td>≥ 65</td><td>344</td><td>41.7</td></tr><tr><td> missing</td><td>19</td><td>2.3</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td> Female</td><td>344</td><td>41.7</td></tr><tr><td> Male</td><td>480</td><td>58.3</td></tr><tr><td>Primary diagnosis</td><td></td><td></td></tr><tr><td> Lung cancer</td><td>150</td><td>18.2</td></tr><tr><td> Gastrointestinal cancer<sup>a</sup></td><td>267</td><td>32.4</td></tr><tr><td> Breast cancer</td><td>55</td><td>6.7</td></tr><tr><td> Genitourinary cancer<sup>b</sup></td><td>108</td><td>13.1</td></tr><tr><td> Head, neck, and oral cancer</td><td>185</td><td>22.4</td></tr><tr><td> Other cancers<sup>c</sup></td><td>59</td><td>7.2</td></tr><tr><td>Length of time in care</td><td></td><td></td></tr><tr><td> Median (Range)</td><td colspan="2">20 (7–118)</td></tr><tr><td>≤ 14 days</td><td>231</td><td>28.0</td></tr><tr><td> 15–30 days</td><td>361</td><td>43.8</td></tr><tr><td> 31–60 days</td><td>180</td><td>21.8</td></tr><tr><td>> 60 days</td><td>36</td><td>4.4</td></tr><tr><td> Missing</td><td>16</td><td></td></tr></table> |
64872bc676339e44f6ee15de6de8b648ed173c8c098ffcdf801dd63e05ffabe9.png | simple | <table><tr><td></td><td>Vitrectomized group</td><td>Control group</td><td><i>P</i><sup>∗</sup></td></tr><tr><td>Number of eyes</td><td>8</td><td>15</td><td></td></tr><tr><td>Sex (male/female)</td><td>5/3</td><td>3/12</td><td>0.051<sup>∗</sup></td></tr><tr><td>Age</td><td>72.8 ± 10.5</td><td>74.1 ± 5.1</td><td>0.906<sup>†</sup></td></tr><tr><td>Eye (R/L)</td><td>3/5</td><td>7/8</td><td>0.632<sup>∗</sup></td></tr><tr><td>BSCVA (LogMAR)</td><td>1.15 ± 0.60</td><td>0.98 ± 0.52</td><td>0.795<sup>†</sup></td></tr><tr><td>CCT (<i>μ</i>m)</td><td>765 ± 63</td><td>722 ± 88</td><td>0.194<sup>†</sup></td></tr><tr><td>Frequency of previous surgeries</td><td>3.11 ± 0.78</td><td>1</td><td><0.001</td></tr></table> |
06cf3ee0edcc2955fc91dff98ec004a4c71adcea99a03a9b6e0be24a35881d77.png | simple | <table><tr><td></td><td>Unmodified wildtype</td><td>Symmetric mutant</td><td>Left lobe cut</td><td>Right lobe cut</td></tr><tr><td>Unmodified wildtype</td><td>−</td><td></td><td></td><td></td></tr><tr><td>Symmetric mutant</td><td>0.0041*</td><td>−</td><td></td><td></td></tr><tr><td>Left lobe cut</td><td>0.0003*</td><td>>0.5</td><td>−</td><td></td></tr><tr><td>Right lobe cut</td><td>0.0592</td><td>>0.5</td><td>>0.5</td><td>−</td></tr><tr><td>Right lobe shaved</td><td>0.0212*</td><td>>0.5</td><td>>0.5</td><td>>0.5</td></tr></table> |
e0643719d2b9fb73b1050205d70f599d2c9f4bf6d7fa2857861a36d35cf4f224.png | complex | <table><tr><td rowspan="2">Parameters</td><td>SLNB</td><td>PALND</td><td>ALND</td><td>Statistics</td><td rowspan="2"><i>P</i></td></tr><tr><td>(<i>n</i> = 72)</td><td>(<i>n</i> = 158)</td><td>(<i>n</i> = 59)</td><td>(F or X<sup>2</sup>)</td></tr><tr><td>Overall Survival</td><td>97.2 %</td><td>98.1 %</td><td>96.6 %</td><td>0.445</td><td>0.796</td></tr><tr><td>Deaths (n)</td><td>2</td><td>3</td><td>2</td><td></td><td></td></tr><tr><td>Median Survival Time (mo)</td><td>30.0</td><td>30.0</td><td>30.0</td><td>0.251</td><td>0.882</td></tr><tr><td>Disease-Free Survival</td><td>95.8 %</td><td>96.8 %</td><td>94.9 %</td><td>9.033</td><td>0.340</td></tr><tr><td>Event (n)</td><td>3</td><td>5</td><td>3</td><td></td><td></td></tr><tr><td>Local Recurrence</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Contralateral breast cancer</td><td>0</td><td>2</td><td>0</td><td></td><td></td></tr><tr><td>Bone Metastasis</td><td>1</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Lung Metastasis</td><td>0</td><td>0</td><td>1</td><td></td><td></td></tr><tr><td>Multi-Organ</td><td>2</td><td>3</td><td>2</td><td></td><td></td></tr><tr><td>Disease-Free Survival (mo)</td><td>30.0</td><td>30.0</td><td>30.0</td><td>0.303</td><td>0.860</td></tr><tr><td>Follow-Up Time</td><td></td><td></td><td></td><td>1.633</td><td>0.197</td></tr><tr><td> Median (mo)</td><td>24.0</td><td>20.5</td><td>22.0</td><td></td><td></td></tr><tr><td> Range (mo)</td><td>12-33</td><td>12-33</td><td>12-33</td><td></td><td></td></tr></table> |
f84abc5852dbb33864caec249e8150ae425b1374012778a17d8a0102847ed09a.png | complex | <table><tr><td>Compounds</td><td>Conc. (μg/mL)</td><td>Percent inhibition (mean ± SEM)</td><td>IC<sub>50</sub> (μg/mL)</td></tr><tr><td>1</td><td>1000</td><td>72.41 ± 0.45***</td><td>440</td></tr><tr><td></td><td>500</td><td>52.49 ± 0.78***</td><td rowspan="2"></td></tr><tr><td></td><td>250</td><td>35.60 ± 0.75***</td></tr><tr><td>2</td><td>1000</td><td>70.32 ± 0.61***</td><td>460</td></tr><tr><td></td><td>500</td><td>52.48 ± 0.56***</td><td></td></tr><tr><td></td><td>250</td><td>33.61 ± 0.66***</td><td></td></tr><tr><td>3</td><td>1000</td><td>60.40 ± 0.49***</td><td>535</td></tr><tr><td></td><td>500</td><td>54.64 ± 0.70***</td><td></td></tr><tr><td></td><td>250</td><td>30.59 ± 0.67***</td><td></td></tr><tr><td>4</td><td>1000</td><td>45.80 ± 0.61***</td><td>>1000</td></tr><tr><td></td><td>500</td><td>24.75 ± 0.64***</td><td></td></tr><tr><td></td><td>250</td><td>20.34 ± 0.58***</td><td></td></tr><tr><td>Ascorbic</td><td>1000</td><td>93.56 ± 0.37</td><td>20</td></tr><tr><td>acid</td><td>500</td><td>81.71 ± 0.54</td><td></td></tr><tr><td></td><td>250</td><td>78.61 ± 0.23</td><td></td></tr></table> |
ea7c9e7cdc67d22cfec222cd3f0f46657e35b25992c1dedd9be2b2770a4d8183.png | complex | <table><tr><td>Triple genotype</td><td>Carriers (n) %</td><td>Non-carriers (n) %</td></tr><tr><td>Offs (n = 153)</td><td>(71) 46.4</td><td>(82) 53.6</td></tr><tr><td>CTR (n = 301)</td><td>(52) 17.3</td><td>(248) 82.7</td></tr><tr><td>AMI (n = 239)</td><td>(76) 31.8</td><td>(163) 68.2</td></tr><tr><td>Offs<i>vs</i>CTR</td><td colspan="2"><i>χ</i><sup>2</sup> = 43.295, p = 0.0001</td></tr><tr><td>AMI<i>vs</i>CTR</td><td colspan="2"><i>χ</i><sup>2</sup> = 15.372, p = 0.0001; OR = 2.224 (CI: 1.484-3.332)</td></tr></table> |
bcebc09b7be23114bbab352139dc69468962c776857e6b0e609768344f936936.png | complex | <table><tr><td rowspan="3">Indicator</td><td colspan="4">Baby kits n (%)</td><td colspan="4">Transport vouchers n (%)</td></tr><tr><td colspan="2">Control (Agulurude HC III)</td><td colspan="2">Intervention (Ngai HC III)</td><td colspan="2">Control (Amwa HC II)</td><td colspan="2">Intervention (Atipe + Alao HC IIs)</td></tr><tr><td>2013</td><td>2014</td><td>2013</td><td>2014</td><td>2013</td><td>2014</td><td>2013</td><td>2014</td></tr><tr><td>Catchment population</td><td>21,832</td><td>29,375</td><td>24,959</td><td>33,582</td><td>8649</td><td>11,637</td><td>25,878</td><td>26,235</td></tr><tr><td>No. of expected deliveries</td><td>950</td><td>1263</td><td>1086</td><td>1444</td><td>376</td><td>500</td><td>1126</td><td>1128</td></tr><tr><td colspan="9">Four ANC visits</td></tr><tr><td> n (%) from catchment area</td><td>284 (77.0)</td><td>525 (72.6)</td><td>235 (78.3)</td><td>519 (90.4)</td><td>152 (70.7)</td><td>220 (75.6)</td><td>125 (92.6)</td><td>738 (89.5)</td></tr><tr><td> n (%) bypassing</td><td>85 (23.0)</td><td>198 (27.4)</td><td>65 (21.7)</td><td>55 (9.6)</td><td>63 (29.3)</td><td>71 (24.4)</td><td>10 (7.4)</td><td>87 (10.5)</td></tr><tr><td> Total four ANC visits</td><td>369</td><td>723</td><td>300</td><td>574</td><td>215</td><td>291</td><td>135</td><td>825</td></tr><tr><td colspan="9">Institutional delivery</td></tr><tr><td> n (%) from catchment area</td><td>675 (79.4)</td><td>646 (72.2)</td><td>407 (80.4)</td><td>734 (87.6)</td><td>130 (77.8)</td><td>249 (81.4)</td><td>224 (98.2)</td><td>811 (89.9)</td></tr><tr><td> n (%) bypassing</td><td>175 (20.6)</td><td>249 (27.8)</td><td>99 (19.6)</td><td>104 (12.4)</td><td>37 (22.2)</td><td>57 (18.6)</td><td>4 (1.8)</td><td>91 (10.1)</td></tr><tr><td> Total deliveries</td><td>850</td><td>895</td><td>506</td><td>838</td><td>167</td><td>306</td><td>228</td><td>902</td></tr><tr><td colspan="9">PNC visits</td></tr><tr><td> n (%) from catchment area</td><td>61 (83.6)</td><td>307 (74.7)</td><td>29 (100)</td><td>348 (94.3)</td><td>33 (68.8)</td><td>43 (69.4)</td><td>7 (100)</td><td>520 (93.4)</td></tr><tr><td> n (%) bypassing</td><td>12 (16.4)</td><td>104 (25.3)</td><td>0 (0)</td><td>21 (5.7)</td><td>15 (31.2)</td><td>19 (30.6)</td><td>0 (0)</td><td>37 (6.6)</td></tr><tr><td> Total PNC</td><td>73</td><td>411</td><td>29</td><td>369</td><td>48</td><td>62</td><td>7</td><td>557</td></tr><tr><td>Total OPD attendance<sup>a</sup></td><td>20,751</td><td>18,607</td><td>20,809</td><td>17,976</td><td>6834</td><td>6203</td><td>17,169</td><td>14,483</td></tr></table> |
2d5a505b31e1b39b5f74647a03e1975ae7d143b5262b7a159c3193a25febe9bb.png | complex | <table><tr><td>Characteristics (missing data)</td><td>N (%)</td><td>Mean OSP<sup>1 </sup>(SD)</td><td> </td></tr><tr><td>Sex (0)</td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>6,460 (53)</td><td>505 (481)<sup><i>a</i></sup></td><td><i>t</i> = 15.91, <i>p</i> < .001</td></tr><tr><td> Female</td><td>5,728 (47)</td><td>373 (423)<sup><i>b</i></sup></td><td> </td></tr><tr><td>Age (0)</td><td> </td><td> </td><td> </td></tr><tr><td> 12</td><td>370 (3)</td><td>425 (472)</td><td><i>F =</i> 1.90<i>, p =</i> .091</td></tr><tr><td> 13</td><td>2,726 (22)</td><td>442 (451)</td><td> </td></tr><tr><td> 14</td><td>3,348 (28)</td><td>451 (460)</td><td> </td></tr><tr><td> 15</td><td>2,928 (24)</td><td>457 (466)</td><td> </td></tr><tr><td> 16</td><td>2,151 (18)</td><td>422 (460)</td><td> </td></tr><tr><td> 17</td><td>665 (6)</td><td>431 (452)</td><td> </td></tr><tr><td>SEP (0)</td><td> </td><td> </td><td> </td></tr><tr><td> Low</td><td>3,932 (32)</td><td>447 (473)</td><td><i>F =</i> 0.33<i>, p =</i> .718</td></tr><tr><td> Medium</td><td>5,062 (42)</td><td>439 (459)</td><td> </td></tr><tr><td> High</td><td>3,194 (26)</td><td>443 (441)</td><td> </td></tr><tr><td>Location (0)</td><td> </td><td> </td><td> </td></tr><tr><td> Rural/Remote</td><td>4,347 (36)</td><td>487 (447)<sup><i>a</i></sup></td><td><i>t =</i> 7.76<i>, p <</i> .001</td></tr><tr><td> Metropolitan</td><td>7,841 (64)</td><td>420 (446)<sup><i>b</i></sup></td><td> </td></tr><tr><td>Cultural Background (148)</td><td> </td><td> </td><td> </td></tr><tr><td> English</td><td>11,052 (91)</td><td>451 (459)<sup><i>c</i></sup></td><td><i>F =</i> 17.96<i>, p <</i> .001</td></tr><tr><td> European</td><td>208 (2)</td><td>508 (482)<sup><i>d</i></sup></td><td> </td></tr><tr><td> Asian</td><td>703 (6)</td><td>312 (426)<sup><i>a</i></sup></td><td> </td></tr><tr><td> Middle-Eastern</td><td>110 (1)</td><td>381 (503)<sup><i>b</i></sup></td><td> </td></tr><tr><td> Other</td><td>97 (1)</td><td>544 (554)<sup><i>d</i></sup></td><td> </td></tr><tr><td>BMI Category (0)</td><td> </td><td> </td><td> </td></tr><tr><td> Underweight</td><td>587 (5)</td><td>322 (404)<sup><i>a</i></sup></td><td><i>F =</i> 15.36<i>, p <</i> .001</td></tr><tr><td> Healthy Weight</td><td>8,831 (72)</td><td>447 (456)<sup><i>b</i></sup></td><td> </td></tr><tr><td> Overweight</td><td>2,219 (18)</td><td>464 (484)<sup><i>b</i></sup></td><td> </td></tr><tr><td> Obese</td><td>551 (5)</td><td>432 (460)<sup><i>b</i></sup></td><td> </td></tr><tr><td>PA Guidelines (0)</td><td> </td><td> </td><td> </td></tr><tr><td> Meeting</td><td>1,872 (15)</td><td>769 (568)<sup><i>a</i></sup></td><td><i>t =</i> 34.98<i>, p <</i> .001</td></tr><tr><td> Not Meeting</td><td>10,316 (85)</td><td>435 (462)<sup><i>b</i></sup></td><td> </td></tr><tr><td colspan="4">Screen-Based Entertainment Guidelines (38)</td></tr><tr><td> Meeting</td><td>2,395 (20)</td><td>476 (449)<sup><i>a</i></sup></td><td><i>t =</i> 3.85<i>, p <</i> .001</td></tr><tr><td> Not Meeting</td><td>9,755 (80)</td><td>435 (462)<sup><i>b</i></sup></td><td> </td></tr><tr><td>Fruit and Vegetable Guidelines (79)</td><td> </td><td> </td><td> </td></tr><tr><td> Meeting</td><td>1,762 (15)</td><td>613 (528)<sup><i>a</i></sup></td><td><i>t =</i> 17.09<i>, p <</i> .001</td></tr><tr><td> Not Meeting</td><td>10,341 (85)</td><td>413 (440)<sup><i>b</i></sup></td><td> </td></tr><tr><td>Sugar-Sweetened Beverages (116)</td><td> </td><td> </td><td> </td></tr><tr><td> Daily or more often</td><td>1,629 (13)</td><td>481 (507)<sup><i>a</i></sup></td><td><i>t =</i> 3.65<i>, p <</i> .001</td></tr><tr><td> Less than daily</td><td>10,443 (87)</td><td>436 (450)<sup><i>b</i></sup></td><td> </td></tr><tr><td>High-Fat Food (153)</td><td> </td><td> </td><td> </td></tr><tr><td> Weekly or more often</td><td>5,173 (43)</td><td>456 (475)<sup><i>a</i></sup></td><td><i>t =</i> 2.80<i>, p =</i> .005</td></tr><tr><td> Less than weekly</td><td>6,863 (57)</td><td>432 (445)<sup><i>b</i></sup></td><td> </td></tr></table> |
39b4bcceb5e1044c41ca0d0d970c358632e4a8c00bd89c8b6dbcb5d3f05c8aec.png | simple | <table><tr><td>Source organism</td><td>Gene/Protein</td><td>Target rice cultivar</td><td>Reference</td></tr><tr><td><i>Oryza sativa</i></td><td>Glutamine synthetase</td><td>Kinuhikari</td><td>Hoshida et al. (2000)</td></tr><tr><td><i>Avena sativa</i></td><td>Arginine decarboxylase</td><td>TNG-67</td><td>Roy and Wu (2001)</td></tr><tr><td><i>Arthrobacter globiformis</i></td><td>Choline oxidase</td><td>Pusa Basmati-1</td><td>Mohanty et al. (2002)</td></tr><tr><td><i>Hordeum vulgare</i></td><td>LEA protein</td><td>Pusa Basmati 1</td><td>Rohila et al. (2002)</td></tr><tr><td><i>Atriplex gmelini</i></td><td>Vacuolar Na<sup>+</sup>/H<sup>+</sup> antiporter</td><td>Kinuhikari</td><td>Ohta et al. (2002)</td></tr><tr><td><i>O. sativa</i></td><td>MAP kinase</td><td>Nipponbare</td><td>Xiong and Yang (2003)</td></tr><tr><td><i>Escherichia coli</i></td><td>Trehalose -6- phosphate synthase and Trehalose -6- phosphate phosphatase</td><td>Nakdong</td><td>Jang et al. (2003)</td></tr><tr><td><i>Vigna aconitifolia</i></td><td>Δ1-pyrroline-5-carboxylate synthetase</td><td>Kenfong</td><td>Su and Wu (2004)</td></tr><tr><td><i>O. sativa</i></td><td>Vacuolar Na<sup>+</sup>/H<sup>+</sup> antiporter</td><td>Nipponbare</td><td>Fukuda et al. (2004)</td></tr><tr><td>Mouse</td><td>Calcineurin</td><td>Xiushui 04</td><td>Ma et al. (2005)</td></tr><tr><td><i>Arabidopsis thaliana</i></td><td>MYB transcription factor</td><td>TNG-67</td><td>Malik and Wu (2005)</td></tr><tr><td><i>Suaeda salsa</i></td><td>Catalase</td><td>Zhonghua No. 11</td><td>Zhao and Zhang (2006)</td></tr><tr><td><i>A. thaliana</i> and <i>O. sativa</i></td><td>DREB transcription factor</td><td>Kita-ake</td><td>Ito et al. (2006)</td></tr><tr><td><i>O. sativa</i></td><td>NAC transcription factor</td><td>Nipponbare</td><td>Hu et al. (2006)</td></tr><tr><td><i>Suaeda salsa</i></td><td>Vacuolar Na<sup>+</sup>/H<sup>+</sup> antiporter</td><td>Zhonghua-11</td><td>Zhao et al. (2006b)</td></tr><tr><td><i>Schizosaccharo- myces pombe</i></td><td>Plasma membrane Na<sup>+</sup>/H<sup>+</sup> antiporter</td><td>Zhonghua-11</td><td>Zhao et al. (2006a)</td></tr><tr><td><i>Arthrobacter pascens</i></td><td>Choline oxidase</td><td>TNG-67</td><td>Su et al. (2006)</td></tr><tr><td><i>Avicennia marina</i></td><td>SOD</td><td>Pusa Basmati-1</td><td>Prashanth et al. (2008)</td></tr><tr><td><i>E. coli</i></td><td>Catalase</td><td>Nipponbare</td><td>Nagamiya et al. (2007)</td></tr><tr><td><i>O. sativa</i></td><td>Glyoxalase II</td><td>Pusa Basmati-1</td><td>Singla-Pareek et al. (2008)</td></tr><tr><td><i>Pennisetum glaucum</i></td><td>Vacuolar Na<sup>+</sup>/H<sup>+</sup> antiporter</td><td>Pusa Basmati-1</td><td>Verma et al. (2007)</td></tr><tr><td><i>O. sativa</i></td><td>Shaker potassium channel</td><td>Nipponbare</td><td>Obata et al. (2007)</td></tr><tr><td><i>E. coli</i></td><td>Catalase</td><td>Nipponbare</td><td>Motohashi et al. (2010)</td></tr><tr><td><i>O. sativa</i></td><td><i>Ribosome</i>-<i>inactivating protein gene 18</i></td><td>Nipponbare</td><td>Jiang et al. (2012)</td></tr><tr><td><i>O. sativa</i></td><td>Calmodulin-like gene</td><td>Pei’ai 64S</td><td>Xu et al. (2013)</td></tr><tr><td><i>O. sativa</i></td><td>Heat shock transcription factor <i>A7</i></td><td><i>Nipponbare</i></td><td>Liu et al. (2013)</td></tr><tr><td><i>O. sativa</i></td><td>Vesicle trafficking gene</td><td>Zhonghua 11</td><td>Peng et al. (2014)</td></tr><tr><td><i>O. sativa</i></td><td>bZIP transcription factor</td><td>Zhonghua 11</td><td>Liu et al. (2014b)</td></tr><tr><td>Bermudagrass</td><td>DREB transcription factor</td><td>Jonghua 11</td><td>Chen et al. (2015)</td></tr><tr><td><i>Citrus tristeza virus</i></td><td><i>Heat shock protein 70</i></td><td><i>Nipponbare</i></td><td>Hoang et al. (2015)</td></tr><tr><td><i>A. thaliana</i></td><td>Bcl-2 associated gene product</td><td><i>Nipponbare</i></td><td>Hoang et al. (2015)</td></tr><tr><td>Baculovirus</td><td><i>p35</i></td><td><i>Nipponbare</i></td><td>Hoang et al. (2015)</td></tr></table> |
3596433b15c24e89ab218f41da1f0d2b91a7959d18c3122091dfb71f6d89be16.png | simple | <table><tr><td>Herbal medicine</td><td>Method 1</td><td>Method 2</td><td>Method 3</td></tr><tr><td>1 (Dwarf Lilyturf Tuber)</td><td>0.7737</td><td>0.8861</td><td>0.9617</td></tr><tr><td>2 (Radix Glehniae)</td><td>0.6281</td><td>0.8254</td><td>0.9382</td></tr><tr><td>3 (Barbary Wolfberry)</td><td>0.8886</td><td>0.8151</td><td>0.9172</td></tr><tr><td>4 (Chinese Angelica)</td><td>0.5452</td><td>0.8493</td><td>0.9464</td></tr><tr><td>5 (Dried Rehmannia Root)</td><td>0.8382</td><td>0.8481</td><td>0.9490</td></tr><tr><td>6 (Szechwan Chinaberry)</td><td>0.8316</td><td>0.9065</td><td>0.9417</td></tr></table> |
80bb4ec246e3d9f835960a34019f78f44b952e53926c1a5f9e1148fdb03fc50b.png | simple | <table><tr><td>Samples</td><td>Activation energy, <i>E</i><sub><i>a</i></sub> (eV)</td><td>Coherent length, <i>C</i> (Å)</td></tr><tr><td>EMIm 0</td><td>1.055</td><td>0.099</td></tr><tr><td>EMIm 10</td><td>0.967</td><td>0.087</td></tr><tr><td>EMIm 25</td><td>0.928</td><td>0.017</td></tr></table> |
7ce8980cfac9c2f44d9d689d7806eb78912e2b9dc4d62b460b42473dd781bccd.png | complex | <table><tr><td>COPD</td><td colspan="2">Non standardized coefficients</td><td>Standardized coefficient</td><td>t</td><td>Sig.</td></tr><tr><td> </td><td>B</td><td>SD Error</td><td>β</td><td> </td><td> </td></tr><tr><td>CVD</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Constant</td><td>.542</td><td>.464</td><td> </td><td>1.169</td><td>.247</td></tr><tr><td>Age</td><td>.018</td><td>.006</td><td>.373</td><td>3.259</td><td>.002</td></tr><tr><td>BMI</td><td>.011</td><td>.006</td><td>.200</td><td>1.748</td><td>.085</td></tr><tr><td>VC,% predicted</td><td>−.003</td><td>.002</td><td>−.198</td><td>−1.724</td><td>.090</td></tr><tr><td>Pressure overload</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Constant</td><td>1.110</td><td>.330</td><td> </td><td>3.366</td><td>.001</td></tr><tr><td>BMI</td><td>.025</td><td>.012</td><td>.263</td><td>2.060</td><td>.044</td></tr><tr><td>Volume overload</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Constant</td><td>.928</td><td>.480</td><td> </td><td>1.932</td><td>.058</td></tr><tr><td>Sex</td><td>.384</td><td>.148</td><td>.341</td><td>2.598</td><td>.012</td></tr><tr><td>Smoking</td><td>.289</td><td>.112</td><td>.339</td><td>2.576</td><td>.013</td></tr><tr><td>VC, % predicted</td><td>−.006</td><td>.004</td><td>−.212</td><td>−1.763</td><td>.083</td></tr></table> |
dc7e9322856bbe6c4cf90cbc9125fb1ca5a00b61ca0b90e6a11cdb0e232d7e12.png | complex | <table><tr><td></td><td colspan="3">95% confidence</td></tr><tr><td></td><td>Odds ratio</td><td>Interval</td><td><i>P</i></td></tr><tr><td>Dai-kenchu-to</td><td></td><td></td><td></td></tr><tr><td> Nonusers</td><td>Reference</td><td></td><td></td></tr><tr><td> Users</td><td>1.60</td><td>0.86–2.95</td><td>.137</td></tr><tr><td>Age (10-yr age increase)</td><td>1.09</td><td>0.79–1.51</td><td>.592</td></tr><tr><td>Sex (Female)</td><td>0.52</td><td>0.27–1.01</td><td>.054</td></tr><tr><td>Diabetes</td><td>0.73</td><td>0.33–1.60</td><td>.428</td></tr><tr><td>Hypertension</td><td>1.07</td><td>0.47–2.42</td><td>.873</td></tr><tr><td>Cardiac diseases</td><td>0.45</td><td>0.15–1.40</td><td>.169</td></tr><tr><td>Chronic lung diseases</td><td>0.84</td><td>0.09–7.74</td><td>.879</td></tr><tr><td>Hospital volume (per month)</td><td>0.99</td><td>0.94–1.05</td><td>.820</td></tr><tr><td>Type of surgery</td><td></td><td></td><td></td></tr><tr><td> Colectomy</td><td>Reference</td><td></td><td></td></tr><tr><td> Rectal of the resection</td><td>0.95</td><td>0.47–1.94</td><td>.893</td></tr><tr><td> Abdominoperineal resection</td><td>0.62</td><td>0.28–1.41</td><td>.254</td></tr><tr><td>Open or laparoscopic surgery</td><td></td><td></td><td></td></tr><tr><td> Open</td><td>Reference</td><td></td><td></td></tr><tr><td> Laparoscopic</td><td>0.85</td><td>0.26–2.72</td><td>.779</td></tr></table> |
c303d6e86abd006e66e0c565cb7e4f1c8c414cf0bb4dc705068c2d8ba57f997a.png | simple | <table><tr><td></td><td>0° (Baseline)</td><td>−6°</td><td>−12°</td><td>−18°</td><td>−12° and CO<sub>2</sub></td><td>−12° and LBNP</td></tr><tr><td>MD</td><td>0.775± 0.253</td><td>0.840 ± 0.346</td><td>0.757 ± 0.207</td><td>0.748 ± 0.254</td><td>0.797 ± 0.237</td><td>0.877 ± 0.343</td></tr><tr><td>FA</td><td>0.493± 0.146</td><td>0.511 <sup>*</sup>± 0.153</td><td>0.592 ± 0.116</td><td>0.578 ± 0.143</td><td>0.533 ± 0.122</td><td>0.443 <sup>**</sup> ± 0.174</td></tr><tr><td>AD</td><td>1.165± 0.256</td><td>1.276 ± 0.366</td><td>1.261 ± 0.222</td><td>1.244 ± 0.248</td><td>1.264 ± 0.284</td><td>1.232 ± 0.313</td></tr><tr><td>RD</td><td>0.580 ± 0.264</td><td>0.621 ± 0.342</td><td>0.505 ± 0.213</td><td>0.500 ± 0.271</td><td>0.563 ± 0.225</td><td>0.699 ± 0.365</td></tr></table> |
e115cff3eb9be76c60079d0f0e5481170429bd2434e0110ae3161bf2690bd4fe.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Group 1b</td><td colspan="4">Group 2b</td></tr><tr><td>Day 20</td><td>Day 23</td><td>Day 10</td><td>Day 13</td><td>Day 20</td><td>Day 23</td></tr><tr><td></td><td>ODV + SMV</td><td>ODV + SMV + AL‐335</td><td>ODV alone</td><td>ODV + AL‐335</td><td>ODV + SMV</td><td>ODV + SMV + AL‐335</td></tr><tr><td><i>C</i><sub>max</sub> (ng/mL)</td><td>649 (183)</td><td>717 (192)</td><td>582 (221)</td><td>669 (349)</td><td>770 (346)</td><td>780 (321)</td></tr><tr><td>N</td><td>14</td><td>14</td><td>16</td><td>15</td><td>15</td><td>15</td></tr><tr><td>LSM ratioc</td><td>–</td><td>–</td><td>–</td><td>1.06 (0.95‐1.17)</td><td>1.25 (1.11‐1.41)</td><td>1.28 (1.17‐1.40)</td></tr><tr><td><i>T</i><sub>max</sub> (h)</td><td>6.51 (5.0‐8.0)</td><td>6.00 (5.0‐8.0)</td><td>5.00 (5.0‐7.0)</td><td>5.05 (5.0‐8.0)</td><td>7.00 (3.0‐9.0)</td><td>6.00 (5.0‐16.0)</td></tr><tr><td>N</td><td>14</td><td>14</td><td>16</td><td>15</td><td>15</td><td>15</td></tr><tr><td><i>C</i><sub>min</sub> (ng/mL)</td><td>313 (89)</td><td>398 (116)</td><td>235 (132)</td><td>314 (166)</td><td>471 (263)</td><td>508 (270)</td></tr><tr><td>N</td><td>14</td><td>14</td><td>16</td><td>15</td><td>15</td><td>15</td></tr><tr><td>LSM ratioc</td><td>–</td><td>–</td><td>–</td><td>1.30 (1.11‐1.52)</td><td>1.91 (1.63‐2.24)</td><td>2.09 (1.78‐2.45)</td></tr><tr><td>C<sub>last</sub> (ng/mL)</td><td>368 (116)</td><td>55 (21)</td><td>287 (150)</td><td>331 (180)</td><td>507 (268)</td><td>90 (53)</td></tr><tr><td>N</td><td>14</td><td>14</td><td>16</td><td>15</td><td>15</td><td>15</td></tr><tr><td><i>T</i><sub>last</sub> (h)</td><td>23.9 (23.9‐24.0)</td><td>696.0 (696.0‐696.0)</td><td>23.9 (23.9‐24.0)</td><td>23.9 (23.9‐23.9)</td><td>23.9 (23.8‐24.1)</td><td>696.0 (696.0‐815.0)</td></tr><tr><td>N</td><td>14</td><td>14</td><td>16</td><td>15</td><td>15</td><td>15</td></tr><tr><td>AUC<sub>0‐24 h</sub> (ng.h/mL)</td><td>10 734 (3124)</td><td>12 376 (3407)</td><td>8694 (3956)</td><td>10 210 (5252)</td><td>13 908 (6911)</td><td>14 771 (7090)</td></tr><tr><td>N</td><td>14</td><td>14</td><td>16</td><td>15</td><td>15</td><td>15</td></tr><tr><td>LSM ratioc</td><td>–</td><td>–</td><td>–</td><td>1.10 (1.01‐1.20)</td><td>1.50 (1.36‐1.67)</td><td>1.61 (1.46‐1.77)</td></tr><tr><td><i>t</i><sub>1/2</sub> (h)c</td><td>NA</td><td>213.13 (15.9)</td><td>NA</td><td>NA</td><td>NA</td><td>233.9 (35.5)</td></tr><tr><td>N</td><td>NA</td><td>11</td><td>NA</td><td>NA</td><td>NA</td><td>9</td></tr></table> |
250c1c2992381a56ffa64cd08fe3e7061dfee2142cd6c21db2fed5f38e143703.png | complex | <table><tr><td></td><td colspan="3">All respondents reporting valid travel time data</td></tr><tr><td>Mode</td><td colspan="3"></td></tr><tr><td></td><td>Mean (sd)</td><td>Median (IQR) (range)</td><td>Proportion of total</td></tr><tr><td>Car</td><td>24.4 (40.8)</td><td>0.0 (40.0) (0–510)</td><td>39.7%</td></tr><tr><td>Walking</td><td>19.2 (27.8)</td><td>10.0 (30.0) (0–205)</td><td>31.2%</td></tr><tr><td>Bus</td><td>14.6 (30.8)</td><td>0.0 (20.0) (0–210)</td><td>23.7%</td></tr><tr><td>Rail</td><td>1.8 (10.0)</td><td>0.0 (0.0) (0–165)</td><td>2.9%</td></tr><tr><td>Cycling</td><td>0.7 (7.3)</td><td>0.0 (0.0) (0–130)</td><td>1.1%</td></tr><tr><td>Motorcycle</td><td>0.1 (2.0)</td><td>0.0 (0.0) (0–50)</td><td>0.2%</td></tr><tr><td>Other</td><td>0.6 (9.4)</td><td>0.0 (0.0) (0–240)</td><td>1.0%</td></tr><tr><td>Active modes*</td><td>20.0 (28.5)</td><td>10.0 (30.0) (0–205)</td><td>32.4%</td></tr><tr><td>All modes combined</td><td>61.5 (53.2)</td><td>50.0 (63.0) (0–510)</td><td>100.0%</td></tr></table> |
4a098b4dfb1d70a057332f958d801851fb3fda096119a2cde30738a47b5c596c.png | simple | <table><tr><td>OCa patient</td><td>Stage</td><td>Age</td><td>Late menopause</td><td>Previous pregnancy</td><td>Early puberty</td><td>Blood creatinine</td></tr><tr><td>1</td><td>I</td><td>48</td><td>No</td><td>Yes</td><td>No</td><td>Normal</td></tr><tr><td>2</td><td>I</td><td>56</td><td>No</td><td>Yes</td><td>No</td><td>Normal</td></tr><tr><td>3</td><td>I</td><td>62</td><td>No</td><td>Yes</td><td>No</td><td>Normal</td></tr><tr><td>4</td><td>I</td><td>70</td><td>No</td><td>Yes</td><td>No</td><td>Normal</td></tr><tr><td>5</td><td>I</td><td>81</td><td>No</td><td>Yes</td><td>No</td><td>Normal</td></tr><tr><td>6</td><td>II</td><td>46</td><td>No</td><td>Yes</td><td>No</td><td>Normal</td></tr><tr><td>7</td><td>II</td><td>54</td><td>No</td><td>Yes</td><td>No</td><td>Normal</td></tr><tr><td>8</td><td>II</td><td>68</td><td>No</td><td>Yes</td><td>No</td><td>Normal</td></tr><tr><td>9</td><td>II</td><td>47</td><td>No</td><td>Yes</td><td>No</td><td>Normal</td></tr></table> |
2ab2855b32b4bd36f3a5da937dec17ef2761af33945c36295d3f06e08711119e.png | simple | <table><tr><td>Figure</td><td>l, <i>σ</i></td><td>↓<i>D</i></td><td>SNER</td><td><i>μ</i> × <i>μ</i> unit images</td><td><i>M</i> × <i>N</i></td><td>↑<i>L</i></td><td><i>LM</i>×<i>LN</i></td><td><i>α</i></td><td># of Iterations</td></tr><tr><td>Fig. 12</td><td>7, 4</td><td>4</td><td>-</td><td>4 × 4</td><td>64 × 64</td><td>4</td><td>256×256</td><td>0.01</td><td>30</td></tr></table> |
da034dcaff42ce50337e8898864efb093e4a53624419ba674eb66083d1d129b5.png | simple | <table><tr><td></td><td><i>HPV</i></td><td></td><td></td></tr><tr><td></td><td><i>Normal</i></td><td><i>Overexpression</i></td><td><i>P</i></td></tr><tr><td>PCNA</td><td></td><td></td><td></td></tr><tr><td>Normal</td><td>25</td><td>8</td><td>0.002</td></tr><tr><td>Overexpression</td><td>15</td><td>23</td><td></td></tr></table> |
dd0a423fb37910285979329896a25429f527baaaedb5c7d75ad31b97dc32cd41.png | complex | <table><tr><td></td><td></td><td>ISS > 26</td><td>ISS 15-26</td><td>ISS < 15</td><td>p-value</td><td></td></tr><tr><td colspan="7">Demography, injury severity, transfusion and mortality</td></tr><tr><td>N</td><td></td><td>23</td><td>26</td><td>30</td><td></td><td></td></tr><tr><td>Age</td><td>yrs</td><td>45 (25-71)</td><td>57 (43-65)</td><td>42 (28-49)</td><td>0.034</td><td><sup>c</sup></td></tr><tr><td>Gender</td><td>m% (n)</td><td>74% (17)</td><td>62% (16)</td><td>67% (20)</td><td>NS</td><td></td></tr><tr><td>Blunt trauma</td><td>% (n)</td><td>96% (22)</td><td>96% (25)</td><td>83% (25)</td><td>0.142</td><td></td></tr><tr><td>ISS</td><td>score</td><td>34 (29-36)</td><td>22 (17-25)</td><td>9 (5-10)</td><td>NA</td><td></td></tr><tr><td>sTBI</td><td>% (n)</td><td>17% (4)</td><td>46% (12)</td><td>29% (6)</td><td>0.091</td><td></td></tr><tr><td>GCS (PH)</td><td>score</td><td>7 (3-13)</td><td>11 (6-15)</td><td>15 (12-15)</td><td>0.002</td><td><sup>a</sup></td></tr><tr><td>Crystalloids (PH)</td><td>ml</td><td>900 (250-1250)</td><td>275 (0-500)</td><td>250 (25-750)</td><td>0.013</td><td><sup>a, b</sup></td></tr><tr><td>RBC 0-24 h</td><td>units</td><td>2 (0-12)</td><td>1 (0-3)</td><td>0 (0-1)</td><td>0.007</td><td><sup>a</sup></td></tr><tr><td>FFP 0-24 h</td><td>units</td><td>2 (0-9)</td><td>0 (0-1)</td><td>0 (0-0)</td><td>0.003</td><td><sup>a</sup></td></tr><tr><td>PLT 0-24 h</td><td>units</td><td>0 (0-4)</td><td>0 (0-0)</td><td>0 (0-0)</td><td>0.006</td><td><sup>a</sup></td></tr><tr><td>MT (> 10 RBC in 24 h)</td><td>% (n)</td><td>35% (8)</td><td>4% (1)</td><td>3% (1)</td><td>0.001</td><td><sup>a, b</sup></td></tr><tr><td>Mortality</td><td>% (n)</td><td>39% (9)</td><td>15% (4)</td><td>3% (1)</td><td>0.003</td><td><sup>a</sup></td></tr><tr><td colspan="7">Shock, sympathoadrenal activation, cell damage, biochemistry and hemostasis</td></tr><tr><td>SBP (PH)</td><td>mmHg</td><td>150 (108-156)</td><td>136 (125-152)</td><td>130 (123-143)</td><td>NS</td><td></td></tr><tr><td>pH</td><td></td><td>7.31 (7.25-7.33)</td><td>7.40 (7.307.40)</td><td>7.37 (7.33-7.41)</td><td>0.001</td><td><sup>a, b</sup></td></tr><tr><td>Lactate</td><td>mmol/l</td><td>1.7 (1.2-2.2)</td><td>2.5 (1.3-3.1)</td><td>1.5 (0.9-2.1)</td><td>0.049</td><td><sup>c</sup></td></tr><tr><td>SBE</td><td>mmol/l</td><td>-3.6 (-5.7- -1.9)</td><td>-2.7 (-4.6- -0.5)</td><td>-1.0 (-1.8-0.7)</td><td>0.005</td><td><sup>a</sup></td></tr><tr><td>Adrenaline</td><td>pg/ml</td><td>1,062 (328-1,549)</td><td>292 (126-1,077)</td><td>247 (86-354)</td><td>0.002</td><td><sup>a</sup></td></tr><tr><td>Noradrenaline</td><td>pg/ml</td><td>1,235 (434-1,511)</td><td>652 (210-1,288)</td><td>332 (217-1,036)</td><td>0.040</td><td><sup>a</sup></td></tr><tr><td>hcDNA</td><td>%</td><td>16.9 (5.6-27.0)</td><td>5.6 (2.4-10.3)</td><td>0.4 (0.0-9.3)</td><td><0.001</td><td><sup>a</sup></td></tr><tr><td>Hemoglobin</td><td>mmol/l</td><td>8.0 (6.3-9.2)</td><td>8.6 (7.2-9.1)</td><td>8.4 (7.7-8.9)</td><td>NS</td><td></td></tr><tr><td>Platelet count</td><td>10<sup>9</sup>/l</td><td>217 (165-252)</td><td>193 (173-260)</td><td>211 (191-240)</td><td>NS</td><td></td></tr><tr><td>Fibrinogen</td><td>g/l</td><td>2.0 (1.4-2.2)</td><td>2.4 (2.1-2.9)</td><td>2.6 (2.3-2.9)</td><td>0.002</td><td><sup>a, b</sup></td></tr><tr><td>FXIII</td><td>microg/ml</td><td>25 (20-30)</td><td>30 (22-40)</td><td>32 (28-41)</td><td>0.001</td><td><sup>a</sup></td></tr><tr><td>vWF</td><td>%</td><td>190 (110-218)</td><td>200 (132-223)</td><td>204 (146-230)</td><td>NS</td><td></td></tr><tr><td>APTT > 35 sec</td><td>%</td><td>22% (5)</td><td>4% (1)</td><td>0%</td><td>0.009</td><td><sup>a</sup></td></tr><tr><td>INR > 1.2</td><td>%</td><td>43% (10)</td><td>0%</td><td>0%</td><td><0.001</td><td><sup>a, b</sup></td></tr><tr><td colspan="7">Thrombelastography</td></tr><tr><td>R</td><td>min</td><td>5.1 (4.8-5.9)</td><td>5.9 (5.1-6.7)</td><td>6.0 (5.3-6.4)</td><td>0.046</td><td></td></tr><tr><td>Angle</td><td>degrees</td><td>65 (62-68)</td><td>67 (62-7)</td><td>66 (62-70)</td><td>NS</td><td></td></tr><tr><td>MA</td><td>mm</td><td>63 (58-67)</td><td>64 (62-68)</td><td>63 (61-67)</td><td>NS</td><td></td></tr><tr><td>Ly30</td><td>%</td><td>0.2 (0.0-0.7)</td><td>0.0 (0.0-0.2)</td><td>0.3 (0.0-1.0)</td><td>0.040</td><td></td></tr><tr><td colspan="7">Platelet activation and thrombin generation</td></tr><tr><td>sCD40L</td><td>pg/ml</td><td>394 (281-551)</td><td>327 (251-406)</td><td>250 (195-305)</td><td>0.006</td><td><sup>a</sup></td></tr><tr><td>PF1.2</td><td>nmol/l</td><td>4.1 (1.1-13.0)</td><td>15.1 (4.1-45.3)</td><td>4.2 (1.6-9.5)</td><td>0.026</td><td><sup>b, c</sup></td></tr><tr><td>TAT</td><td>ng/ml</td><td>36 (32-41)</td><td>39 (33-44)</td><td>35 (29-40)</td><td>0.181</td><td></td></tr><tr><td colspan="7">Natural anticoagulation</td></tr><tr><td>AT</td><td>10<sup>3 </sup>U/l</td><td>0.89 (0.69-0.96)</td><td>0.9 (0.8-1.00)</td><td>0.98 (0.90-1.07)</td><td>0.002</td><td><sup>a</sup></td></tr><tr><td>PC</td><td>%</td><td>92 (75-116)</td><td>107 (96-123)</td><td>117 (100-129)</td><td>0.031</td><td><sup>a</sup></td></tr><tr><td>APC</td><td>ng/ml</td><td>10.4 (9.4-12.1)</td><td>10.5 (8.7-13.5)</td><td>8.0 (6.8-10.5)</td><td>0.005</td><td><sup>a, c</sup></td></tr><tr><td>TFPI</td><td>ng/ml</td><td>64 (48-86)</td><td>67 (52-80)</td><td>54 (41-74)</td><td>NS</td><td></td></tr><tr><td colspan="7">Fibrinolysis</td></tr><tr><td>D-dimer</td><td>ng/ml</td><td>173 (172-176)</td><td>170 (144-175)</td><td>128 (36-148)</td><td><0.001</td><td><sup>a, c</sup></td></tr><tr><td>tPA</td><td>ng/ml</td><td>7.3 (5.5-15.4)</td><td>7.8 (4.7-13.7)</td><td>5.2 (2.0-9.9)</td><td>0.063</td><td></td></tr><tr><td>PAI-1</td><td>ng/ml</td><td>24 (11-37)</td><td>31 (14-68)</td><td>20 (13-27)</td><td>0.145</td><td></td></tr><tr><td>PAP</td><td>ng/ml</td><td>316 (22-599)</td><td>475 (83-1152)</td><td>225 (54-393)</td><td>0.159</td><td></td></tr></table> |
15b78a8fce1c70b35eaf9904e435e99774dd00b748d8dbd230242de81f0b3241.png | simple | <table><tr><td>Clinical presentation</td><td>Key chunking propositions</td></tr><tr><td>Dysphagia</td><td>- Oropharyngeal vs. esophageal- Mechanical vs. motility</td></tr><tr><td>Elevated liver enzymes</td><td>- Hepatocellular vs. cholestatic- Intra vs. extrahepatic cholestasis</td></tr><tr><td>Nausea and vomiting</td><td>- GI vs. non-GI causes- GI vs. metabolic vs. CNS vs. drugs</td></tr><tr><td>Diarrhea</td><td>- Small bowel vs. large bowel- Steatorrhea (malabsorption) vs. non-steatorrhea- Osmotic vs. secretory vs. inflammatory vs. motility</td></tr></table> |
341680ed6d9dc7db348930d37e1b9bbf94b373a6fe0dc1b7fb60c5097370cd9a.png | complex | <table><tr><td>Protein Accession</td><td>Protein Description</td><td>101-35 °C/101-27 °C</td><td>101-37 °C/101-27 °C </td><td>Functional Category</td></tr><tr><td colspan="5">Up-regulated</td></tr><tr><td>A2WMG6</td><td>Salt stress root protein RS1</td><td>1.65 ± 0.24</td><td>1.51 ± 0.34</td><td>Stress response</td></tr><tr><td>A2XCH7</td><td>Tonoplast intrinsic protein (Tonoplast water channel)</td><td>1.62 ± 0.16</td><td>1.58 ± 0.20</td><td>transporter</td></tr><tr><td>A2Y1Q8</td><td>Similar to TCH2 (TOUCH 2); calcium ion binding</td><td>1.62 ± 0.15</td><td>1.78 ± 0.20</td><td>Signaling</td></tr><tr><td>A2Y8H4</td><td>Aldo/keto reductase domain containing protein</td><td>1.54 ± 0.06</td><td>1.59 ± 0.13</td><td>Metabolic</td></tr><tr><td>A2YCB4</td><td>Thioredoxin fold domain containing protein</td><td>1.57 ± 0.09</td><td>1.78 ± 0.19</td><td>Redox</td></tr><tr><td>A2YI28</td><td>Reticulon-like protein</td><td>1.59 ± 0.26</td><td>2.02 ± 0.20</td><td>Endoplasmic reticulum, ER</td></tr><tr><td>A2YM28</td><td>Thiamine thiazole synthase, chloroplastic</td><td>1.55 ± 0.12</td><td>1.8 ± 0.31</td><td>Starch metabolic</td></tr><tr><td>A2YQ88</td><td>Similar to PWWP domain containing protein</td><td>1.51 ± 0.22</td><td>1.51 ± 0.29</td><td>DNA binding</td></tr><tr><td>A2Z0W7</td><td>Mannose-6-phosphate isomerase</td><td>1.81 ± 0.07</td><td>1.89 ± 0.20</td><td>Metabolic</td></tr><tr><td>B8B8G2</td><td>Tubulin alpha chain</td><td>1.54 ± 0.24</td><td>1.52 ± 0.23</td><td>Cell structure</td></tr><tr><td>B8BF32</td><td>HAD superfamily hydrolase-like, type 3 domain containing protein</td><td>2.03 ± 0.59</td><td>3.15 ± 0.60</td><td>Metabolic</td></tr><tr><td colspan="5">Down-regulated</td></tr><tr><td>A2X3J5</td><td>40S ribosomal protein S3a</td><td>0.66 ± 0.17</td><td>0.63 ± 0.12</td><td>Ribosome</td></tr><tr><td>A2X6N1</td><td>60S ribosomal protein L6</td><td>0.6 ± 0.02</td><td>0.61 ± 0.05</td><td>Ribosome</td></tr><tr><td>A2XCC4</td><td>Similar to 60S ribosomal protein L21</td><td>0.46 ± 0.07</td><td>0.56 ± 0.07</td><td>Ribosome</td></tr><tr><td>A2XM46</td><td>Similar to 60S ribosomal protein L13a-4</td><td>0.65 ± 0.05</td><td>0.62 ± 0.04</td><td>Ribosome</td></tr><tr><td>A2YIS2</td><td>Similar to 60S ribosomal protein L4</td><td>0.65 ± 0.07</td><td>0.66 ± 0.06</td><td>Ribosome</td></tr><tr><td>A2YNM6</td><td>Similar to 60S ribosomal protein L27a-3</td><td>0.59 ± 0.07</td><td>0.66 ± 0.05</td><td>Ribosome</td></tr><tr><td>A2YVK0</td><td>Similar to 60S ribosomal protein L34</td><td>0.6 ± 0.14</td><td>0.55 ± 0.10</td><td>Ribosome</td></tr><tr><td>A2ZLS7</td><td>Similar to 60S ribosomal protein L2 (fragment)</td><td>0.61 ± 0.05</td><td>0.59 ± 0.05</td><td>Ribosome</td></tr><tr><td>B8AHZ6</td><td>40S ribosomal protein S8</td><td>0.62 ± 0.03</td><td>0.63 ± 0.03</td><td>Ribosome</td></tr><tr><td>B8B6Q3</td><td>Similar to Pleiotropic drug resistance protein 3</td><td>0.66 ± 0.01</td><td>0.56 ± 0.01</td><td>Transporter</td></tr></table> |
409fbd315eb43ce46bf0d25fe07bde77e6bdefb561b7430954610ebcf2951c54.png | simple | <table><tr><td>Variable</td><td>Frequency</td><td>Percentage (%)</td></tr><tr><td><i>Healthcare decision-making autonomy</i></td><td> </td><td> </td></tr><tr><td>Autonomous</td><td>1,117</td><td>21.9</td></tr><tr><td>Not autonomous</td><td>3,990</td><td>78.1</td></tr><tr><td><i>Large household purchases decision-making</i></td><td> </td><td> </td></tr><tr><td>Autonomous</td><td>948</td><td>18.6</td></tr><tr><td>Not autonomous</td><td>4,159</td><td>81.4</td></tr><tr><td><i>Visit to family members decision-making</i></td><td> </td><td> </td></tr><tr><td>Autonomous</td><td>1,097</td><td>21.5</td></tr><tr><td>Not autonomous</td><td>4,008</td><td>78.5</td></tr></table> |
85ea4fc0ca438c605dc3a0090cebe42dd824f3d6246f59bb3121c35ee75090db.png | simple | <table><tr><td> </td><td>WT</td><td><i>kua1-1</i></td><td><i>OX-1</i></td><td><i>35S:Prx57</i></td></tr><tr><td>Cel</td><td>98.44±14.5</td><td>109.48±14.7</td><td>105.20±3.3</td><td>96.14±3.7</td></tr><tr><td>UAs</td><td>45.14±7.8</td><td>49.86±4.4</td><td>48.04±3.4</td><td>43.91±6.3</td></tr><tr><td>Rha</td><td>6.82±1.0</td><td>5.80±1.6</td><td>5.70±1.4</td><td>5.79±1.7</td></tr><tr><td>Fuc</td><td>1.15±0.1</td><td>0.93±0.2</td><td>1.05±0.2</td><td>1.02±0.3</td></tr><tr><td>Ara</td><td>7.89±1.0</td><td>6.88±1.2</td><td>7.34±1.5</td><td>7.94±2.0</td></tr><tr><td>Xyl</td><td>7.35±0.8</td><td>5.89±1.3</td><td>6.28±1.6</td><td>6.13±1.8</td></tr><tr><td>Man</td><td>2.55±0.4</td><td>1.83±0.5</td><td>2.18±1.0</td><td>1.97±0.5</td></tr><tr><td>Gal</td><td>16.51±1.9</td><td>16.88±3.0</td><td>16.62±2.8</td><td>15.70±3.4</td></tr><tr><td>Glc</td><td>8.46±1.3</td><td>11.40±4.1</td><td>13.98±2.8</td><td>8.56±2.2</td></tr></table> |
2128ee9f4b9494353c30f263f88da45d588964ad24331c725e8477052e19fec4.png | complex | <table><tr><td></td><td colspan="2">Female</td><td colspan="2">Male</td></tr><tr><td>Measure</td><td>White</td><td>African-American</td><td>White</td><td>African-American</td></tr><tr><td colspan="5">Adjusted mean (SE) BMD (g/cm<sup>2</sup>)a</td></tr><tr><td> Lowest</td><td>0.789 (0.006)</td><td>0.898 (0.010)</td><td>0.961 (0.007)</td><td>1.036 (0.011)</td></tr><tr><td> Middle</td><td>0.776b (0.006)</td><td>0.882 (0.009)</td><td>0.944c (0.006)</td><td>1.023 (0.010)</td></tr><tr><td> Highest</td><td>0.771b (0.007)</td><td>0.873 (0.012)</td><td>0.934c (0.009)</td><td>1.011 (0.013)</td></tr><tr><td colspan="5">Unadjusted proportion with back pain (%)a</td></tr><tr><td> Lowest</td><td>29.5</td><td>22.3</td><td>30.5</td><td>24.8</td></tr><tr><td> Middle</td><td>28.7</td><td>25.4</td><td>26.8</td><td>20.4</td></tr><tr><td> Highest</td><td>27.5</td><td>23.8</td><td>29.8</td><td>30.8</td></tr><tr><td colspan="5">Unadjusted proportion with osteoporotic (%) fractures<sup>a,d</sup></td></tr><tr><td> Lowest</td><td>5.7</td><td>3.0</td><td>1.1</td><td>0.2</td></tr><tr><td> Middle</td><td>6.2</td><td>1.0</td><td>0.4</td><td>0.4</td></tr><tr><td> Highest</td><td>8.2</td><td>1.8</td><td>1.0</td><td>0.4</td></tr></table> |
d81ed0c0a406ad3977dde082d89ab39c41b5af9c176a7d2e99c3a224d2bcd2fb.png | simple | <table><tr><td>Plan</td><td>Diameter (cm)</td><td>Mean Hippocampal Dose (Gy)</td><td>Mean Hippocampal dose (Gy<sup>2</sup>)</td><td>HI-PTV whole brain</td><td>TC-PTV metastases</td><td>TC-PTV whole brain</td></tr><tr><td>DS 1</td><td>1</td><td>12.55</td><td>8.90</td><td>0.34</td><td>0.52</td><td>0.82</td></tr><tr><td>F 1</td><td>1</td><td>13.95</td><td>10.22</td><td>0.36</td><td>0.51</td><td>0.92</td></tr><tr><td>O 1</td><td>1</td><td>12.82</td><td>9.15</td><td>0.64</td><td>0.54</td><td>0.99</td></tr><tr><td>P 1</td><td>1</td><td>13.25</td><td>9.55</td><td>0.47</td><td>0.54</td><td>0.91</td></tr><tr><td>T 1</td><td>1</td><td>36.10</td><td>33.9</td><td>0.55</td><td>0.53</td><td>0.96</td></tr><tr><td>DS 2</td><td>2</td><td>13.46</td><td>9.75</td><td>0.78</td><td>0.55</td><td>0.92</td></tr><tr><td>F 2</td><td>2</td><td>13.49</td><td>9.78</td><td>0.78</td><td>0.72</td><td>0.90</td></tr><tr><td>O 2</td><td>2</td><td>13.68</td><td>9.96</td><td>0.53</td><td>0.52</td><td>0.92</td></tr><tr><td>P 2</td><td>2</td><td>14.87</td><td>11.12</td><td>0.57</td><td>0.54</td><td>0.93</td></tr><tr><td>T 2</td><td>2</td><td>42.00</td><td>40.27</td><td>0.68</td><td>0.48</td><td>0.90</td></tr><tr><td>DS 3</td><td>3</td><td>17.80</td><td>14.18</td><td>0.77</td><td>0.49</td><td>0.93</td></tr><tr><td>F 3</td><td>3</td><td>15.45 </td><td>11.70 </td><td>0.90</td><td>0.42</td><td>0.91</td></tr><tr><td>O 3</td><td>3</td><td>13.66</td><td>9.94</td><td>0.60</td><td>0.51</td><td>0.93</td></tr><tr><td>P 3</td><td>3</td><td>14.76</td><td>11.01</td><td>0.84</td><td>0.46</td><td>0.93</td></tr><tr><td>T 3</td><td>3</td><td>50.4</td><td>47.16</td><td>0.85</td><td>0.52</td><td>0.80</td></tr></table> |
73eefb1e81fbf23be8e01e17b00a75035b7943dcd47194e3b892dbecfd4f894e.png | complex | <table><tr><td>Rewarming technique</td><td>Rewarming rate</td><td>Notes & controversies</td><td>Rewarming complications</td></tr><tr><td colspan="4">PASSIVE REWARMING [79]</td></tr><tr><td>Passive rewarming</td><td>0.5–4 °C hr<sup>-1</sup> (dependent upon patient’s thermoregulatory function and metabolic reserves) [79, 242].</td><td>Protect from further heat loss and allow patient to self-rewarm. Minimal controversy for mild hypothermia if the patient is able to self-rewarm.</td><td>Negligible in isolated mild hypothermia. For colder patients and those with secondary hypothermia or comorbid illness, there may be morbidity associated with a prolonged rewarming process if the patient has poor tolerance for the hypothermia-induced organ dysfunction (i.e. hypotension, coagulopathy, arrhythmias, impaired cellular function etc.).</td></tr><tr><td>Passive rewarming with active movement</td><td>1–5 °C hr<sup>-1</sup></td><td>Exercise has been shown to increase afterdrop in physiology studies from ~0.3 °C in controls to ~1 °C in exercised subjects, however the exercised subjects rewarmed more quickly [243].</td><td>No reported complications. Some authors highlight the theoretical risk that the slightly increased afterdrop could contribute to morbidity and mortality. No adverse events were noted [243].</td></tr><tr><td colspan="4">ACTIVE EXTERNAL REWARMING</td></tr><tr><td>Active rewarming e.g. forced air surface [244] Arctic Sun® [245–247]</td><td>0.5-4 °C hr<sup>-1</sup></td><td>Protect from further heat loss, deliver external heat and (if required) warmed IV fluids. Minimal controversies.</td><td>Similar to passive rewarming.</td></tr><tr><td colspan="4">ACTIVE INTERNAL REWARMING</td></tr><tr><td>Bladder lavage</td><td>Variable. Adds ~0.5–1 °C hr<sup>-1</sup></td><td>Helpful if rewarming rate is slow. Minimal controversies. Rewarming is intermittent & slow because of small surface area. Poor control of infusate temperature [242, 248, 249].</td><td>Negligible unless difficult catheterization.</td></tr><tr><td>Gastric lavage</td><td>Adds ~0.5–1 °C hr<sup>-1</sup></td><td>Not commonly used due to risk vs. benefit ratio [249].</td><td>Potential for aspiration, fluid & electrolyte shifts.</td></tr><tr><td>Intravascular catheter rewarming e.g. Icy® catheter (CoolGuard®) [76, 250–252]Quattro® [253] Cool Line® [254] Innercool® [255]</td><td>Device specific (adds ~0.5–2.5 °C hr<sup>-1</sup>)</td><td>Uncertain indication for use, potential for benefit exists in colder and sicker co-morbid patients with stable circulation.</td><td>Potential for haemorrhage or thrombosis, potentially worsening hypotension in unstable patients.</td></tr><tr><td>Thoracic [79, 256, 257] or Peritoneal lavage [79, 258]</td><td>Adds ~1–2 °C hr<sup>-1</sup></td><td>Not commonly used unless patient is unstable and ECLS rewarming is not available.</td><td>Potential for haemorrhage, lung or bowel trauma, fluid & electrolyte shifts. Thoracic lavage has the potential to impair CPR quality.</td></tr><tr><td>Continuous venovenous haemofiltration [190, 242, 259–261]</td><td>Adds ~1.5–3 °C hr<sup>-1</sup></td><td>Not commonly used unless ECLS rewarming not available. Requires adequate blood pressure. Heparinisation required.</td><td>Problems rare. Local vascular complications. Air embolism. Hypotension.</td></tr><tr><td>Haemodialysis [242, 262–266]</td><td>Adds ~2–3 °C hr<sup>-1</sup></td><td>Not commonly used, patient must be able to increase cardiac output to perfuse the external circuit. Heparinisation required.</td><td>Potential for hypotension, haemorrhage, thrombosis, haemolysis, etc.</td></tr><tr><td>Veno-venous rewarming (usually with an ECMO circuit) [248]</td><td>~4–10 °C hr<sup>-1</sup></td><td>Not commonly used. Provides no circulatory or ventilatory support in case of cardiac arrest. Patient must be able to increase cardiac output to provide circuit perfusion.</td><td>Potential for hypotension, haemorrhage, thrombosis, haemolysis, etc.</td></tr><tr><td>Extra-corporeal life support (VA-ECMO or CPB)</td><td>~4–10 °C hr<sup>-1</sup></td><td>Preferred rewarming method for patients in cardiac arrest. CPB can use femoral route avoiding need for sternotomy [1, 42]</td><td>Potential for haemorrhage, thrombosis, haemolysis, etc. (as with all intravascular devices).</td></tr></table> |
32e94f9defc5a4bb56618d46f59806c3ba38a0b0b4c0fc53dfe323e46260f1e3.png | simple | <table><tr><td></td><td>Foot Length</td><td>Ball Length</td><td>Ball Width</td><td>MIdfoot Width</td><td>Heel Width</td><td>Dorsal Arch Hgt</td><td>AHR</td></tr><tr><td>FEMALES(N = 97)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Left</td><td>24.4(1.2)</td><td>17.8(0.9)</td><td>9.1(0.5)</td><td>8.0(0.6)</td><td>6.1(0.4)</td><td>6.2(0.4)</td><td>0.349(0.026)</td></tr><tr><td>Right</td><td>24.4(1.2)</td><td>17.9(0.9)</td><td>9.2(0.5)</td><td>8.1(0.6)</td><td>6.1(0.4)</td><td>6.1(0.4)</td><td>0.342(0.030)</td></tr><tr><td>MALES(N = 58)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Left</td><td>26.7(1.3)</td><td>19.5(0.9)</td><td>10.2(0.5)</td><td>9.1(0.6)</td><td>6.8(0.4)</td><td>6.9(0.5)</td><td>0.354(0.03)</td></tr><tr><td>Right</td><td>26.7(1.2)</td><td>19.6(0.9)</td><td>10.2(0.6)</td><td>9.2(0.6)</td><td>6.8(0.4)</td><td>6.8(0.5)</td><td>0.348(0.030)</td></tr></table> |
912db0afad8d8fab3c2006cd49e1f5fd4dd866d3dcf82ad03cea3244abd12f80.png | complex | <table><tr><td colspan="2">Description of main review characteristics and the data extracted from reviews for each characteristic</td></tr><tr><td>Aim</td><td>Adapted from review objectives.</td></tr><tr><td>Scope – <i>Study design</i>, <i>Participants</i>, <i>Interventions</i>, <i>Comparison arms</i>, <i>Outcomes</i></td><td>Adapted from review selection criteria; the number and type of studies and participant numbers included were also extracted.</td></tr><tr><td>Number and types of studies</td><td></td></tr><tr><td>Number of participants</td><td></td></tr><tr><td>Analysis</td><td>Indicates whether meta-analysis and/or narrative data analysis was performed.</td></tr><tr><td>Setting</td><td>Country and predominant settings in which included studies were conducted and interventions delivered.</td></tr><tr><td>Recipient</td><td>Adapted from the Consumers and Communication Review Group scope, which groups reviews via direction of the communication processes (<i>e.g</i>. to the consumer; from the consumer; between provider and consumer; between consumers), so describing both the primary intervention recipient and the major direction of communication processes.</td></tr><tr><td>Provider</td><td>Who delivered the intervention to the recipient. Also describes important characteristics such as experience or training required to deliver the intervention.</td></tr><tr><td>Format</td><td>The predominant delivery format(s) of the intervention. May also include important characteristics such as frequency, intensity or delivery to individuals or groups.</td></tr><tr><td>Quality</td><td>Quality of included studies: summary based on review authors' criteria used to rate included study quality and authors' assessment of included study quality.</td></tr><tr><td></td><td>Quality of the review: based on AMSTAR; includes the overall quality score and summary of criteria that review methods failed to meet.</td></tr><tr><td>Authors' conclusions</td><td>Authors' conclusions added as a composite of points raised in the Discussion and Implications (for practice, for research) sections of the Cochrane review.</td></tr></table> |
bf9e8a17922f519ad42115120046dd1fc6769b3a8d9d98819d55d13145ba4062.png | complex | <table><tr><td colspan="7">Risk of Bias Summary Analysis</td><td></td></tr><tr><td>Risk of Bias Severity</td><td>Bias due to confounding</td><td>Bias in selection of participants into study</td><td>Bias in measurement of interventions</td><td>Bias due to departures from intended interventions</td><td>Bias due to missing data</td><td>Bias in measurement of outcomes</td><td>Bias in selection of reported result</td></tr><tr><td>Low</td><td>N=8; 6%</td><td>N=136; 95% </td><td>N=136; 95% </td><td>N=139; 97%</td><td>N=135; 94% </td><td>N=143; 100% </td><td>N=127; 89% </td></tr><tr><td>Moderate</td><td>N=112; 78%</td><td>N=7; 5% </td><td>N=7; 5% </td><td>N=3; 2% </td><td>N=8; 6% </td><td>N=0; 0% </td><td>N=16; 11% </td></tr><tr><td>Serious</td><td>N=21; 15%</td><td>N=0; 0% </td><td>N=0; 0% </td><td>N=1; 1% </td><td>N=0; 0% </td><td>N=0; 0% </td><td>N=0; 0% </td></tr><tr><td>Critical</td><td>N=2; 1%</td><td>N=0; 0%</td><td>N=0; 0% </td><td>N=0; 0% </td><td>N=0; 0% </td><td>N=0; 0% </td><td>N=0; 0% </td></tr></table> |
cd25153769254bba6d16530d0246149c7b2fbbd0c6c130632bd4a563d84c16dc.png | complex | <table><tr><td rowspan="2">Genotype</td><td colspan="4">rs11245007 (C/T)</td></tr><tr><td>CC</td><td>CT</td><td>TT</td><td>CT + TT</td></tr><tr><td>All subjects</td><td></td><td></td><td></td><td></td></tr><tr><td>Cases (n = 1532)</td><td>432 (28.20)</td><td>738 (48.17)</td><td>362 (23.63)</td><td>1100 (71.80)</td></tr><tr><td>Controls (n = 1573)</td><td>443 (28.16)</td><td>768 (48.82)</td><td>362 (23.01)</td><td>1130 (71.84)</td></tr><tr><td>Crude OR (95 % CI)</td><td>1.00</td><td>0.985 (0.834,1.164)</td><td>1.025 (0.842, 1.249)</td><td>0.998 (0.854, 1.167)</td></tr><tr><td><i>P</i></td><td></td><td>0.863</td><td>0.802</td><td>0.982</td></tr><tr><td>Adjusted OR (95 % CI)<sup>a</sup></td><td>1.00</td><td>0.796 (0.638,0.992)</td><td>0.952 (0.735,1.235)</td><td>0.844 (0.687,1.037)</td></tr><tr><td><i>P</i></td><td></td><td>0.0420</td><td>0.7124</td><td>0.1069</td></tr><tr><td>Parity <3<sup>b</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Cases (n = 1293)</td><td>347 (26.84)</td><td>636 (49.19)</td><td>310 (23.98)</td><td>946 (73.16)</td></tr><tr><td>Controls (n = 1122)</td><td>314 (27.99)</td><td>564 (50.27)</td><td>244 (21.75)</td><td>808 (72.01)</td></tr><tr><td>Adjusted OR (95 % CI)<sup>a</sup></td><td>1.00</td><td>0.962 (0.751,1.232)</td><td>1.324 (0.987,1775)</td><td>1.066 (0.846,1.345)</td></tr><tr><td><i>P</i></td><td></td><td>0.7605</td><td>0.0607</td><td>0.5865</td></tr><tr><td>Parity ≥3<sup>b</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Cases (n = 188)</td><td>67(35.64)</td><td>81 (43.09)</td><td>40 (21.28)</td><td>121 (64.36)</td></tr><tr><td>Controls (n = 426)</td><td>119 (27.93)</td><td>194 (45.54)</td><td>113 (26.53)</td><td>307 (72.07)</td></tr><tr><td>Adjusted OR (95 % CI)<sup>a</sup></td><td>1.00</td><td>0.517 (0.304,0.879)</td><td>0.469 (0.251,0.876)</td><td>0.499 (0.307,0.813)</td></tr><tr><td><i>P</i></td><td></td><td>0.0148</td><td>0.0175</td><td>0.0053</td></tr><tr><td>Family history of cancer<sup>c</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Cases (n = 474)</td><td>126 (26.58)</td><td>238 (50.21)</td><td>110 (23.21)</td><td>348 (73.42)</td></tr><tr><td>Controls (n = 169)</td><td>31 (18.34)</td><td>95 (56.21)</td><td>43 (25.44)</td><td>138 (81.66)</td></tr><tr><td>Adjusted OR (95 % CI)<sup>a</sup></td><td>1.00</td><td>0.530 (0.299,0.937)</td><td>0.592 (0.304,1.151)</td><td>0.548 (0.317,0.946)</td></tr><tr><td><i>P</i></td><td></td><td>0.0289</td><td>0.1223</td><td>0.0308</td></tr><tr><td>No family history of cancer<sup>c</sup></td><td></td><td></td><td></td><td></td></tr><tr><td>Cases (n = 1057)</td><td>306 (28.95)</td><td>500 (47.30)</td><td>251 (23.75)</td><td>751 (71.05)</td></tr><tr><td>Controls (n = 1401)</td><td>411 (29.34)</td><td>672 (47.97)</td><td>318 (22.70)</td><td>990 (70.66)</td></tr><tr><td>Adjusted OR (95 % CI)<sup>a</sup></td><td>1.00</td><td>0.919 (0.723,1.166)</td><td>1.130 (0.854,1.494)</td><td>0.985 (0.788,1.230)</td></tr><tr><td><i>P</i></td><td></td><td>0.4860</td><td>0.3933</td><td>0.8908</td></tr></table> |
12121a802e73046f1dccb6042dd1c3d77b5ac34a3ed2c094544bc5c189448233.png | simple | <table><tr><td>BD type</td><td>Description</td></tr><tr><td>BD-0</td><td>Schizophrenia</td></tr><tr><td>BD-1/2</td><td>Schizobipolar disorder</td></tr><tr><td>BD-I</td><td>'Classic' bipolar disorder</td></tr><tr><td>BD-I1/2</td><td>Depression with protracted hypomania</td></tr><tr><td>BD-II</td><td>Hypomania plus major depression</td></tr><tr><td>BD-II1/2</td><td>Depression superimposed on cyclothymic temperament</td></tr><tr><td>BD-III</td><td>Recurrent depression, plus hypomania occurring solely in association with antidepressant or other somatotherapy</td></tr><tr><td>BD-III1/2</td><td>Mood swings that persist beyond stimulant and/or alcohol abuse</td></tr><tr><td>BD-IV</td><td>Depression superimposed on a hyperthymic temperament</td></tr><tr><td>BD-V</td><td>Recurrent depressions without discrete hypomania, but mixed hypomanic episodes (irritability/agitation/racing thoughts) during depression</td></tr><tr><td>BD-VI</td><td>Bipolarity in the frame of dementia</td></tr></table> |
1787e4ed7eb1c24f08cca067d7a157f4bc981547f1be80c6d87cfd1b92226dcd.png | simple | <table><tr><td>Lipid</td><td>Genotype/allele</td><td>Unstandardized coefficient</td><td>Std. error</td><td>Standardized coefficient</td><td><i>t</i></td><td><i>P</i></td></tr><tr><td>TC</td><td>ACAT-1 rs1044925 genotype</td><td>−0.099</td><td>0.043</td><td>−0.053</td><td>−2.287</td><td>0.022</td></tr><tr><td> </td><td>LIPC -250G>A allele</td><td>0.101</td><td>0.046</td><td>0.050</td><td>2.170</td><td>0.030</td></tr><tr><td> </td><td>LIPG 584C>T genotype</td><td>0.149</td><td>0.043</td><td>0.079</td><td>3.503</td><td>0.000</td></tr><tr><td> </td><td>LIPG 584C>T allele</td><td>0.169</td><td>0.049</td><td>0.077</td><td>3.425</td><td>0.001</td></tr><tr><td> </td><td>MTHFR 677C>T genotype</td><td>0.218</td><td>0.037</td><td>0.133</td><td>5.854</td><td>0.000</td></tr><tr><td> </td><td>MTHFR 677C>T allele</td><td>0.269</td><td>0.046</td><td>0.133</td><td>5.841</td><td>0.000</td></tr><tr><td> </td><td>PPARD +294T>C allele</td><td>0.147</td><td>0.050</td><td>0.068</td><td>2.963</td><td>0.003</td></tr><tr><td>TG</td><td>MTHFR 677C>T genotype</td><td>0.146</td><td>0.054</td><td>0.062</td><td>2.701</td><td>0.007</td></tr><tr><td> </td><td>MYLIP rs3757354 genotype</td><td>−0.102</td><td>0.042</td><td>−0.057</td><td>−2.456</td><td>0.014</td></tr><tr><td> </td><td>PPARD +294T>C allele</td><td>0.321</td><td>0.086</td><td>0.087</td><td>3.732</td><td>0.000</td></tr><tr><td> </td><td>SCARB1 rs5888 genotype</td><td>−0.041</td><td>0.023</td><td>−0.049</td><td>−2.039</td><td>0.042</td></tr><tr><td>HDL-C</td><td>ACAT-1 rs1044925 genotype</td><td>−0.057</td><td>0.022</td><td>−0.062</td><td>−2.643</td><td>0.008</td></tr><tr><td> </td><td>ACAT-1 rs1044925 allele</td><td>−0.051</td><td>0.025</td><td>−0.048</td><td>−2.024</td><td>0.043</td></tr><tr><td> </td><td>LIPC -250G>A genotype</td><td>0.038</td><td>0.016</td><td>0.055</td><td>2.366</td><td>0.018</td></tr><tr><td> </td><td>LIPG 584C>T genotype</td><td>0.086</td><td>0.018</td><td>0.108</td><td>4.667</td><td>0.000</td></tr><tr><td> </td><td>LIPG 584C>T allele</td><td>0.080</td><td>0.021</td><td>0.087</td><td>3.762</td><td>0.000</td></tr><tr><td> </td><td>MTHFR 677C>T genotype</td><td>0.097</td><td>0.017</td><td>0.132</td><td>5.718</td><td>0.000</td></tr><tr><td> </td><td>MTHFR 677C>T allele</td><td>0.123</td><td>0.021</td><td>0.136</td><td>5.868</td><td>0.000</td></tr><tr><td> </td><td>MYLIP rs3757354 genotype</td><td>0.036</td><td>0.015</td><td>0.058</td><td>2.465</td><td>0.014</td></tr><tr><td>LDL-C</td><td>ABCA-1 V825I genotype</td><td>0.075</td><td>0.025</td><td>0.068</td><td>2.954</td><td>0.003</td></tr><tr><td> </td><td>MTHFR 677C>T genotype</td><td>0.075</td><td>0.029</td><td>0.059</td><td>2.562</td><td>0.010</td></tr><tr><td> </td><td>MTHFR 677C>T allele</td><td>0.120</td><td>0.036</td><td>0.077</td><td>3.334</td><td>0.001</td></tr><tr><td>ApoA1</td><td>ACAT-1 rs1044925 genotype</td><td>−0.042</td><td>0.013</td><td>−0.074</td><td>−3.143</td><td>0.002</td></tr><tr><td> </td><td>ACAT-1 rs1044925 allele</td><td>−0.042</td><td>0.016</td><td>−0.063</td><td>−2.672</td><td>0.008</td></tr><tr><td> </td><td>LIPC -250G>A genotype</td><td>0.036</td><td>0.012</td><td>0.068</td><td>3.020</td><td>0.003</td></tr><tr><td> </td><td>LIPG 584C>T genotype</td><td>0.040</td><td>0.012</td><td>0.076</td><td>3.303</td><td>0.001</td></tr><tr><td> </td><td>LIPG 584C>T allele</td><td>0.039</td><td>0.014</td><td>0.064</td><td>2.781</td><td>0.005</td></tr><tr><td> </td><td>MTHFR 677C>T genotype</td><td>0.053</td><td>0.010</td><td>0.118</td><td>5.130</td><td>0.000</td></tr><tr><td> </td><td>MTHFR 677C>T allele</td><td>0.068</td><td>0.013</td><td>0.123</td><td>5.338</td><td>0.000</td></tr><tr><td>ApoB</td><td>MTHFR 677C>T genotype</td><td>0.032</td><td>0.008</td><td>0.086</td><td>3.781</td><td>0.000</td></tr><tr><td> </td><td>MTHFR 677C>T allele</td><td>0.042</td><td>0.010</td><td>0.092</td><td>4.049</td><td>0.000</td></tr><tr><td>ApoA1/ApoB</td><td>LIPC -250G>A genotype</td><td>0.070</td><td>0.026</td><td>0.063</td><td>2.649</td><td>0.008</td></tr></table> |
4102d2dcff43b271e762b066f44ca0d566586e1ebbc6ef3c5442d68cf242e072.png | complex | <table><tr><td colspan="2">Characteristics</td><td>Local Lab (n=734), n (%)</td></tr><tr><td>Age</td><td>Median±SD</td><td>60.4±11.50</td></tr><tr><td></td><td><60 </td><td>337(46.0)</td></tr><tr><td></td><td>≥60 </td><td>395(54.0)</td></tr><tr><td></td><td>NA</td><td>2</td></tr><tr><td>Gender</td><td>Male</td><td>525(71.8)</td></tr><tr><td></td><td>Female</td><td>206(28.2)</td></tr><tr><td></td><td>NA</td><td>3</td></tr><tr><td>Tissue type</td><td> Resection</td><td>693(94.4)</td></tr><tr><td></td><td> Biopsy</td><td>41(5.6)</td></tr><tr><td>Stage<sup>*</sup></td><td> I-IIIa</td><td>428(58.3)</td></tr><tr><td></td><td> IIIb/IIIc</td><td>187(25.5)</td></tr><tr><td></td><td> IV</td><td>82(11.2)</td></tr><tr><td></td><td> NA</td><td>37(5.0)</td></tr><tr><td>Tumor location</td><td> Stomach</td><td>535(72.9)</td></tr><tr><td></td><td> GE junction</td><td>199(27.1)</td></tr><tr><td></td><td> Intestinal</td><td>292(39.8)</td></tr><tr><td>Lauren</td><td>Diffuse</td><td>254(34.6)</td></tr><tr><td></td><td>Mixed</td><td>188(25.6)</td></tr></table> |
a0d4429ac16fb835e91fc66bba0ae76dc48215e5afc1f67b9390f2102ce43148.png | complex | <table><tr><td rowspan="2">Variables</td><td rowspan="2">Category</td><td>Cases</td><td>Controls</td><td>Crude OR</td><td rowspan="2"><i>P</i>-value</td></tr><tr><td>No (%)</td><td>No (%)</td><td>(95 % CI)</td></tr><tr><td rowspan="2">Knew about immunization</td><td>Yes</td><td>101 (55.5)</td><td>263 (72.6)</td><td>1</td><td></td></tr><tr><td>No</td><td>81 (44.5)</td><td>99 (27.3)</td><td>2.13 (1.46, 3.09)</td><td><0.001*</td></tr><tr><td rowspan="2">Knew the schedule of vaccines</td><td>Yes</td><td>50 (49.5)</td><td>134 (51)</td><td>1</td><td></td></tr><tr><td>No</td><td>51 (50.5)</td><td>129 (49)</td><td>1.06 (0.67, 1.67)</td><td>0.8</td></tr><tr><td rowspan="2">Knew the benefits of immunization</td><td>Yes</td><td>88 (87.9)</td><td>256 (97.7)</td><td>1</td><td></td></tr><tr><td>No</td><td>13 (12.1)</td><td>6 (2.3)</td><td>6.30 (2.32, 17.08)</td><td><0.001*</td></tr><tr><td rowspan="2">Knew about vaccine side effects</td><td>Yes</td><td>25 (24.8)</td><td>47 (18)</td><td>1.49 (0.85, 2.56)</td><td rowspan="2">0.16</td></tr><tr><td>No</td><td>76 (75.2)</td><td>214 (82)</td><td>1</td></tr><tr><td rowspan="2">Attitude towards benefits of immunization</td><td>Positive</td><td>165 (94.8)</td><td>339 (96.6)</td><td>1</td><td></td></tr><tr><td>Negative</td><td>9 (5.2)</td><td>12 (3.4)</td><td>1.54 (0.63, 3.73)</td><td>0.33</td></tr><tr><td rowspan="2">Perception about vaccine side effects</td><td>Positive</td><td>104 (60.1)</td><td>236 (65.9)</td><td>1</td><td></td></tr><tr><td>Negative</td><td>69 (39.8)</td><td>122 (34.1)</td><td>1.28 (0.86, 1.88)</td><td>0.21</td></tr><tr><td rowspan="2">Attitude towards the last received child immunization</td><td>Positive</td><td>90 (49.7)</td><td>176 (49)</td><td>1</td><td></td></tr><tr><td>Negative</td><td>91 (50.3)</td><td>183 (51)</td><td>0.97 (0.68, 1.39)</td><td>0.8</td></tr></table> |
c370b2324ff6af489c133ba010c26d23dc8bbd1b19b29eb8b5db07087cd25c21.png | complex | <table><tr><td rowspan="2">Food Groups</td><td colspan="4">Men (<i>n</i> = 968)</td><td colspan="4">Women (<i>n</i> = 1078)</td></tr><tr><td>Rice Staple</td><td>Wheat Staple</td><td>Snacks</td><td>Prudent</td><td>Rice Staple</td><td>Wheat Staple</td><td>Snacks</td><td>Prudent</td></tr><tr><td>Rice</td><td>0.413</td><td>−0.503</td><td>−0.462</td><td></td><td>0.415</td><td>−0.565</td><td></td><td></td></tr><tr><td>Wheat</td><td></td><td>0.619</td><td></td><td></td><td></td><td>0.575</td><td></td><td></td></tr><tr><td>Deep fried wheat</td><td></td><td>0.213</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Instant noodles</td><td>−0.221</td><td>0.213</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Coarse grains</td><td></td><td></td><td></td><td>0.966</td><td></td><td>0.278</td><td></td><td>0.929</td></tr><tr><td>Starchy roots and tubers</td><td>0.295</td><td>−0.439</td><td>0.352</td><td></td><td></td><td></td><td>0.428</td><td></td></tr><tr><td>Vegetables</td><td>0.580</td><td></td><td>−0.370</td><td></td><td>0.684</td><td></td><td></td><td></td></tr><tr><td>Fruits</td><td></td><td></td><td>0.277</td><td>0.966</td><td></td><td>0.280</td><td>0.464</td><td>0.928</td></tr><tr><td>Pork</td><td>0.244</td><td></td><td>−0.216</td><td>−0.202</td><td>0.267</td><td></td><td>−0.279</td><td></td></tr><tr><td>Poultry</td><td>0.571</td><td></td><td></td><td></td><td>0.319</td><td></td><td></td><td></td></tr><tr><td>Other livestock meats</td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Organ meats</td><td>0.226</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Processed meats</td><td>0.466</td><td></td><td></td><td></td><td></td><td>−0.355</td><td></td><td>0.274</td></tr><tr><td>Fresh water fish and seafood</td><td></td><td>−0.447</td><td></td><td></td><td>0.286</td><td></td><td></td><td>0.203</td></tr><tr><td>Dairy</td><td></td><td>0.383</td><td></td><td>0.317</td><td></td><td>0.591</td><td></td><td></td></tr><tr><td>Legumes</td><td></td><td>0.370</td><td></td><td></td><td></td><td>0.264</td><td></td><td></td></tr><tr><td>Eggs</td><td></td><td></td><td>−0.446</td><td></td><td>0.464</td><td></td><td></td><td></td></tr><tr><td>Seeds and nuts</td><td>0.288</td><td></td><td></td><td></td><td></td><td>0.201</td><td>0.669</td><td></td></tr><tr><td>Fungi and algae</td><td>0.312</td><td></td><td></td><td></td><td>0.474</td><td>0.200</td><td></td><td></td></tr><tr><td>Western fast food</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cakes and pastries</td><td></td><td></td><td>0.433</td><td></td><td></td><td></td><td>0.541</td><td></td></tr><tr><td>Candy and chocolates</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Soft drinks</td><td></td><td></td><td>0.407</td><td></td><td></td><td>0.363</td><td></td><td></td></tr><tr><td>Alcoholic beverages</td><td></td><td></td><td>0.306</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Tea</td><td></td><td>0.344</td><td>0.201</td><td>0.220</td><td></td><td>0.236</td><td></td><td></td></tr></table> |
f02effa9b408ff5cdcadbd41b253beefa6b71c90d9d13a190c5fc6d9a27a36e5.png | complex | <table><tr><td>Characteristic</td><td>Greenland (<i>n</i> = 513) </td><td>Warsaw, Poland (<i>n</i> = 180)</td><td>Kharkiv, Ukraine (<i>n</i> = 557)</td></tr><tr><td>Maternal age at delivery (years)</td></tr><tr><td>18–24</td><td>235 (45.8)</td><td>12 (6.7)</td><td>299 (53.7)</td></tr><tr><td>25–29</td><td>119 (23.2)</td><td>110 (61.1)</td><td>164 (29.4)</td></tr><tr><td>30–34</td><td>82 (16.0)</td><td>55 (27.8)</td><td>76 (13.6)</td></tr><tr><td>35–45</td><td>77 (15.0)</td><td>8 (4.4)</td><td>18 (3.2)</td></tr><tr><td>Prepregnancy BMI (kg/m<sup>2</sup>)</td></tr><tr><td>< 18.5</td><td>14 (2.7)</td><td>11 (6.1)</td><td>79 (14.2)</td></tr><tr><td>18.5–24.9</td><td>306 (59.6)</td><td>154 (85.6)</td><td>410 (73.6) </td></tr><tr><td>25.0–29.9</td><td>136 (26.5)</td><td>13 (7.2)</td><td>56 (10.1)</td></tr><tr><td>≥ 30</td><td>57 (11.1)</td><td>2 (1.1)</td><td>12 (2.2)</td></tr><tr><td>Maternal height (cm)</td><td>162.0 ± 6.8</td><td>166.3 ± 5.2</td><td>165.28 ± 6.0</td></tr><tr><td>Parity</td></tr><tr><td>0 </td><td>161 (31.4)</td><td>153 (85.0)</td><td>440 (79.0)</td></tr><tr><td>1 </td><td>153 (29.8)</td><td>24 (13.3)</td><td>95 (17.1)</td></tr><tr><td>2 </td><td>104 (20.3)</td><td>2 (1.1)</td><td>12 (2.2)</td></tr><tr><td>≥ 3</td><td>95 (18.5)</td><td>1 (0.6)</td><td>10 (1.8)</td></tr><tr><td>Serum cotinine (ng/mL)</td></tr><tr><td>< 5.0</td><td>208 (40.5)</td><td>178 (98.9)</td><td>465 (83.5)</td></tr><tr><td>5.0–49.9</td><td>87 (17.0)</td><td>2 (1.1)</td><td>54 (9.7)</td></tr><tr><td>≥ 50.0</td><td>218 (42.5)</td><td>0 (0.0)</td><td>38 (6.8)</td></tr><tr><td>Maternal education </td></tr><tr><td>No postsecondary</td><td>244 (50.9)</td><td>8 (4.4)</td><td>221 (39.7)</td></tr><tr><td>Some postsecondary</td><td>235 (49.1)</td><td>172 (95.6)</td><td>335 (60.3)</td></tr><tr><td>Missing</td><td>34</td><td>0</td><td>1</td></tr><tr><td>Alcohol intake (drinks/week)<sup><i>a</i></sup></td></tr><tr><td>< 7</td><td>450 (87.7)</td><td>169 (93.9)</td><td>553 (99.3)</td></tr><tr><td>≥ 7</td><td>63 (12.3)</td><td>11 (6.1)</td><td>4 (0.7)</td></tr><tr><td>Fish or seafood (days/week)</td><td>1.87 ± 1.53</td><td>1.28 ± 1.06</td><td>1.08 ± 1.53</td></tr><tr><td>Missing</td><td>12</td><td>10</td><td>60</td></tr><tr><td>Serum vitamin D (ng/mL)</td><td>17.56 ± 9.51</td><td>28.34 ± 11.73</td><td>22.46 ± 10.73</td></tr><tr><td>Timing of blood sampling (gestational weeks)</td></tr><tr><td>1–13 </td><td>66 (13.3)</td><td>1 (0.6)</td><td>157 (28.9)</td></tr><tr><td>14–26</td><td>229 (46.1)</td><td>11 (6.2)</td><td>156 (28.7)</td></tr><tr><td>≥ 27</td><td>202 (40.6)</td><td>166 (93.3)</td><td>231 (42.5)</td></tr><tr><td>Missing</td><td>16</td><td>2</td><td>13</td></tr><tr><td>Season of blood sampling</td></tr><tr><td>October–March</td><td>274 (53.5)</td><td>135 (75.8)</td><td>353 (64.5)</td></tr><tr><td>April–September</td><td>238 (46.5)</td><td>43 (24.2)</td><td>194 (35.5)</td></tr><tr><td>Missing</td><td>1</td><td>2</td><td>10</td></tr><tr><td>Infant sex</td></tr><tr><td>Female</td><td>237 (46.2)</td><td>92 (51.1)</td><td>264 (47.4)</td></tr><tr><td>Male</td><td>276 (53.8)</td><td>88 (48.9)</td><td>293 (52.6)</td></tr><tr><td>Term birth weight (g)</td></tr><tr><td>< 2,500</td><td>11 (2.1)</td><td>1 (0.6)</td><td>7 (1.3)</td></tr><tr><td>2,500–2,999</td><td>44 (8.6)</td><td>18 (10.0)</td><td>98 (17.6)</td></tr><tr><td>3,000–3,499</td><td>142 (27.7)</td><td>71 (39.4)</td><td>269 (48.3)</td></tr><tr><td>3,500–3,999</td><td>175 (34.1)</td><td>66 (36.7)</td><td>158 (28.4)</td></tr><tr><td>≥ 4,000</td><td>141 (27.5)</td><td>24 (13.3)</td><td>25 (4.5)</td></tr><tr><td>Gestational age (weeks)</td><td>39.85 ± 1.34</td><td>39.53 ± 1.25</td><td>39.21 ± 1.00</td></tr><tr><td colspan="4"><sup><i>a</i></sup>During the period around conception.</td></tr></table> |
dfd9d5ea877e67f1e8714d1478cbb7d6ada1c8e33d19f1bf959e4176fdf05f3b.png | complex | <table><tr><td> </td><td colspan="2">Girls (<i>n </i>= 603)</td><td colspan="2">Boys (<i>n </i>= 509)</td><td><i>p</i></td></tr><tr><td rowspan="2">Age</td><td colspan="2">10 – 16 years</td><td colspan="2">11 – 16 year</td><td rowspan="2">.003</td></tr><tr><td colspan="2"><i>M</i> = 13.32, <i>SD</i> = 0.79</td><td colspan="2"><i>M</i> = 13.46, <i>SD</i> = 0.83</td></tr><tr><td rowspan="3">Grade</td><td>36.7%</td><td>grade 7</td><td>33.8%</td><td>grade 7</td><td rowspan="3"><i>n.s.</i></td></tr><tr><td>36.3%</td><td>grade 8</td><td>36.9%</td><td>grade 8</td></tr><tr><td>27.0%</td><td>grade 9</td><td>29.3%</td><td>grade 9</td></tr><tr><td>BMI</td><td colspan="2"><i>M</i> = 18.63, <i>SD</i> = 2.57</td><td colspan="2"><i>M</i> = 18.70, <i>SD</i> = 2.73</td><td><i>n.s.</i></td></tr></table> |
d82ea9917e2216716538e81337b08fa94bd6f524b15f6e2d6d3cb56c8dad607f.png | simple | <table><tr><td>Gene ID</td><td>log<sub>2</sub> Ratio</td><td><i>P</i>-value</td><td>Annotation</td><td>Stress response<sup>∗</sup></td></tr><tr><td>LOC_Os07g44499</td><td>8.19</td><td>8.60E-07</td><td>Peroxidase</td><td>D, S</td></tr><tr><td>LOC_Os08gl4860</td><td>6.67</td><td>1.25E-29</td><td>Hydroxyacid oxidase 1</td><td>D</td></tr><tr><td>LOC_Os01g52240</td><td>6.05</td><td>7.61E-36</td><td>Type I chlorophyll a/b-binding protein</td><td>D</td></tr><tr><td>LOC_Os08gl5080</td><td>5.58</td><td>1.93E-26</td><td>Proline rich protein 3</td><td>D, S</td></tr><tr><td>LOC_Os02g39620</td><td>4.95</td><td>1.72E-08</td><td>Stress-induced protein OZI1</td><td>D, S</td></tr><tr><td>LOC_Osllg24140</td><td>4.53</td><td>2.59E-22</td><td>Uclacyanin-like protein 35</td><td></td></tr><tr><td>LOC_Os07g44480</td><td>4.47</td><td>2.67E-06</td><td>Peroxidase</td><td>D, A</td></tr><tr><td>LOC_Os01g02010</td><td>4.19</td><td>4.75E-05</td><td>Arabinogalactan protein 12</td><td>S, C</td></tr><tr><td>LOC_Os08g27850</td><td>3.76</td><td>7.07E-74</td><td>MBF1 transcription factor</td><td></td></tr><tr><td>LOC_Os08g28670</td><td>3.61</td><td>2.19E-15</td><td>Bet v I allergen family protein</td><td></td></tr><tr><td>LOC_Os01g41710</td><td>2.95</td><td>5.55E-37</td><td>Chlorophyll a-b binding protein 2</td><td>D</td></tr><tr><td>LOC_Os08g16070</td><td>2.91</td><td>5.16E-06</td><td>Stress response</td><td></td></tr><tr><td>LOC_Os07g41350</td><td>2.83</td><td>6.63E-21</td><td>B12D-like protein 1</td><td>S, C</td></tr><tr><td>LOC_Os06gl6170</td><td>2.82</td><td>1.10E-06</td><td>Protein of unknown DUF231</td><td>D</td></tr><tr><td>LOC_Os01g58970</td><td>2.75</td><td>2.57E-10</td><td>Cytochrome P450 protein</td><td>D, C</td></tr><tr><td>LOC_Os06g45940</td><td>2.67</td><td>5.15E-30</td><td><i>OsHAKB13</i></td><td>D, S,C</td></tr><tr><td>LOC_Os05gl2280</td><td>2.58</td><td>9.65E-09</td><td>Clumping factor A precursor</td><td></td></tr><tr><td>LOC_Osl0g41430</td><td>2.46</td><td>2.87E-09</td><td>Cyclin-U 4;3</td><td>D, S,C</td></tr><tr><td>LOC_Os01g07700</td><td>2.32</td><td>2.57E-09</td><td>Conserved hypothetical protein</td><td>C</td></tr><tr><td>LOC_Os07g37240</td><td>2.21</td><td>1.74E-11</td><td>Chlorophyll A-B binding protein</td><td>D, S,C</td></tr><tr><td>LOC_Os02g44080</td><td>2.20</td><td>2.57E-09</td><td><i>OsTIP2</i></td><td>S, C</td></tr><tr><td>LOC_Osl0g31740</td><td>2.19</td><td>1.60E-06</td><td>Glycine-rich cell wall structural protein 2</td><td></td></tr><tr><td>LOC_Os06g01210</td><td>2.14</td><td>1.24E-07</td><td><i>OsPLAS</i></td><td></td></tr><tr><td>LOC_Osllg20790</td><td>2.12</td><td>4.79E-06</td><td>Adenylate kinase B</td><td>D, S</td></tr><tr><td>LOC_Os05g01680</td><td>2.09</td><td>2.91E-05</td><td>LEA related protein</td><td></td></tr><tr><td>LOC_Osl0g40700</td><td>2.07</td><td>1.23E-06</td><td>Beta-expansin 6</td><td>D, S, C</td></tr><tr><td>LOC_Os06g40818</td><td>2.07</td><td>2.80E-05</td><td>Aspartic proteinase</td><td>D, S, C</td></tr><tr><td>LOC_Os08g01380</td><td>2.02</td><td>4.79E-05</td><td>Ferredoxin I</td><td>D, S, C</td></tr><tr><td>LOC_Os02g03620</td><td>2.00</td><td>2.39E-05</td><td>RING-HC protein 9</td><td>D, S, C</td></tr><tr><td>LOC_Os03gl2290</td><td>1.99</td><td>2.36E-37</td><td><i>OsGSl;2</i></td><td>D, S</td></tr><tr><td>LOC_Os04g38600</td><td>1.94</td><td>6.85E-19</td><td><i>GADPH</i></td><td>D, S, C</td></tr><tr><td>LOC_Os05g47700</td><td>1.89</td><td>1.94E-11</td><td>Lipid transfer protein 2;4</td><td>D, S, C</td></tr><tr><td>LOC_Os01g73200</td><td>1.80</td><td>1.26E-39</td><td>Peroxidase BP 1</td><td>D</td></tr><tr><td>LOC_Osl2g36210</td><td>1.78</td><td>9.13E-19</td><td>Similar to MPI.</td><td></td></tr><tr><td>LOC_Os07gl5370</td><td>1.74</td><td>1.59E-09</td><td><i>OsNRAMPS</i></td><td>D, S, C</td></tr><tr><td>LOC_Os09g25490</td><td>1.73</td><td>1.17E-12</td><td>Cellulose synthase catalytic subunit genes 9</td><td>D, S, C</td></tr><tr><td>LOC_Os02g07410</td><td>1.71</td><td>1.05E-09</td><td>Glycine cleavage H-protein</td><td>D, S</td></tr><tr><td>LOC_Os08g05960</td><td>1.69</td><td>3.48E-10</td><td>Defense-responsive gene 10</td><td>D, S, C</td></tr><tr><td>LOC_Os01gl3690</td><td>1.69</td><td>4.96E-07</td><td>ligA</td><td>D, S, C</td></tr><tr><td>LOC_Os03g59210</td><td>1.68</td><td>2.68E-09</td><td>Conserved hypothetical protein</td><td>D, S</td></tr><tr><td>LOC_Os02g51080</td><td>1.65</td><td>6.26E-06</td><td><i>LYL1</i></td><td>D, S, C</td></tr><tr><td>LOC_Os08g38170</td><td>1.63</td><td>2.21E-09</td><td>Methyladenine glycosylase</td><td>D, S, C</td></tr><tr><td>LOC_Os07g36090</td><td>1.62</td><td>1.01E-06</td><td>Ribosomal protein L28</td><td>D</td></tr><tr><td>LOC_Os05g09440</td><td>1.61</td><td>4.21E-34</td><td><i>0sNADP-ME3</i></td><td>D, S, C</td></tr><tr><td>LOC_Os03g08710</td><td>1.59</td><td>5.25E-08</td><td>Thionin 26</td><td></td></tr><tr><td>LOC_Os08g01350</td><td>1.59</td><td>1.57E-05</td><td>Transmembrane protein 18</td><td>D</td></tr><tr><td>LOC_Os03g01700</td><td>1.59</td><td>1.40E-16</td><td><i>LSI2</i></td><td>D, S</td></tr></table> |
0a9c5a4daca72b5f85c92d503f42a1439d98653c9737eb7b13e8dcafcae2a47f.png | complex | <table><tr><td></td><td>All</td><td>IFX</td><td>TCZ</td><td>ABT</td><td><i>p</i> Value<sup>a</sup></td></tr><tr><td>Number of patients</td><td>209</td><td>140</td><td>38</td><td>31</td><td>–</td></tr><tr><td>Female sex, <i>n</i> (%)</td><td>172 (82.3 %)</td><td>113 (80.7 %)</td><td>34 (89.5 %)</td><td>25 (80.6 %)</td><td>0.46626</td></tr><tr><td>Age, yr, median (IQR)</td><td>59.0 (47.0–66.0)</td><td>57.5 (46.0–64.3)</td><td>56.0 (44.8–64.0)</td><td>67.0 (62.0–74.0)</td><td>0.00003</td></tr><tr><td>Disease duration, yr, median (IQR)</td><td>3.3 (1.1–10.5)</td><td>3.3 (1.1–10.3)</td><td>4.2 (1.5–9.4)</td><td>2.4 (0.5–14.5)</td><td>0.86013</td></tr><tr><td colspan="6">Concomitant drug use</td></tr><tr><td> Steroid use, <i>n</i> (%)</td><td>80 (38.3 %)</td><td>56 (40.0 %)</td><td>14 (36.8 %)</td><td>10 (32.3 %)</td><td>0.75247</td></tr><tr><td> Steroid dose, mg/day, median (IQR)</td><td>0 (0–5.0)</td><td>0 (0–5.0)</td><td>0 (0–3.0)</td><td>0 (0–2.5)</td><td>0.34861</td></tr><tr><td> MTX dose, mg/week, median (IQR)</td><td>8.0 (8.0–8.0)</td><td>8.0 (8.0–10.0)</td><td>8.0 (6.0–8.0)</td><td>8.0 (6.0–8.0)</td><td>0.00271</td></tr><tr><td> csDMARD use<sup>b</sup> (except MTX), <i>n</i> (%)</td><td>29 (13.9 %)</td><td>20 (14.3 %)</td><td>5 (13.2 %)</td><td>4 (12.9 %)</td><td>1.00000</td></tr><tr><td colspan="6">Serological markers</td></tr><tr><td> RF positivity, <i>n</i> (%)</td><td>154 (74.8 %)<sup>c</sup></td><td>103 (74.1 %)<sup>d</sup></td><td>28 (73.7 %)</td><td>23 (79.3 %)<sup>e</sup></td><td>0.88544</td></tr><tr><td> RF titer, median (IQR)</td><td>55 (15–115)<sup>c</sup></td><td>53 (14–115)<sup>d</sup></td><td>54 (17–115)</td><td>77 (22–106)<sup>e</sup></td><td>0.94307</td></tr><tr><td> ACPA positivity, <i>n</i> (%)</td><td>85 (85.9 %)<sup>f</sup></td><td>51 (85.0 %)<sup>g</sup></td><td>13 (100 %)<sup>h</sup></td><td>21 (80.8 %)<sup>i</sup></td><td>0.31205</td></tr><tr><td> ACPA titer, median (IQR)</td><td>85.6 (12.8–100)<sup>f</sup></td><td>100 (13.3–100)<sup>g</sup></td><td>83 (42.9–100)<sup>h</sup></td><td>62.1 (9.8–100)<sup>i</sup></td><td>0.89773</td></tr><tr><td>TJC28, median (IQR)</td><td>6.0 (2.0–8.0)</td><td>6.0 (2.0–8.3)</td><td>6.0 (3.0–8.8)</td><td>6.0 (3.0–8.0)</td><td>0.68798</td></tr><tr><td>SJC28, median (IQR)</td><td>6.0 (3.0–11.0)</td><td>7.0 (3.8–11.0)</td><td>6.0 (4.0–8.0)</td><td>5.0 (3.0–8.0)</td><td>0.46376</td></tr><tr><td>PtGA, mm, median (IQR)</td><td>53 (28–72)</td><td>52 (27–72)</td><td>52 (31–67)</td><td>63 (41–73)</td><td>0.34811</td></tr><tr><td>PhGA, mm, median (IQR)</td><td>43 (30–60)</td><td>43 (29–63)</td><td>43 (33–60)</td><td>45 (31–56)</td><td>0.91700</td></tr><tr><td>CRP, mg/dl, median (IQR)</td><td>0.9 (0.4–2.4)</td><td>1.0 (0.4–2.6)</td><td>0.6 (0.2–2.0)</td><td>0.8 (0.4–2.0)</td><td>0.19092</td></tr><tr><td>ESR, mm/h, median (IQR)</td><td>42 (25–69)</td><td>45 (28–69)</td><td>37 (22–60)</td><td>37 (23–74)</td><td>0.27517</td></tr><tr><td>DAS28-ESR, median (IQR)</td><td>5.3 (4.4–6.1)</td><td>5.3 (4.4–6.2)</td><td>5.1 (4.5–5.8)</td><td>5.5 (4.7–6.1)</td><td>0.65899</td></tr><tr><td>SDAI score, median (IQR)</td><td>22.5 (16.2–31.3)</td><td>23.2 (15.6–32.2)</td><td>22.1 (16.8–28.5)</td><td>23.3 (16.8–31.5)</td><td>0.96973</td></tr><tr><td>CDAI score, median (IQR)</td><td>21.7 (14.9–28.9)</td><td>21.9 (14.6–29.6)</td><td>20.6 (16.4–26.0)</td><td>22.8 (15.1–28.5)</td><td>0.99430</td></tr></table> |
80416f0805d2bc2f5ee823354a671eb902a4d85936e05d3a63662b029fe2cda4.png | complex | <table><tr><td></td><td>Analysate</td></tr><tr><td rowspan="7">Red blood cells</td><td>Haemoglobin</td></tr><tr><td>Red corpuscle count</td></tr><tr><td>Haematocrit</td></tr><tr><td>Mean corpuscular volume</td></tr><tr><td>Mean corpuscular</td></tr><tr><td>Haemoglobin concentration</td></tr><tr><td>Red blood cell distribution width</td></tr><tr><td rowspan="2">White blood cells</td><td>White cell count Total count</td></tr><tr><td>Differential count</td></tr><tr><td rowspan="2">Platelets</td><td>Platelets Count</td></tr><tr><td>Mean platelet volume</td></tr><tr><td rowspan="6">Urea</td><td>Urine specific gravity</td></tr><tr><td>Ery</td></tr><tr><td>Urea nitrogen</td></tr><tr><td>Uric acid (UA)</td></tr><tr><td>Creatinine (Cr)</td></tr><tr><td>Urine protein</td></tr><tr><td rowspan="4">Liver function tests (plasma)</td><td>Alkaline phosphatise</td></tr><tr><td>Alanine transaminase (ALT)</td></tr><tr><td>Aspartate aminotransferase (AST)</td></tr><tr><td>Phosphatise Transglutaminase (TG)</td></tr><tr><td rowspan="5">Liver function tests (serum)</td><td>HBsAg</td></tr><tr><td>Anti-HBs</td></tr><tr><td>HBeAg</td></tr><tr><td>Anti-HBe</td></tr><tr><td>Anti-HBc</td></tr><tr><td rowspan="5">Lipids (plasma)</td><td>Total cholesterol (TC)</td></tr><tr><td>Total bilirubin (TBIL)</td></tr><tr><td>Triglycerides (TG)</td></tr><tr><td>Low density lipoprotein (LDL)</td></tr><tr><td>Very Low density lipoprotein (VLDL)</td></tr><tr><td rowspan="6">General chemistry (plasma)</td><td>C-reactive protein</td></tr><tr><td>Homocysteine</td></tr><tr><td>Steroids</td></tr><tr><td>Glucose</td></tr><tr><td>Insulin</td></tr><tr><td>Glycosylated hemoglobin</td></tr><tr><td colspan="2">Bio-specimen banking</td></tr><tr><td> White blood cells</td><td>DNA, RNA extraction and analyses</td></tr><tr><td> Serum</td><td>Pedtidome profiling</td></tr><tr><td> Plasma</td><td>Glycome</td></tr></table> |
14ff2a3a69f74043b64702b531fd5c29259e4737ab42e094aaa769e70dfb90df.png | complex | <table><tr><td>Gene</td><td>Direction</td><td>Primer sequence</td><td>Product size</td><td>Reference</td></tr><tr><td rowspan="2">CYP2E1</td><td>Forward</td><td>TCCAGGTTTGCACCAGACTCT</td><td rowspan="2">76 bp</td><td rowspan="2">[26]</td></tr><tr><td>Reverse</td><td>TCCTCGCTCCTCCTGAGAAG</td></tr><tr><td rowspan="2">TP53 Exon 7</td><td>Forward</td><td>GTG GTA CCG TAT GAG CCA CC</td><td rowspan="2">157 bp</td><td rowspan="2">[27]</td></tr><tr><td>Reverse</td><td>CAA CCT GGC ACA CAG CTT CC</td></tr><tr><td rowspan="2">COX2</td><td>Forward</td><td>AAA GCC TCGTCCAGATGCTA</td><td rowspan="2">249 bp</td><td rowspan="2">[26]</td></tr><tr><td>Reverse</td><td>ATGGTGGCTGTCTTGGTAGG</td></tr><tr><td rowspan="2">GAPDH</td><td>Forward</td><td>ACCACAGTCCATGCCATCAC</td><td rowspan="2">460 bp</td><td rowspan="2">[28]</td></tr><tr><td>Reverse</td><td>TCCACCACCCTGTTG CTGTA</td></tr></table> |
33c9dc9adcb52f41b2bcbf397db0082513655dc4c4798b6022a408035641ba69.png | complex | <table><tr><td></td><td colspan="4">Year 2000 vs Year 2008</td><td></td></tr><tr><td></td><td colspan="2">URBAN RESIDENCE</td><td colspan="2">RURAL RESIDENCE</td><td></td></tr><tr><td></td><td>OR(CI)P-ValueUnadjusted</td><td>OR(CI)P-ValueAdjusted*</td><td>OR(CI)P-ValueUnadjusted</td><td>OR(CI)P-ValueAdjusted*</td><td>Effect modification§</td></tr><tr><td>Ever Wheeze</td><td>1.40(1.21-1.62)P <0.01</td><td>1.33(1.13-1.55)P <0.01</td><td>1.55(1.25-1.94)P <0.01</td><td>1.66(1.30-2.13)P <0.01</td><td>P = 0.35</td></tr><tr><td>Current Wheeze</td><td>1.11(0.89-1.39)P = 0.37</td><td>1.08(0.84-1.37)P = 0.56</td><td>1.84(1.30-2.59)P <0.01</td><td>1.81(1.24-2.64)P <0.01</td><td>P = 0.04</td></tr><tr><td>Diagnosis AsthmaEver</td><td>1.50(1.26-1.78)P <0.01</td><td>1.39(1.15-1.68)P <0.01</td><td>2.04(1.57-2.65)P <0.01</td><td>2.20(1.64-2.94)P <0.01</td><td>P = 0.02</td></tr><tr><td>Severity of Asthma</td><td>1.41(0.89-2.22)P = 0.14</td><td>1.30(0.80-2.11)P = 0.29</td><td>2.67(1.48-4.82)p < 0.01</td><td>2.99(1.54-5.58)p < 0.01</td><td>P = 0.05</td></tr><tr><td>Current Eczema</td><td>1.45(1.08-1.95)P = 0.01</td><td>1.46(1.07-2.00)P = 0.02</td><td>1.06(0.66-1.70)P = 0.80</td><td>1.14(0.68-1.89)P = 0.62</td><td>P = 0.32</td></tr><tr><td>Diagnosis EczemaEver</td><td>2.33(1.91-2.84)P <0.01</td><td>2.05(1.66-2.54)P <0.01</td><td>1.79(1.31-2.44)P <0.01</td><td>1.58(1.12-2.22)P = 0.01</td><td>P = 0.14</td></tr><tr><td>Current AllergicRhinoconjuctivitis</td><td>1.01(0.67-1.52)P = 0.96</td><td>0.84(0.54-1.29)P = 0.42</td><td>1.93(1.05-3.57)P = 0.04</td><td>2.25(1.16-4.37)P = 0.02</td><td>P = 0.04</td></tr><tr><td>Diagnosis RhinitisEver</td><td>1.66(1.21-2.26)P <0.01</td><td>1.54(1.10-2.14)P = 0.01</td><td>3.10(1.88-5.11)P <0.01</td><td>2.79(1.64-4.75)P <0.01</td><td>P = 0.07</td></tr></table> |
d257a596a08b538c29f88ab508f9ce3e5a1dd08917fd0e22ab59bb6ec7dcc40e.png | simple | <table><tr><td>Pt.</td><td>Sex/age at dgn (years)</td><td>Symptoms</td><td>Primary site</td><td>Tumor extension</td><td>Tumor size</td><td>TNM</td><td>Kadishstage</td></tr><tr><td>1</td><td>M/4</td><td>Seizures</td><td>Rhinopharynx</td><td>Intracranial, bone erosion, cervical lymph nodes</td><td>> 5 cm</td><td>T2b, N1, M0</td><td>C</td></tr><tr><td>2</td><td>M/2</td><td>Exophthalmos</td><td>Nasal cavity, rhinopharynx and ethmoid sinuses</td><td>Orbital cavity, submandibular lymph node, bone erosion</td><td>> 5 cm</td><td>T2b, N1, M0</td><td>C</td></tr><tr><td>3</td><td>F/16</td><td>Recurrent epistaxis</td><td>Paranasal sinuses</td><td>-</td><td>> 5 cm</td><td>T1b, N0, M0</td><td>B</td></tr><tr><td>4</td><td>M/10</td><td>None</td><td>Nasal cavity, rhinopharynx and maxillary sinuses</td><td>Bone erosion</td><td>< 5 cm</td><td>T2a, N0, M0</td><td>B</td></tr><tr><td>5</td><td>M/1</td><td>Recurrent epistaxis</td><td>Nasal cavity, ethmoid sinuses</td><td>Intracranial, bone erosion</td><td>> 5 cm</td><td>T2b, N0, M0</td><td>C</td></tr><tr><td>6</td><td>M/11</td><td>Nasal obstruction</td><td>Nasal cavity, maxillary and ethmoid sinuses</td><td>-</td><td>> 5 cm</td><td>T2b, N0, M0</td><td>B</td></tr><tr><td>7</td><td>M/5</td><td>Cranial nerve palsy</td><td>Nasal cavity pterygomandibular, infratemporal fossae</td><td>Intracranial, orbital cavity, bone erosion</td><td>> 5 cm</td><td>T2b, N0, M0</td><td>C</td></tr><tr><td>8</td><td>F/18</td><td>Proptosis</td><td>Nasal cavity</td><td>Intracranial, orbital cavity, retromandibular and laterocervical lymph nodes, bone erosion</td><td>> 5 cm</td><td>T2b, N1, M0</td><td>C</td></tr><tr><td>9</td><td>F/17</td><td>Headache</td><td>Maxillary and ethmoid sinuses</td><td>Orbital cavity, bone erosion</td><td>> 5 cm</td><td>T2b, N0, M0</td><td>C</td></tr></table> |
c7ea071197220fecc1a48d805ccb926260cb13a4a29aa66c776a32028df4bf78.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="3">Univariate</td><td colspan="3">Multivariate</td></tr><tr><td>HR (95 % CI)</td><td><i>χ</i><sup>2</sup></td><td><i>P</i></td><td>HR (95 % CI)</td><td><i>χ</i><sup>2</sup></td><td><i>P</i></td></tr><tr><td>Age (years)</td><td>0.669 (0.282-1.586)</td><td>0.835</td><td>0.361</td><td>-</td><td>-</td><td>-</td></tr><tr><td><65</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≥65</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Histotype</td><td>1.458 (0.720-2.950)</td><td>1.099</td><td>0.295</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Serous</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Others</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Grade</td><td>1.244 (0.759-2.041)</td><td>0.750</td><td>0.386</td><td>-</td><td>-</td><td>-</td></tr><tr><td>G1-2</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>G3</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ascites (mL)</td><td>0.990 (0.552-1.774)</td><td>0.001</td><td>0.973</td><td>-</td><td>-</td><td>-</td></tr><tr><td><1000</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>>1000</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Residual tumor (cm)</td><td>3.333 (1.650-6.732)</td><td>11.266</td><td>0.001*</td><td>3.050 (1.499-6.205)</td><td>9.471</td><td>0.002*</td></tr><tr><td><1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≥1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Class III β-tubulin</td><td>1.870 (1.022-3.423)</td><td>4.121</td><td>0.042*</td><td>1.915 (1.036-3.538)</td><td>4.301</td><td>0.038*</td></tr><tr><td>Positive</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Negative</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Sox2</td><td>2.623 (1.273-5.407)</td><td>6.829</td><td>0.009*</td><td>2.100 (1.009-4.373)</td><td>3.935</td><td>0.047*</td></tr><tr><td>Positive</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Negative</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nuclear Survivin</td><td>1.838 (1.009-3.349)</td><td>3.959</td><td>0.047*</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Positive</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Negative</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cytoplasmic Survivin</td><td>0.958 (0.495-1.852)</td><td>0.016</td><td>0.898</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Positive</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Negative</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> |
4b7747fdf61744c08c3356841fdffaf17ed9d61805d69aa30d0c1f2e531d9215.png | simple | <table><tr><td></td><td>Simultaneous mixed</td><td>Sequential mixed</td><td>Online</td></tr><tr><td><i>Total costs</i></td><td></td><td></td><td></td></tr><tr><td>AMPCo rental of list</td><td>$15,830</td><td>$15,830</td><td>$15,830</td></tr><tr><td>Monetary incentives</td><td>$60,000</td><td>$60,000</td><td>$60,000</td></tr><tr><td>Web survey costs</td><td>$4,000</td><td>$4,000</td><td>$4,000</td></tr><tr><td>AMPCO handling and postage</td><td>$97,157</td><td>$72,024</td><td>$65,361</td></tr><tr><td>Printing of letters, further info, fax sheet, envelopes</td><td>$17,981</td><td>$18,470</td><td>$18,458</td></tr><tr><td>Printing of surveys</td><td>$21,284</td><td>$19,794</td><td>$10,995</td></tr><tr><td>Data entry</td><td>$33,684</td><td>$16,630</td><td>$6,636</td></tr><tr><td>Total</td><td>$249,936</td><td>$206,748</td><td>$181,280</td></tr><tr><td><i>Incremental cost effectiveness ratios (compared to online mode)</i></td><td></td><td></td><td></td></tr><tr><td>Response rate</td><td>19.71%</td><td>20.69%</td><td>12.95%</td></tr><tr><td>Estimated number of responses</td><td>10,677</td><td>11,208</td><td>7,015</td></tr><tr><td>Change in response rate compared to online</td><td>6.76%</td><td>7.74%</td><td>-</td></tr><tr><td>Change in number of responses compared to online</td><td>3,662</td><td>4,193</td><td>-</td></tr><tr><td>Change in total cost compared to online</td><td>$68,656</td><td>$25,468</td><td>-</td></tr><tr><td>Additional cost per 1% increase in response rate<sup>1 </sup></td><td>$10,156</td><td>$3,290</td><td>-</td></tr><tr><td>Additional cost per additional response<sup>2 </sup></td><td>$18.75</td><td>$6.07</td><td>-</td></tr></table> |
389b86269310cf5ad8e864ad9f2e73ce89d8a0aabf307401f066d1f39aae287f.png | complex | <table><tr><td>Measurement</td><td>Hill</td><td>Linear</td><td>Polynomial</td><td>Power</td></tr><tr><td colspan="5">Admission SBP</td></tr><tr><td> BMD</td><td>1.50</td><td>2.57</td><td>0.22</td><td>1.46</td></tr><tr><td> BMDL</td><td>1.42</td><td>1.57</td><td>0.07</td><td>1.42</td></tr><tr><td> AIC</td><td>1,840</td><td>1,838</td><td>1,840</td><td>1,838</td></tr><tr><td colspan="5">Admission DBP</td></tr><tr><td> BMD</td><td>NC</td><td>2.71</td><td>NC</td><td>1.91</td></tr><tr><td> BMDL</td><td>NC</td><td>1.62</td><td>NC</td><td>1.43</td></tr><tr><td> AIC</td><td>NC</td><td>1,698</td><td>NC</td><td>1,699</td></tr><tr><td colspan="5">Maximum SBP</td></tr><tr><td> BMD</td><td>1.46</td><td>2.50</td><td>0.15</td><td>1.45</td></tr><tr><td> BMDL</td><td>1.41</td><td>1.55</td><td>0.06</td><td>1.41</td></tr><tr><td> AIC</td><td>1,895</td><td>1,897</td><td>1,895</td><td>1,893</td></tr><tr><td colspan="5">Maximum DBP</td></tr><tr><td> BMD</td><td>1.50</td><td>2.95</td><td>0.15</td><td>1.47</td></tr><tr><td> BMDL</td><td>1.43</td><td>1.71</td><td>0.06</td><td>1.43</td></tr><tr><td> AIC</td><td>2,009</td><td>2,009</td><td>2,009</td><td>2,007</td></tr></table> |
6ff1cdb53fdb6eabe106ee0d1f0714ad46c28d2595550d2466191f874abf5875.png | complex | <table><tr><td><i>Characteristics</i></td><td><i>Total</i></td><td><i>LZAP low</i></td><td><i>LZAP high</i></td><td>P-value</td></tr><tr><td>Number of cases</td><td>178</td><td>81 (45.5%)</td><td>97(55.5%)</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>Gender</i></td><td> </td><td> </td><td> </td><td>0.88</td></tr><tr><td> Male</td><td>86 (48.3%)</td><td>38 (46.9%)</td><td>48 (49.5%)</td><td> </td></tr><tr><td> Female</td><td>91 (51.1%)</td><td>42 (51.9%)</td><td>49 (50.5%)</td><td> </td></tr><tr><td> NA</td><td>1 (0.56%)</td><td>0</td><td>1 (1.2%)</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>Age at Dx</i></td><td> </td><td> </td><td> </td><td>0.34</td></tr><tr><td> Median</td><td>63</td><td>66</td><td>64</td><td> </td></tr><tr><td> Range</td><td>35–89</td><td>42–89</td><td>35–83</td><td> </td></tr><tr><td> Mean</td><td>62.4</td><td>65.8</td><td>64.3</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="5"><i>Staging</i></td></tr><tr><td colspan="5"> <i>T</i></td></tr><tr><td>T1–T2</td><td>53 (29.8%)</td><td>26 (32.1%)</td><td>27 (27.8%)</td><td>1.00</td></tr><tr><td>T3–T4</td><td>19 (10.7%)</td><td>10 (12.3%)</td><td>9 (9.3%)</td><td> </td></tr><tr><td>NA</td><td>106 (59.6%)</td><td>45 (55.6%)</td><td>61 (62.9%)</td><td> </td></tr><tr><td colspan="5"> <i>N</i></td></tr><tr><td>N0</td><td>34 (19.1%)</td><td>18 (22.2%)</td><td>16 (16.5%)</td><td>0.25</td></tr><tr><td>N1–3</td><td>42 (23.6%)</td><td>16 (19.8%)</td><td>26 (26.8%)</td><td> </td></tr><tr><td>NA</td><td>102 (57.3%)</td><td>47 (58.0%)</td><td>55 (56.7%)</td><td> </td></tr><tr><td colspan="5"> <i>Stage</i></td></tr><tr><td>I–II</td><td>124 (69.7%)</td><td>62 (76.5%)</td><td>62 (63.9%)</td><td>0.10</td></tr><tr><td>III–IV</td><td>53 (29.8%)</td><td>19 (23.5%)</td><td>34 (35.1%)</td><td> </td></tr><tr><td>NA</td><td>1 (0.56%)</td><td>0</td><td>1 (1.2%)</td><td> </td></tr></table> |
a5a2d568c5eb904e240039c8ce48338197c5d7d46e6dc5470018b24de62959cc.png | simple | <table><tr><td>Diseases</td><td>PAF</td></tr><tr><td>Preterm [20]</td><td>0.0679 </td></tr><tr><td>Lung Cancer [21]</td><td>male 0.6837/female 0.2057 </td></tr><tr><td>Chronic Obstructive Pulmonary Disease [22]</td><td>0.3024 </td></tr><tr><td>Asthma [23] </td><td>0.1319 </td></tr><tr><td>Ischemic Heart Disease [22] </td><td>0.3265 </td></tr><tr><td>Pneumonia [24]</td><td>0.1340 </td></tr></table> |
5b8b9641e53f884e9e88e127919d257849ea3709b696ccee064cd8270beaac6e.png | simple | <table><tr><td>Target relationship orientation</td><td>1</td><td>2</td></tr><tr><td>Monogamous</td><td></td><td></td></tr><tr><td>(1) Social distance</td><td>–</td><td></td></tr><tr><td>(2) Promiscuity rating</td><td>0.07</td><td>–</td></tr><tr><td>(3) STI ratings</td><td>0.07</td><td>0.52<sup>∗∗</sup></td></tr><tr><td>Open relationships</td><td></td><td></td></tr><tr><td>(1) Social distance</td><td>–</td><td>–</td></tr><tr><td>(2) Promiscuity rating</td><td>0.13<sup>∗∗</sup></td><td>0.45<sup>∗∗</sup></td></tr><tr><td>(3) STI ratings</td><td>0.19<sup>∗∗</sup></td><td></td></tr><tr><td>Polyamorous</td><td></td><td></td></tr><tr><td>(1) Social distance</td><td>–</td><td>–</td></tr><tr><td>(2) Promiscuity rating</td><td>0.22<sup>∗∗</sup></td><td>0.59<sup>∗∗</sup></td></tr><tr><td>(3) STI ratings</td><td>0.33<sup>∗∗</sup></td><td></td></tr><tr><td>Swingers</td><td></td><td></td></tr><tr><td>(1) Social distance</td><td>–</td><td>–</td></tr><tr><td>(2) Promiscuity rating</td><td>0.08</td><td>0.51<sup>∗∗</sup></td></tr><tr><td>(3) STI rating</td><td>0.27<sup>∗∗</sup></td><td></td></tr></table> |
c51bf0ac49a0cfc89c70a2c0199234df2fbf26e4ef41cb50e45af8cd462debd8.png | simple | <table><tr><td> </td><td>Normal-weight <i>n</i> = 165</td><td>Overweight <i>n</i> = 54</td><td>Obese <i>n</i> = 163</td><td>normal-weight versus overweight <i>P </i></td><td>normal-weight versus obese <i>P </i></td><td>overweight versus obese <i>P </i></td></tr><tr><td>Walking</td><td>0.2 ± 0.7</td><td>0.5 ± 1.1</td><td>0.9 ± 1.2</td><td>0.014</td><td>0.000</td><td>0.025</td></tr><tr><td>Running</td><td>0.3 ± 0.7</td><td>0.7 ± 1.1</td><td>1.3 ± 1.3</td><td>0.001</td><td>0.000</td><td>0.001</td></tr><tr><td>Hopping</td><td>0.1 ± 0.5</td><td>0.3 ± 0.9</td><td>0.9 ± 1.3</td><td>0.200</td><td>0.000</td><td>0.001</td></tr><tr><td>Bending</td><td>0.1 ± 0.3</td><td>0.4 ± 0.9</td><td>0.6 ± 1.2</td><td>0.003</td><td>0.000</td><td>0.171</td></tr><tr><td>Climbing stairs</td><td>0.1 ± 0.5</td><td>0.5 ± 1.0</td><td>1.4 ± 1.4</td><td>0.014</td><td>0.000</td><td>0.000</td></tr><tr><td>Feeling clumsy or awkward</td><td>0.4 ± 0.7</td><td>0.6 ± 1.1</td><td>1.1 ± 1.3</td><td>0.353</td><td>0.000</td><td>0.008</td></tr><tr><td>Getting up from chairs</td><td>0.0 ± 0.3</td><td>0.0 ± 0</td><td>0.0 ± 0.3</td><td>0.410</td><td>0.163</td><td>0.154</td></tr></table> |
a52c5f94aaba88608f704af6c58f2e11cd496c98bc462f1eb1a46ead9f2db2f4.png | complex | <table><tr><td>Characteristics</td><td>Value</td></tr><tr><td>Number of patients</td><td>38</td></tr><tr><td>Age (years)</td><td>35.9 ± 9.0 (range 17–58)</td></tr><tr><td>Male to female ratio</td><td>29:16</td></tr><tr><td colspan="2">Fracture locations</td></tr><tr><td> T11</td><td>5 patients</td></tr><tr><td> T12</td><td>12 patients</td></tr><tr><td> L1</td><td>17 patients</td></tr><tr><td> L2</td><td>4 patients</td></tr><tr><td>Surgical duration (minutes)</td><td>90.7 ± 21.9</td></tr><tr><td>Blood loss (milliliters)</td><td>89.2 ± 31.9</td></tr><tr><td>Postoperative stay (days)</td><td>3.2 ± 0.9</td></tr><tr><td>Hospital stay (days)</td><td>4.8 ± 1.0</td></tr></table> |
04f0f9e238c14f93863f59242683da9656e6671eb232a51360f433e47e7c3f57.png | complex | <table><tr><td>Variables</td><td>Value</td></tr><tr><td colspan="2">Age, years</td></tr><tr><td>median years (IQR)</td><td>25 (23-28)</td></tr><tr><td>≤ 20 y (%)</td><td>23/375 (6.1)</td></tr><tr><td>20-35 y (%)</td><td>331/375 (88.3)</td></tr><tr><td>> 35 y (%)</td><td>21/375 (5.6)</td></tr><tr><td>Han Chinese (%)</td><td>371/393 (94.4)</td></tr><tr><td colspan="2">Job</td></tr><tr><td>Farmer (%)</td><td>200/389 (51.4)</td></tr><tr><td>Unemployed (%)</td><td>84/389 (21.6)</td></tr><tr><td>Others (%)†</td><td>105/389 (27.0)</td></tr><tr><td>BMI, median (IQR)</td><td>26.0 (23.4-29.3)</td></tr><tr><td>≤ 25.0 (%)</td><td>99/243 (40.7)</td></tr><tr><td>25-30 (%)</td><td>99/243 (40.7)</td></tr><tr><td>30-35 (%)</td><td>35/243 (14.4)</td></tr><tr><td>> 35 (%)</td><td>10/243 (4.1)</td></tr><tr><td>Gestational age§</td><td></td></tr><tr><td>1<sup>st </sup>trimester (0-14 week) (%)</td><td>20/394 (5.1)</td></tr><tr><td>2<sup>nd </sup>trimester (15-27 week) (%)</td><td>88/394 (22.3)</td></tr><tr><td>3<sup>rd </sup>trimester (≥ 28 week) (%)</td><td>286/394 (72.6)</td></tr><tr><td colspan="2">Chronic pre-existing disease</td></tr><tr><td>Respiratory diseases** (%)</td><td>11/388 (2.8)</td></tr><tr><td>Cardiovascular diseases*** (%)</td><td>13/393 (3.3)</td></tr><tr><td>Diabetes mellitus (%)</td><td>4/394 (1.0)</td></tr><tr><td>Cancer or hematological diseases (%)</td><td>3/394 (0.8)</td></tr><tr><td>Immune suppressed (%)</td><td>1/390 (0.3)</td></tr><tr><td>Pneumonia (%)</td><td>351/390 (90.0)</td></tr><tr><td colspan="2">Symptoms and Lab findings</td></tr><tr><td>T ≥ 38°C (%)</td><td>340/374 (90.9)</td></tr><tr><td>Cough (%)</td><td>372/393 (94.7)</td></tr><tr><td>Dyspnoea (%)</td><td>199/393 (50.6)</td></tr><tr><td>Hemoptysis (%)</td><td>55/392 (14.0)</td></tr><tr><td>Pleural effusion (%)</td><td>44/226 (19.5)</td></tr><tr><td>CNS symptom ※ (%)</td><td>48/392 (12.2)</td></tr><tr><td>WBC (×10<sup>9</sup>/L)</td><td>7.4 ± 3.7</td></tr><tr><td>Platelet (×10<sup>9</sup>/L)</td><td>169.0 ± 65.7</td></tr><tr><td>CK > 200 u/L (%)</td><td>77/306 (19.5)</td></tr><tr><td>CRP (mg/L)</td><td>42 (16-101)</td></tr><tr><td>ESR (mm/h)</td><td>35 (23-50)</td></tr><tr><td>PaO<sub>2</sub>/FiO<sub>2</sub>, median (IQR)</td><td>154.7 (89.5-320.5)</td></tr><tr><td>APACHE II scores, median (IQR)</td><td>7 (4-11)</td></tr></table> |
75ed2824e108f796cf60676313156afe04513b4eae37373d1a48a58b90f46c20.png | complex | <table><tr><td></td><td></td><td colspan="2">Item-test correlation</td></tr><tr><td><i>N</i>∘</td><td>Item</td><td>Cognitive scale</td><td>Affective scale</td></tr><tr><td>1</td><td>Her/his parents’ or siblings’ emotions don’t affect her/him much</td><td></td><td>0.20</td></tr><tr><td>2</td><td>After being with a relative who is sad about something, s/he usually feels sad</td><td></td><td>0.40</td></tr><tr><td>4</td><td>S/he gets frightened when s/he watches characters in a good scary movie</td><td></td><td>0.32</td></tr><tr><td>5</td><td>S/he gets caught up in other people’s feelings easily</td><td></td><td>0.52</td></tr><tr><td>7</td><td>S/he doesn’t become sad when he/she sees other people crying</td><td></td><td>0.42</td></tr><tr><td>8</td><td>Other people’s feelings don’t bother her/him at all</td><td></td><td>0.47</td></tr><tr><td>11</td><td>S/he often becomes sad when watching sad things on TV or in films</td><td></td><td>0.50</td></tr><tr><td>13</td><td>Seeing a person who has been angered has no effect on her/his feelings</td><td></td><td>0.40</td></tr><tr><td>15</td><td>S/he tends to feel scared when s/he is with friends or relatives who are afraid</td><td></td><td>0.23</td></tr><tr><td>17</td><td>S/he often gets swept up in her/his siblings’ or friend’s feelings</td><td></td><td>0.39</td></tr><tr><td>18</td><td>Her/his relatives or friend’s unhappiness doesn’t make her/him feels anything</td><td></td><td>0.48</td></tr><tr><td>3</td><td>S/he can understand her/his friend’ or relative’s happiness when that person does well at something</td><td>0.38</td><td></td></tr><tr><td>6</td><td>S/he finds it hard to know when other children are frightened</td><td>0.18</td><td></td></tr><tr><td>9</td><td>When someone is feeling ‘down’ s/he can usually understand how that person feels</td><td>0.56</td><td></td></tr><tr><td>10</td><td>S/he can usually work out when other children are scared</td><td>0.50</td><td></td></tr><tr><td>12</td><td>S/he can often understand how people are feeling even before they tell her/him</td><td>0.46</td><td></td></tr><tr><td>14</td><td>S/he can usually work out when people are cheerful</td><td>0.48</td><td></td></tr><tr><td>16</td><td>S/he can usually realize quickly when either of her/his parents is angry</td><td>0.37</td><td></td></tr><tr><td>19</td><td>S/he is not usually aware of her/his loved ones’ feelings</td><td>0.47</td><td></td></tr><tr><td>20</td><td>S/he has trouble figuring out when other members of the family are happy</td><td>0.42</td><td></td></tr></table> |
5a562a69e426f73c739e22d52ca07e70be32b9d5cd226b3974bb3fa5a36b03b4.png | simple | <table><tr><td>Diagnosis category</td><td>Number of missions</td></tr><tr><td>Cardiac arrest<sup>a</sup></td><td>2</td></tr><tr><td>Acute coronary syndrome</td><td>6</td></tr><tr><td>Circulatory emergency<sup>b</sup></td><td>6</td></tr><tr><td>Respiratory emergency</td><td>2</td></tr><tr><td>Trauma</td><td>8</td></tr><tr><td>Neurological emergency</td><td>3</td></tr><tr><td>Gastrointestinal emergency</td><td>5</td></tr><tr><td>Other emergency</td><td>3</td></tr></table> |
fcf0ead789d670e9ed36b8b37b473b70dd00e9c135bee8beab4b859c2c70e7d3.png | simple | <table><tr><td>Trait</td><td>Variance (%)</td></tr><tr><td><i>α</i>-Amylase</td><td>52.2</td></tr><tr><td>Diastatic power</td><td>74.1</td></tr><tr><td>Malt extract</td><td>54.0</td></tr><tr><td>Heading date</td><td>70.4</td></tr><tr><td>Plant height</td><td>64.2</td></tr><tr><td>Lodging</td><td>40.3</td></tr><tr><td>Grain protein content</td><td>45.6</td></tr><tr><td>Yield</td><td>22.4</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.